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Summary 
Flos Magnoliae, one of the commonly used Chinese herbal medicines (CHM), has a long 
history of clinical application for rhinitis, sinusitis and headache. More than 20 different Flos 
Magnoliae species can be found in the market. Thus, a systematic evaluation of the authentic 
species and quality assessment of Flos Magnoliae from different botanic sources could be a 
complicated process. The major aim of this thesis was to study the molecular, chemical and 
pharmacological profiles of different Flos Magnoliae species and varieties, as well as different 
Flos Magnoliae products. The main approaches included establishment of DNA and 
chromatographic fingerprinting profiles, determination of the contents of magnolin and 
fargesin, and comparison of the anti-histamine release effects of different Flos Magnoliae 
samples.  
 
Firstly, DNA-based techniques were used to identify the genetic relationships between six 
Magnolia spp. The distinct genetic distances of their molecular profiles from Flos Magnoliae 
materials were demonstrated after amplification by random amplified polymorphic DNA 
(RAPD). The present study using ten random primers and polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) analysis by 5s-rRNA gene after 
digestion by restriction enzymes (HhaI, PstI, SmaI, and EcoRV) represents the first report of 
DNA fingerprinting profiles of these Flos Magnoliae species.  
 
Secondly, the optimised thin layer chromatography (TLC) approach is rapid, specific and 
simultaneous for qualitatively analysis of magnolin and fargesin in ethanol extracts of 
different Flos Magnoliae species and varieties. All M. biondii batches and M. kobus were 
found to contain magnolin and fargesin. Magnolin, but not fargesin was detected from M. 
liliflora. No magnolin and fargesin were found in other Flos Magnoliae species.  
 XXXV 
Thirdly, bioactive components, magnolin and fargesin were quantitatively determined by the 
newly developed high performance liquid chromatography (HPLC) method. By choosing an 
appropriate gradient elution system of acetonitrile and water with the UV detection 
wavelength at 278nm, magnolin and fargesin were baseline separated without interference 
peaks in the HPLC chromatograms. By using this method, magnolin was detected from the 
ethanol extracts of M. biondii, M. kobus and M. liliflora, while fargesin was only found from 
the ethanol extracts of M. biondii and M. kobus. Furthermore, the significant differences of 
the content of magnolin and fargesin were observed in samples from different Flos Magnoliae 
sources.  
 
Fourthly, the HPLC fingerprinting profiles of different Flos Magnoliae sources were studied 
for the first time. Various parameters, including the retention time, the relative retention time, 
the peak area, the relative peak area, the total peak area of 13 common peaks and the 
overlapping ratio were evaluated. The consistency of the fingerprints was observed among M. 
biondii batches, whilst the chromatographic profiles among the other Flos Magnoliae species 
were distinguished. In addition, the Flos Magnoliae products, which were collected from 
different herbal suppliers, and the M. biondii batches, which were grown in different 
cultivation sites, were clearly identified and authenticated by their HPLC fingerprinting 
features.  
 
Finally, the effects of different samples on mast cell derived histamine release induced by 
compound 48/80 in rat peritoneal mast cells (RPMC) were studied, using HPLC with post-
derivatization. The significant differences in inhibition of histamine release were observed 
among various species or even among the same species but different varieties. Moreover, the 
inhibitory effects of the Flos Magnoliae sources from different herbal suppliers and 
cultivation sites on compound 48/80 induced histamine release were evaluated. To the best 
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knowledge, it is the first report of the anti-histamine release effects by the bioactive lignan, 
magnolin, and volatile oil from M. biondii.  
 
In conclusion, the present study verified that the variations of botanic species and varieties, 
cultivation environments, and manufacturer process might cause the differences of the 
chemical compositions and pharmacological actions of Flos Magnoliae products. Thus, in 
order to insuring the quality, efficacy and consistency of Flos Magnoliae, proper quality 
control of Flos Magnoliae species is important. Furthermore, local grown Flos Magnoliae 
species may be used for anti-allergic and anti-inflammatory applications. For the future 
direction, it would have been interesting to characterise the chemical structures of these 
components, which may contribute to the anti-allergic effects of Flos Magnoliae, if it had not 
been for time constraints. Even though the inhibitory effects of mast cells derived histamine 
release were demonstrated in the present study, assays on mediators involved in the anti-
allergic actions may provide additional evidences on the clinical application of Flos 
Magnoliae for rhinitis and sinusitis. Further to that, assays on anti-allergic effects of the major 
chemical compounds from Flos Magnoliae on these mediators may apply chances to discover 
new therapeutic agents.  
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1.1 Introduction of Flos Magnoliae  
Flos Magnoliae (Chinese name: Xin-yi) is one of the most commonly used Chinese medicinal 
herb, and has a long history of clinical application for rhinitis, sinusitis and headache (The 
Pharmacopoeia Commission of People's Republic of China, 2005, Bensky and Gamble, 1993). 
Few species from genus Magnolia (Family Magnoliaceae) have been considered as the 
original sourcE for medicinal Flos Magnoliae (Fu, 2000). The medicinal use of Flos 
Magnoliae was originally recorded in <Shennong’s Classic of Materia Medica> about two 
thousand years ago (Yu et al., 1999). Owing to its versatile therapeutic properties, Flos 
Magnoliae has been widely used in modern practice of herbal medicines.  
 
Recently, with the revival interested in Chinese herbal medicines (CHM), Flos Magnoliae and 
it is related therapeutic products have captured a considerable proportion of the global market. 
Owing to the significant therapeutic effects, the market for medicinal plants, including Flos 
Magnolia is ever-growing 
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1.1.1 The Genus Magnolia 
Magnoliaceae, as one of the primitive flowering plants family, includes more than 200 species 
of well-defined trees and shrubs, which plays the key role for the researches of angiosperm 
phylogeny (Kim et al., 2001). Magnoliaceae family was natively appeared in Asia until the 
18th century when it spread from the Himalayas to Japan and from North-eastern America to 
Central America and finally reached in Venezuela (Hutchinson, 1973, Pei and Chen, 1991) 
(Figure 1.1). Most of the plants from Magnoliaceae distribute in tropic and subtropic regions 
of the Northern Hemisphere, for instance in South-east Asia and America. The rest of the 
family reaches to the Southern Hemisphere (Wang et al., 2004b). Subsequently, it has been 
planted throughout the world, including Australia.  
 
1.1.1.1 Taxonomy of Magnoliaceae 
As the most primitive living family of flowering plants, the Magnoliaceae is an exclusive 
family diverse from any other plant families (Pei and Chen, 1991). There are 14 genera, 
forming three tribes in the Magnoliaceae (Pei and Chen, 1991). However, the taxonomy 
classification of the Magnoliaceae is still arguable (Table 1.1).  
 
The Magnolia spp., considered as the medicinal sources for Flos Magnoliae, includes the 
largest genera, Magnolia (over 30 species), which is common to Asia and America. Other 
genera include the genera with terminal flowers, such as Manglietia, Manglietiastrum, 
Talauma, Parakmeria, Kmeria, Alcimandra and Liridendron, and as well as the genera with 
axillary flowers, such as Michelia, Paramichelia and Tsoongiodendron.  
 
Among the species from genus Magnolia, more than 20 Magnolia spp. have been used in the 
commercial products or CHM practice as the sourcing of Flos Magnoliae. These species are 
located in the section Yulania, section Buergeria, section Tulipastrum and section Theorhodon 
 4 
(Pei and Chen, 1991, Magnolia Society, 2003). Based on the Chinese Pharmacopoeia 
(Pharmacopoeia Commission of People's Republic of China, 2000), three species, namely, M. 
biondii, M. denudata and M. sprengeri are listed under the pharmaceutical name Flos 
Magnoliae. However, there are more than 20 different Magnolia species have been used as 
substitutes or adulterants (Fu, 2000, Zhao and Cao, 1990, Li et al., 1994a). It has been 
suggested that M. sargentiana (Sichuan Province, China) (State Administration of Traditional 
Chinese Medicine "Chinese Materia Medica" Editorial Committee, 1998), M. liliflora (Shanxi 
Province, China) (Zhao and Cao, 1990), M. cylindrica (Zhejiang Province, China) (Li et al., 
1994a), M. campbellii (Yunnan Province, China) (Fu, 2000), M. pilocarpa (Hubei and Anhui 
Province, China) (Zhao et al., 1987), M. wilsonii (Sichuan and Yunnan Province, China) (Fu, 
2000) and M. kobus (Japan) (PFAF, 2000) can be used as Flos Magnoliae in CHM practice. 
Furthermore, in Australia, M. liliflora, and M. salicifolia have been included as the ‘listed’ 
medicines by Therapeutic Goods Administration (TGA) (TGA, 2004). 
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Figure 1.1 The distribution patterns of Family Magnoliaceae (Hutchinson, 1973, Pei and Chen, 1991). The blue circles indicate the approximate 
distribution ranges of Magnolia spp.  
 6 
Table 1.1 Classification of the Magnoliaceae. Specified taxa, which have been considered as 
the botanic sources of Flos Magnoliae, are shown in the red characters. 
Pei & Chen 
 (Pei and Chen, 1991) 
Magnolia Society  
(Magnolia Society, 2003) 
NCBI Taxonomy Database  
(Bischoff et al., 2004) 
Family: Magnoliaceae Family: Magnoliaceae 
Tribe: Magnolieae Subfamily: Magnolioideae 
Family: Magnoliaceae 
Genus: Manglietia 
Genus: Manglietiastrum 
Genus: Talauma, 
Genus: Parakmeria, 
Genus: Kmeria 
Genus: Alcimandra 
Genus: Michelia 
Genus: Paramichelia 
Genus: Tsoongiodendron 
Genus: Liriodendron 
Genus: Pachylarnax 
Genus: Dugandiodendron 
Genus: Kmeris 
Genus: Liriodendron 
Genus: Manglietia 
Genus: Michelia 
Genus: Pachylarnax 
Genus: Talauma 
 
 
 
Genus: Magnolia Genus: Magnolia 
Subgenus: Magnolia Subgenus: Magnolia 
Subgenus: Yulania Subgenus: Yulania 
Section: Yulania 
M. campbellii 
M. sprengeri 
M. sargentiana 
M. denudata 
M. salicifolia 
Section: Yulania 
M. denudata 
M. campbellii 
M. sprengeri 
M. sargentiana 
M. salicifolia 
Section: Buergeria 
M. biondii 
Section: Buergeria 
M. biondii 
M. kobus 
Section: Tulipastrum 
M. liliflora 
Section: Tulipastrum 
M. liliflora 
Section: Theorhodon 
M. grandilora 
 
Genus: Magnolia 
 
M. biondii 
M. campbellii 
M. denudata 
M. kobus 
M. liliflora 
M. sargentiana  
M. sprengeri 
M. salicifolia 
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1.1.1.2 Distribution of Flos Magnoliae species used in this thesis 
1.1.1.2.1 Flos Magnoliae species in China  
M. biondii, which is the most commonly used Flos Magnoliae species in native of central 
China, but cultivated in many regions of the country, such as Gansu Province, Shanxi 
Province, western Henan Province, western Hubei Province and eastern Sichuan Province 
(State Administration of Traditional Chinese Medicine "Chinese Materia Medica" Editorial 
Committee, 1998, Fu, 2000). M. denudata has been cultivated for both medicinal and 
ornamental uses in China. It is believed to have originated in eastern China, and the wild 
species are only seen in the mountain regions, such as Anhui Province, Fujian Province, 
Guangdong Province, Guizhou Province, Hunan Province, Jiangsu Province and Zhejiang 
Province (Fu, 2000, State Administration of Traditional Chinese Medicine "Chinese Materia 
Medica" Editorial Committee, 1998, Pei and Chen, 1991). The home of M. sprengeri is in 
western China, with a range extending from western Hubei Province, western Henan Province, 
eastern Sichuan Province, Guizhou Province and Yunnan Province in China (Pei and Chen, 
1991, Fu, 2000). As one of the similar taxa of M. sprengeri, M. sargentiana is also widely 
cultivated in central-southern Sichuan Province and northern Yunnan Province (Fu, 2000). M. 
liliflora is commonly seen in the region of south of Yangtze River in China (Pei and Chen, 
1991). It is now widely cultivated in central and eastern China, such as Shanxi Province, 
Fujian Province and Sichuan Province (Fu, 2000). M. campbellii, as one of the rarest species, 
is cultivated ranged from the eastern Himalayas to Tibet and Yunnan Province, China (Pei 
and Chen, 1991).  
 
1.1.1.2.2 Flos Magnoliae species in other countries 
M. kobus replaces M. biondii as the authentic Flos Magnoliae species in Japan and Korea and 
widely distributes in southern Japan and on the coast of southern Korea (Table 5.1) (PFAF, 
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2000). Meanwhile, commonly used Flos Magnoliae species, including M. liliflora and M. 
denudata, have been cultivated in Japan and Korea (Pei and Chen, 1991).  
As the native plants of United States, the species that are recognised as the botanic origins of 
Flos Magnoliae are widely cultivated around the country (Bailey and Bailey, 1976). M. 
campbellii, M. denudata, M. kobus, M. liliflora, M. sargentiana and M. sprengeri have been 
found in United States (Bailey and Bailey, 1976).  
 
Although Magnolia spp. are not the native plants in Australia, the family has been imported 
and widely cultivated by local nurseries (Australian National Botanic Gardens, 2004, 
Australian Nurseries Online, 2006).  Furthermore, M. liliflora has been included as the ‘listed’ 
medicine in TGA, Australia (TGA, 2004). 
 
1.1.1.3 Genetic features of Magnolia spp. 
Over the last two decades, with the development of molecular cloning and polymerase chain 
reaction (PCR) techniques, deoxyribose nucleic acid (DNA) based markers have been well 
established for the evaluation of taxonomic relationship and genetic mapping of plants. These 
techniques have been commonly used to identify and authenticate the species of medicinal 
materials (Joshi et al., 2004). It has been applied to validate reference strains of Magnolia spp. 
The sequence of chloroplast matK gene has been introduced to screen different Magnolia 
species from East Asia, China and America (Wang et al., 2004d, Azuma et al., 2001). The 
findings support the phylogenetic relationship between different species from various genera 
based on their morphological and fossil evidence, and also generate the evolutionary history 
of Family Magnoliaceae by disjunction of more than 200 species (Azuma et al., 2001). Kim et 
al (2001) reported that the Chloroplast ndhF gene was employed to reveal the taxonomic 
relationship between different sections and genera. Meanwhile, the genomic outcomes have 
identified some diverse lineages according to certain taxa position, such as redefining the 
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polyphyletic genus Magnolia, section Rytidospermum and subgenus Talauma, and further 
recognising the relationships between Michelia and subgenus Magnolia. 
 
As a simple and efficient molecular detection method, random amplified polymorphic DNA 
(RAPD) has been used to generate the genetic distances of medicinal plant of Flos Magnoliae. 
Wang et al (2004c) used the RAPD technique to revise the phenotypic relationship between 
20 taxa from subgenus Yulania, by screening with fifteen 10-mer random primers. By 
combining the morphological observation and RAPD identification, the close relationship 
between those taxa were established. Further study also observed the significant genetic 
distance between the species derived from Asia and the species from America among 17 taxa 
of subgenus Yulania using RAPD analysis (Wang et al., 2004e). 
 
1.1.2 Flos Magnoliae and traditional Chinese medicine  
Clinical usage of Flos Magnoliae has a long history in traditional CHM and has been traced 
back to the Han Dynasty. The therapeutic functions of Flos Magnoliae were recorded in the 
oldest and comprehensive medical literatures, <Shen Nong Ben Cao Jing>, the earliest 
Chinese Materia Medica of the first century BC, which was preceded by a long verbal history 
of the application of Flos Magnoliae in ancient China (Yu et al., 1999). From the CHM 
perspective, it has a wind-dispelling property, pungent flavour and warm nature, and it enters 
the lung and stomach meridians (Bensky and Gamble, 1993). Based on the traditional Chinese 
medicine theory, pungent and warm properties of herbs have the effects to release the exterior 
disorders, which are defined as mild fever, severe chills, accompanied by headache, body and 
neck pains, and absence of thirst (Bensky and Gamble, 1993). Flos Magnoliae has the 
property of expelling wind cold from the Five Zangs (5 viscera) of the body. It can also 
relieve headache. Prolonged intake would descend the Qi, reduce body weight, brighten the 
eyes, as well as increase longevity. Since then, Flos Magnoliae has been appeared in most of 
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the classic CHM literatures. A summary of the appearances of Flos Magnoliae in the classic 
CHM literatures is presented in Table 1.2.  
 
Modern scientific research has found that Flos Magnoliae is a key herb for symptomatic 
management of allergic rhinitis, sinusitis and headache (The Pharmacopoeia Commission of 
People's Republic of China, 2005). It has various pharmacological actions (see Section 1.1.5). 
In Japan, Flos Magnoliae is regarded as an important folk herb for headache treatment (PFAF, 
2000). In Korean, Flos Magnoliae has been successfully demonstrated for the management of 
rheumatic arthritis (Kim et al., 2003).  
 
Most of the Magnolia spp. have economic values. In addition to the Flos Magnoliae species, 
M. officinalis and M. officinalis var. biloba have also been introduced as another commonly 
used CHM, Cortex Magnoliae Officinalis (Ho-pu) (The Pharmacopoeia Commission of 
People's Republic of China, 2005). Furthermore, almost all the Magnolia spp. are valuable 
ornamental plants (Hutchinson, 1973). The species, which have the relatively high quality, are 
recognised as furniture timbers (Fu, 2000). Besides the above-mentioned economic 
importance, the essential oil of Magnolia spp. is also used as natural resource of stacte, spice, 
flavouring essence, food and cosmetics for a long history (Fu, 2000). 
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Table 1.2 Documentation of Flos Magnoliae in classic CHM literatures  
Book Title  
(In Chinese) 
Book Title 
(In English) 
Author Era 
神农本草经 Shennong’s Classic of Materia Medica Anonymous 220 – 225 B.C 
本草经集注 Collection of Commentaries on the Classic of Materia Medica Tao, Hong Jing 502 – 536 A.D. 
雷公炮炙论 Leigong’s Discussion of Processing of Materia Medica Lei, Xiao 420 – 479 A. D. 
千金翼方 A Supplement to Recipes Worth A Thousand Gold Sun, Si Miao  682 A.D. 
本草图经 Illustrated classic of Materia Medica Su, Song 1061 A.D. 
证类本草 Classified Materia Medica Tang, Shen Wei 1108 A.D. 
本草衍义 Extension of Materia Medica Kou, Zong Shuang 1116 A.D. 
本草纲目 Compendium of Materia Medica Li, Shi Zhen 1596 A.D. 
本草备要 Essential of Materia Medica Wang, Ang 1694 A.D. 
本草从新 Thoroughly Revised Materia Medica Wu, Yi Luo 1757 A.D. 
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1.1.3 Botanic features of Magnolia spp. 
1.1.3.1 Magnolia spp.  
Magnolia, trees or shrubs, is the most well known genus of Magnoliaceae family. Its leaves 
are evergreen and are simple, stipules large, deciduous and leaving an annular scar on the 
shoot, enclosing the young buds. Early in the spring, large flowers cover the tree before new 
leaves appear. The plants are solitary terminal or axillary. Flowers are usually unisexual; 
sepals and petals are frequently similar, in several series and imbricate; stamens numerous 
and opening lengthwise; carpels usually numerous; in fruit circumscissile and woody 
(Hutchinson, 1973). The images of different Magnolia spp., which have been used as the 
sources of medicinal Flos Magnoliae illustrated in Figure 1.2.  
 
1.1.3.2 Medicinal Flos Magnoliae  
1.1.3.2.1 Morphological features  
Based on the classification of genus Magnolia by Magnolia Society (Magnolia Society, 2003), 
the botanical origins of Flos Magnoliae belong to the genus Magnolia, subgenus Yulania, 
section Yulania, Buergeria, and Tulipastrum. Differences of their distributions and the 
appearances of the flowers from these sections show in Table 1.3. Table 1.4 further describes 
the distributions and habits of the Flos Magnoliae species, which were selected for the present 
study. The buds are collected in late winter and early spring before blooming, and dried in the 
shade (Fu, 2000). The buds of Flos Magnoliae are long and ovoid, having the shape of a 
writing brush, and texture light and delicate; odour, aromatic; taste bitter (State 
Administration of Traditional Chinese Medicine "Chinese Materia Medica" Editorial 
Committee, 1998) (Figure 1.3). Morphological identification shows considerable difference 
between different species of Magnolia (Table 1.5). Some morphological differences, 
including the shapes and sizes of the buds, and numbers of the segments, were distinguished 
between different Flos Magnoliae species, including M. biondii, M. denudata, M. sprengeri, 
 13 
M. soulangeana, M. liliflora, M. cylindrica, M. steboidii, M. sinostellata M. amoena, and M. 
elliptillimba (Li et al., 1994b, Huang, 1990, State Administration of Traditional Chinese 
Medicine "Chinese Materia Medica" Editorial Committee, 1998).  
 
 
 
                            M. denudata                                                       M. sprengeri 
 
 
                            M. liliflora                                                            M. kobus 
 
Figure 1.2 Images illustrating four medicinal Flos Magnoliae species 
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Table 1.3 Key to three sections of genus Yulania, which has been recognised as the sourcing of medicinal Flos Magnoliae (Pei and Chen, 1991, 
Hutchinson, 1973) 
Section Distribution Tree Flower appurtenance Colour of flowers Sepals and petals 
Yulania 
East and West China, 
Himalayas 
Deciduous tree Before new leaves appear White, pink or purple Similar 
Buergeria 
East China 
Japan and Korea 
Deciduous shrub 
or tree 
Before new leaves appear Pink Dissimilar 
Tulipastrum China and America Deciduous shrub 
Before new leaves appear or 
when leafing 
Red or purple Similar 
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Table 1.4 Taxonomy, distributions and habits of the Flos Magnoliae species, selected in this thesis 
Taxon Habit 
Botanic name Chinese name Synonym 
Distribution 
Type Mature height (m) 
M. biondii 望春玉兰 M. fargesii Temperate Asia and China Deciduous tree 6-12 
M. campbellii 滇藏木兰 M. mollicomata Temperate and tropical Asia, and China Deciduous tree 24-30 
M. denudata 玉兰 
M. conspicua 
M. yulan 
M. heptapeta 
Temperate Asia and China Deciduous tree 15-22 
M. kobus 日本辛夷 M. praecocissima Temperate Asia Deciduous tree 4-6 
M. liliflora 紫玉兰 M. quinquepeta Temperate Asia and China Deciduous shrub 1-3 
M. sargentiana  凹叶木兰  Temperate Asia and China Deciduous tree 8-20 
M. sprengeri 武当木兰 M. diva Temperate Asia and China Deciduous tree 10-20 
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M. biondii 
 
M. sprengeri 
 
M. sargentiana 
 
Figure 1.3 Images illustrating the dried buds of three Flos Magnoliae species  
 17 
Table 1.5 Morphological differences between the medicinal buds of different Flos Magnoliae species (Han, 2005, Li et al., 1994b, Li et al., 
1994a, The Pharmacopoeia Commission of People's Republic of China, 2005). 
Name of species Shape Pedicle Lenticels 
Perianth-
segments 
Outer and inner whorls 
Small scaly buds between 
2 layers of bracts 
M. biondii Long ovoid Stouter Whitish 9 Polygeneous Yes 
M. denudata Long ovoid Stouter Brownish 9 Monogeneous No  
M. sprengeri Long ovoid Stouter Red brownish 10-12-15 Monogeneous No  
M. soulangeana Ovoid 
Short, with grey-whitish short 
tomenta 
Light brownish 6-9 Polygeneous No  
M. liliflora Long ovoid Short, with whitish or yellowish 
short tomenta 
Grey-whitish 9 Polygeneous Yes 
M. cylindrica 
Long ovoid or 
ovoid 
Short, with light yellowish short 
tomenta 
Grey-yellowish 9 Polygeneous No  
M. steboidii Ovoid Short, with yellowish short tomenta Grey-whitish 9 Monogeneous No  
M. sinostellata 
Long ovoid or 
ovoid 
Short, with yellowish short tomenta Grey-yellowish 12-18 Monogeneous Yes 
M. amoena Long ovoid 
Short, with grey-whitish short 
tomenta 
Grey-yellowish 9 Monogeneous No  
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1.1.3.2.2 Histological features  
The macroscopic form of the transverse sections of Flos Magnoliae shows one layer of 
epidermal cells. Cortex is relatively broad and vascular bundles are scattered. Phloem bundles 
are wide and xylem bundles are relatively narrow. Numerous stone cells and oil cells can be 
found in cortex and pith (Huang, 1990). A recent study identified the microscopic structures 
of the cuticle at the corolla surface of four Flos Magnoliae species, including M. biondii, M. 
denudata, M. sprengeri and M. liliflora (Tang, 2006).   
 
The macroscopic form of the powder of Flos Magnoliae has been listed in the Chinese 
Pharmacopoeia, as one of the major identification approaches in the monograph. Greyish-
green or yellowish-green powder has abundant non-glandular hairs, which are scattered and 
regularly broken. The inflated image of the basal cells looks like stone cells. The grouped 
stone cells are elliptical, with obliterated pit canals. The brownish-yellow secretion appears in 
the stone cells. There are some oil droplets in the numerous oil cells. The anticlinal wall of the 
epidermal cells is bead (The Pharmacopoeia Commission of People's Republic of China, 
2005). 
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1.1.4 Phytochemistry of Flos Magnoliae  
Efficient detection and characterisation of the components from Flos Magnoliae are important 
in understanding of chemical and pharmacological basis of Flos Magnoliae. Various 
analytical techniques, such as thin liquid chromatography (TLC), high performance liquid 
chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), and nuclear 
magnetic resonance (NMR) have been used in studying the chemical components of Flos 
Magnoliae (Su et al., 2001, Xu et al., 2003, Ma and Han, 1995, Yang et al., 1998). 
 
The major components of Flos Magnoliae can be grouped into two classes: lipid soluble and 
water soluble (Yang and Zhang, 1998). The lipid soluble, normally obtained by extraction 
with alcohol solvents, is rich in volatile oil and lignans (Yang and Zhang, 1998). In recent 
years, the water-soluble components of Flos Magnoliae, alkaloids and flavonoids, have also 
attracted some attentions (Chen et al., 1994b, Gao et al., 1994).  
 
1.1.4.1 Lipid-soluble components 
1.1.4.1.1 Volatile oil 
Volatile oils are typically very complex mixtures and contain many classes of compounds, e.g. 
hydrocarbons, alcohols, aldehydes, ketones, or esters. The authentic Flos Magnoliae has been 
suggested containing more than 1% of volatile oil (The Pharmacopoeia Commission of 
People's Republic of China, 2005). The principle constituents of the volatile oil are 
bicyclogermacrene, bornyl acetate, calarene, camphene, camphor, caryophyllene, cineol, citral, 
citronellol, cymene, diethyl phthalate, elemol, eudesmol, farnesol, geraniol, limonene, linalool, 
methyl eugenol, methyl heptenone, muurolene, myrcene, nerolidol, pinene, sabinene, 
terpinene, tert-butylbenzene, and torreyol, which consist of more than 93% of the total 
volatile compositions (Chen et al., 1994a) (Figure 1.4). 
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The yield of volatile oil varies with the species, growing locations and collecting seasons (Hu 
and Wu, 1995). Mass spectrometry, coupled with gas chromatography (GC-MS), has been 
demonstrated to be a valuable analytical technique for characterisation of volatile oil from 
Flos Magnoliae (Table 1.6). Quantitative evaluation of volatile ingredients in different species 
from Magnolia spp. have been intensively studied (Nagasawa et al., 1969). The routine 
methods of steam distillation and solvent extraction have been applied to its volatile oil 
analysis. In addition, a supercritical fluids (SCF) method has been employed to extract the 
volatile oil compounds from two Flos Magnoliae species, M. biondii and M. liliflora, by 
supercritical carbon dioxide (SCCO2) (Zhang, 1999, Zhang et al., 2005b). The result showed 
that extraction rate of SCCO2 flow was 3.8 - 4.2%, which was more than extraction by steam 
distillation (2.4%). At the same time, 54 components from the SCCO2 extract of M. biondii 
were determined in comparison with the volatile oil by steam distillation extract, which 
contained 34 volatile compounds (Zhang, 1999). Differences of the main compounds from 
volatile oil from M. liliflora extracted by different methods have also been demonstrated 
(Table 1.7) (Zhang et al., 2005b). Previous research found that five Flos Magnoliae species, 
namely, M. biondii, M. denudata, M. cylindrical, M. amoena and M. liliflora have significant 
difference in volatile compositions, M. denudate contained highest content of volatile oil of 
4.5%, whereas M. liliflora was least (1.2%) (Hu and Wu, 1995, Yang et al., 1998). Meanwhile, 
the analysis of three species, listed in the Chinese Pharmacopoeia, found that M. biondii, M. 
denudata and M. sprengeri contained 91, 71 and 88 volatile components, respectively, and the 
contents of the major components were varying (Table 1.8) (Yang et al., 1998).  
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    Bicyclogermacrene              Bornyl acetate           Calarene 
 
 
         Camphene                 Camphor      Caryophyllene 
 
 
 
 
 
          1,8-cineole        Citral     Citronelleol 
 
 
 
 
Figure 1.4 Chemical structures of some identified volatile components from Flos Magnoliae  
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            Cymene          Diethyl phthalate                 Elemol 
 
 
            Eudesmol                Farnesol                 Geraniol 
 
 
             Linalool     Limonene   Methyl eugenol 
       Methyl heptenone                  Muurolene      Myrcene 
 
Continued Figure 1.4 Chemical structures of some identified volatile components from Flos 
Magnoliae  
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                 Nerolidol           α-pinene                             β-pinene          
 
 
 
 
               Sabinene            Terpinene             Tert-butylbenzene 
 
 
 
 
              Torreyol 
 
 
 
 
Continued Figure 1.4 Chemical structures of some identified volatile components from Flos 
Magnoliae  
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Table 1.6 Different GC-MS systems for analysis of the volatile components from Flos Magnoliae  
 Zhang et al. (1999) Wei et al. (2000) Yang et al. (1998) Ma et al. (2005) 
Model PH-5890 QP-5000 Pye-204 HP-6890 
Column 
HP1 (SE-30) 
60m×0.2mm 
DB-1 
30m×0.25mm 
SE-54 
30m×0.32mm 
HP-1NNoωax 
25m×0.2mm×0.25µm 
Temperature 
program  
Rise from initial 60 oC (held 
for 1min) to 240 oC at 
8oC/min (held for15min). 
Auxiliary oven：230 oC 
Rise from initial 60 oC to 
120 oC at 3oC/min, rise to 
160 oC at 1.5oC/min, rise to 
250 oC at 8oC/min, 
Auxiliary oven：230 oC  
 
Rise from initial 50oC to 
210 oC at 4oC/min  
  
 
Rise from initial 60 oC to 
80oC at 5oC/min (held for 
5min), decrease to 60 oC at 
5oC/min (held for 10min), 
rise to 230 oC at 10oC/min. 
Auxiliary oven：230 oC 
Carrier gas He He He He 
Pressure (kPa) 120 80 78.4 - 
Inject (µl) 0.2 1.0 0.2 0.2 - 0.4  
GC 
Distribution 10:1 10:1 40:1 80:1 
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Continued Table 1.6 Different GC-MS systems for analysis of volatile components from Flos Magnoliae  
 
 Zhang et al. (1999) Wei et al. (2000) Yang et al. (1998) Ma et al. (2005) 
Model PH-5972 QP-5000 MM-7070H PH-5973 
Interface 
temperature  
280 oC - - 240 oC 
Electron Energy 
(eV) 
70 70 70 70 
Scope (u) 12-550 40-400 20-350 20-4000 
MS 
Scanning speed 550 u/s - 1 s/dec - 
Major findings 
64 volatile compounds were 
identified. 
33 volatile compounds were 
identified. 
91 volatile compounds were 
identified. 
80 volatile compounds were 
identified. 
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Table 1.7 Comparison of the content of the major volatile components from M. liliflora using GC-MS  
Relative content (%) 
Retention time (min) Compound 
SCCO2 Steam distillation 
5.14 α-pinene 4.03 3.26 
6.14 Sabinene  7.61 7.62 
6.23 β-pinene 6.37 6.65 
7.49 1,8-cineole 17.88 17.13 
10.15 Camphor 4.75 4.71 
11.25 α-terpineol 3.55 3.74 
16.31 β-caryophyllene 2.03 1.50 
22.22 Farnesol 15.99 21.11 
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Table 1.8 Quantitative analysis of the total volatile oil and four volatile components from different Flos Magnoliae species using GS-MS 
Relative content (%) 
Name of species 
Total volatile oil content  
(%) α-pinene β-pinene Camphene 1,8-cineole 
References 
M. biondii  2.15 4.02 7.71 2.25 18.39 
M. sprengeri  1.70 9.65 13.62 0.99 0.24 
M. denudata  2.60 4.50 11.77 0.78 15.00 
(Yang et al., 1998) 
M. liliflora  1.2 - 2.02 - 13.39 
M. cylindrica  1.6 8.16 33.45 1.60 7.96 
M. amoena 2.3 6.37 10.97 2.13 25.35 
(Hu and Wu, 1995) 
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1.1.4.1.2 Lignans and neolignans 
Lignans and neolignans are optically active dimeric natural products formed essentially by the 
union of two phenylpropane (C6-C3) units, and widely distributed in the plant kingdom (Moss, 
2000). Lignans and neolignans have been considered as one of the major secondary 
metabolites found in genus Magnolia (Kakisawa, 1972). Over the last two decades, the 
methods of separation and isolation of lignans and neolignans from different Flos Magnoliae 
species have been established using different techniques, including TLC (Su et al., 2001), 
ultraviolet (UV) spectrometry (Ma and Han, 1995), HPLC (Fang et al., 2002) and NMR 
(Mitsuo et al., 1992a). Various lignans and neolignans, including fargesin, 
demethoxyaschantin, aschantin, pinoresinol dimethyl ether, magnolin, lirioresinol-β-
dimerthyl ether, fargesone A, fargesone B, denudatin B, magnosalin and magnoshinin have 
been identified (Jung et al., 1998, Kobayashi et al., 1996b, Kobayashi et al., 1998, Mitsuo et 
al., 1992a, Mitsuo et al., 1996, Pan et al., 1987). The chemical structures of some lignans and 
neolignans are shown in Figure 1.5. 
 
Recently, the bioactive compound, magnolin has been employed as a marker compounds for 
quality control of Flos Magnoliae using TLC and HPLC (The Pharmacopoeia Commission of 
People's Republic of China, 2005). The quantitative levels of magnolin and fargesin from 
three Flos Magnoliae sources have been analysed using TLC and HPLC as well (Xu et al., 
2003, Su et al., 2001, Fang et al., 2002). Magnolin and fargesin from M. biondii, M. denudata 
and M. sprengeri were determined by a HPLC method using C18 column and with the mobile 
phase consisted with acetonitrile and water (50:50, %-w:w) (Table 1.9) (Xu et al., 2003). 
Moreover, there are significant differences of the compositions of lignans and neolignans in 
different Flos Magnoliae species (Table 1.10). 
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      Magnolin         Fargesin      
 
               Pinoresinol dimethyl ether          Lirioresinol-β-dimerthyl ether 
                        Magnosalin             Magnoshinin 
 
Figure 1.5 Chemical structures of some identified lignans and neolignans from Flos 
Magnoliae  
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            Fargesone A                           Fargesone B 
 
 
 
 
      Denudation B        Aschantin 
 
Continued Figure 1.5 Chemical structures of some identified lignans and neolignans from 
Flos Magnoliae 
 
 
Table 1.9 Quantitative analysis of magnolin and fargesin from three Flos Magnoliae species 
using HPLC (Xu et al., 2003). 
Name of species Replicates  Magnolin (%) Fargesin (%) 
M. biondii   5 batches 1.26 ~ 1.77 0.078~0.129 
M. denudata  2 batches 0.007 ~ 0.024  
M. sprengeri  1 batch 0.016  
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Table 1.10 Identified lignans and neolignans from different Flos Magnoliae species 
Name of species Compounds References 
M. biondii 
Biondinin B 
Biondinin E 
Pinoresinol dimethyl ether 
Fargesin 
Lirioresinol-β-dimerthyl ether 
Magnolin 
Demethoxyaschantin  
Fargesone A 
Fargesone B 
(Ma et al., 1996) 
M. denudata 
Licarin A 
Denudatin B 
(Iida et al., 1982, Kwon et al., 1999) 
M. liliflora 
Denudatin A 
Denudatin B 
(Iida and Ito, 1983) 
M. salicifolia 
Magnosalin 
Magnoshinin 
(Kimura et al., 1992) 
M. soulangeana 
Demethoxyaschantin  
Cyclohexadienone 
Denudatin A 
Denudatin B 
Saulangianin I 
Pinoresinol dimethyl ether 
(Abdallah, 1993) 
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1.1.4.2 Water-soluble components  
Three water-soluble compounds from aqueous extraction of Flos Magnoliae, including 
magnoflorine, biondnoid and ethyl-E-p-hydroxyl-cinnamate, have been isolated and their 
structures have been identified (Gao et al., 1994, Chen et al., 1994b) (Figure 1.6). However, 
the bioactivities of these compounds are still unclear.  
 
 
 
 
        Magnoflorine                                    ethyl-E-P-hydroxylcinnamate              
 
 
 
 
 
 
 
 
 
 
 
 
Biondnoid I 
 
 
Figure 1.6 Chemical structures of some identified water-soluble components from Flos 
Magnoliae 
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1.1.5 Pharmacological aspects of Flos Magnoliae 
The pharmacological actions of Flos Magnoliae have been extensively studied (Yang and 
Zhang, 1998). The main pharmacological actions of Flos Magnoliae include anti-
inflammation, anti-allergy, anti-angiogenesis, anti-proliferation, anti-hypertension, Ca2+ 
antagonist and anti-microbe activities (Bensky and Gamble, 1993). 
 
1.1.5.1 Anti-inflammation and anti-allergy 
The anti-inflammatory effects of Flos Magnoliae have been demonstrated by various in vivo 
and in vitro studies to be related to cellular events and inflammatory mediators during the 
acute or chronic inflammatory responses (Kim et al., 2003, Kim et al., 1999, Kimura et al., 
1992, Kobayashi et al., 1998).  
 
In vivo studies 
Several acute inflammatory animal models have been used for determination of the anti-
inflammatory or anti-allergic effects of Flos Magnoliae, including ear-swelling response 
induced by 2,4-dimethylphenol or compound 48/80 in WBB6F1 +/+ mice (Wang et al., 2000b, 
Kim et al., 1999), and anti-dinitrophenyl IgE antibody-induced passive cutaneous anaphylaxis 
(Kim et al., 1999). Functional study showed the remarkable inhibitions by Flos Magnoliae of 
the capillary permeability of blood vessels and degranulation of mast cells (Kim et al., 1999). 
Liang and Yang (2005) reported that Flos Magnoliae has the astringent action and capillary 
dilation, which protected the mucosal surface and improved local blood circulation resulting 
in the suppression of inflammation, when injected to chronic maxillary sinusitis rabbits. The 
anti-inflammatory effects of M. biondii on Freund’s adjuvant induced primary foot 
tumefaction on Wistar rats was studied (Wang et al., 2004a).  
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The active ingredients, magnoshinin and magnosalin have been shown to significantly inhibit 
croton oil-induced pouch granuloma formation and pouch exudation (Kimura et al., 1990, 
Kimura et al., 1991). Kimura et al (1990) suggesting a mechanism of selective inhibition of 
angiogenesis by magnosalin may be involved in the anti-inflammatory effects of Flos 
Magnoliae. Magnosalin and magnoshinin have also been demonstrated to induce fetal bovine 
serum (FBS) - stimulated and interleukin (IL)-1-alaph (IL-1α) - stimulated tube formations, 
which resulted in inhibition of endothelial cell proliferation (Kobayashi et al., 1996a, Kimura 
et al., 1992). These findings suggested that magnosalin and magnoshinin might have potential 
inhibitory effects on chronic inflammation. 
 
In vitro studies  
The anti-inflammatory effects of Flos Magnoliae are likely to be due to its effects on the 
secretion of the inflammatory and allergic mediators. Histamine is one of the most potent 
mediators that contributes to many processes of inflammation and hypersensitivity (Rang et 
al., 2003).  Recent studies found that the volatile oil from Flos Magnoliae inhibited the 
histamine release from mice’s swelling feet, which may cause decrease of capillary 
permeability (Wang et al., 2000c, Wang et al., 2000b). Similarly, the volatile oil from Flos 
Magnoliae has been found to inhibit Prostaglandin E2 (PGE2) formation from rat peritoneal 
macrophages (Lim et al., 2002), and other inflammatory mediators, such as platelet-activating 
factor (PAF), precursor of PAF phospholipase A2, IL-1α, nitric oxide (NO) and tumour 
necrosis factor-α (TNF-α) (Lim et al., 2002, Wang et al., 2002).  
 
Lignans and neolignans, including magnolin, lirioresinol-β-dimerthyl ether, pinoresinol 
dimerthyl ether, fargesin, demethoxyaschantin and aschantin, isolated from M. biondii, have 
been demonstrated to have potent PAF antagonistic activities (Pan et al., 1987). In addition, 
pinoresinol dimerthyl ether, magnolin, lirioresinol-β-dimerthyl ether were demonstrated 
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having inhibitory effects on TNF-α production in lipopolysaccharide (LPS) – stimulated 
murine macrophage cell line (Chae et al., 1998)  
 
A recent report from Korea suggested that the ethanol extraction of Flos Magnoliae provoked 
apoptosis of RBL-2H3 cells through mitochondria and caspase, which may also be associated 
with the anti-inflammatory effect of Flos Magnoliae (Kim et al., 2003). 
 
1.1.5.2 Anti-microbial and anti-fungal actions 
The decoctions of Flos Magnoliae inhibited many pathogenic fungi in vitro, which commonly 
cause dermatophytosis (Bensky and Gamble, 1993). In addition to the anti-fungal effects, one 
of the major Flos Magnoliae species, M. biondii, has been demonstrated to have potential 
anti-bacterial effects on Staphylococcus aureus, Beta Streptococcus and Diplococcus 
pneumonia et al (Wang and Li, 1999).  
 
1.1.5.3 Other effects  
Anti-hypertension 
The intravenous, intraperitoneal or intramuscular injection of Flos Magnoliae aqueous 
extraction reduced blood pressure in anaesthetised animals (Bensky and Gamble, 1993). 
However, it had no significant hypotensive effect on secondary hypertension in anaesthetised 
animals (Bensky and Gamble, 1993).  
 
Effects on the Uterus 
The decoction of Flos Magnoliae could stimulate the uterus of rabbits and dogs (Bensky and 
Gamble, 1993). 
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1.1.5.4 Toxicology 
There is little published toxicology data on Flos Magnoliae. Flos Magnoliae decoction 
administered intravenously in dog or rabbit in the doses of 1g/kg or 4.75g/kg, respectively, 
resulted in no mortality. The LC50 of ethanol extracts from two Flos Magnoliae varieties, 
which were from different locations of China (Henan or Sichuan Province), was 38.21g/kg or 
93.55g/kg in mice by oral administration, respectively (State Administration of Traditional 
Chinese Medicine "Chinese Materia Medica" Editorial Committee, 1998).    
 
For the subacute toxicological investigation, oral administration of 18g/kg (ethanol extraction) 
or 30g/kg (decoction) of Flos Magnoliae in rats for one month did not cause any 
haematological, clinical, chemical or histological alteration (State Administration of 
Traditional Chinese Medicine "Chinese Materia Medica" Editorial Committee, 1998).  
 
1.1.5.5 Adverse effects 
Reports of harmful effects of Flos Magnoliae are rare, although two cases in China, reported 
oedema and red wheals on the patients’ skin after oral administration of Flos Magnoliae 
decoctions (Zhang and Zhu, 1996). Further research found that alkaloids, tubocurarine and 
associated substances in Flos Magnoliae, may cause respiratory paralysis on experimenting 
animals (Dharmananda, 2004).  
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1.1.6 Clinical applications 
1.1.6.1 Single herb or phytochemical compounds  
The volatile oil of Flos Magnoliae has been demonstrated to produce symptomatic relief of 
seasonal allergic rhinitis and chronic allergic rhinitis (Gu et al., 1999). However, there is no 
report on randomised clinical trials for Flos Magnoliae as a single herb or herbal preparation.  
 
1.1.6.2 CHM formula  
On the other hand, the therapeutic efficacy of the CHM formulas and the commercial 
therapeutic products, which contained Flos Magnoliae, have been elucidated in several 
clinical studies over last decade (Table 1.11 and Table 1.12) (Chen and Li, 1998, Gu et al., 
1999, Zheng, 1996, Han, 1998, Luo, 2000, Xue et al., 2003b). Recently, a CHM formula, 
which contained Flos Magnoliae, has been demonstrated to produce symptomatic relief and 
improvement of quality of life for patients with hay fever in a randomised placebo controlled 
trial (Xue et al., 2003a).    
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Table 1.11 The compositions of the formulas and therapeutic products, which contained Flos Magnoliae, used for clinical application for rhinitis 
and sinusitis 
Name of formula Composition Additives (% - w/v) Indications Reference 
Xin-yi Nose Drop 
 
Flos Magnoliae                            60g 
Herba Centipedae                       180g 
Herba Menthae                           180g 
Radix Scutellariae                        60g 
Glycerol                                     200ml 
Tweenum-80    0.5% 
Seasonal and 
persistent 
allergic rhinitis 
and sinusitis 
(Luo, 2000) 
Compound Xinyi Nasal Drops  
 
Herba Houttuyniae                      15g 
Herba Centipedae                         9g 
Flos Magnoliae                             9g 
Herba Schizonepetae                    3g 
Radix Angelicae Sinensis             9g 
Herba Menthae                             6g 
Fructus Xanthii                            6g 
Glycerol    1% 
Seasonal and 
persistent 
allergic rhinitis  
(Li et al., 2000c) 
Xin-yi Volatile oil Injection Volatile oil of Flos Magnoliae  Tweenum-80    0.5% Seasonal 
allergic rhinitis  
(Hu et al., 1998) 
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Continued Table 1.11 The compositions of the formulas and therapeutic products, which contained Flos Magnoliae, used for clinical 
application for rhinitis and sinusitis 
Name of formula Composition Additives (% - w/v) Indications Reference 
Xin-yi Cang-er Tang I 
 
Flos Magnoliae                                       12g  
Fructus Xanthii                                       12g 
Radix Angelicae Dahuricae                    12g 
Rhizoma Et Radix Ligustici                   12g 
Rhizoma Chuanxiong                             12g 
Radix Platycodonis                                 10g 
Caulis Akebiae                                        10g 
Radix Et Rhizoma Glycyrrhizae               6g 
- 
Sinusitis (Chen and Li, 1998) 
 
Xin-yi Ping Feng San 
Radix Astragali                                     240g 
Rhizoma Atractylodis Macrocephalae  180g 
Flos Magnoliae                                     120g 
Fructus Xanthii                                       60g 
Rhizome Chuanxiong                             60g 
- 
Persistent allergic 
rhinitis  
(Gu et al., 1999) 
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Table 1.12 A review of clinical studies of Flos Magnoliae for rhinitis or sinusitis  
Study design 
Patients 
conditions 
Concentration of 
Flos Magnoliae 
Main outcomes 
References 
Randomised 
placebo 
controlled trial 
Seasonal allergic 
rhinitis (placebo 27 
and treatment, 28) 
2.25% 
After 8 weeks treatment, 89% of the patients completed the 
trial. Significant improvements of nasal or non-nasal 
symptomatic relief and quality of life in the treatment group 
compare with the placebo group. 
Eleven patients reported mild adverse event.  
(Xue et al., 2003b) 
Case study 
(placebo and 
treatment 
comparison) 
Rhinitis (placebo 
20, treatment 128) 
Nasal drop 
(12.5%) 
After three months treatment, the significant improvement of 
nasal symptoms of 92.5% of 128 patients, compare to the 
placebo group. 
(Luo, 2000) 
Case study 
Allergic rhinitis or 
chronic rhinitis 
Volatile oil 
(single herb) 
The nasal symptoms were relieved for 82% of 82 patient with 
allergic rhinitis and 66% of 18 patient with chronic rhinitis 
(Gu et al., 1999) 
Case Study 
Rhinitis and 
sinusitis 
Compound nasal drop 
(15.8%) 
After two sessions of treatment, compound Xinyi nasal drop 
were improve 86.3% of the patients with rhinitis or sinusitis. 
(Li et al., 2000c) 
Case study 
Acute and chronic 
sinusitis 
13.5% 
After three sessions of treatment, significantly inhibitory 
effects on nasal symptoms from more than 90% patients with 
sinusitis. 
(Chen, 1998) 
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1.2 Quality assessment of Chinese herbal medicine (CHM) 
1.2.1 Prevalence / popularity  
1.2.1.1 Complementary and alternative medicine (CAM) 
The term CAM, is often “ used interchangeably with traditional medicine in some countries, it 
refers to a broad set of health care practices that are not part of that country’s own tradition 
and are not integrated into the dominant health care system” by World Health Organization 
(WHO) (WHO, 2001, WHO, 2004a). The definition of CAM from National Centre for 
Complementary and Alternative Medicine (NCCAM), United States, is “ a group of diverse 
medical and health care systems, practices and products that are not presently considered to be 
part of conventional medicine” (NCCAM, 2002). The major therapeutical approaches 
involved in CAM therapies are shown in Table 1.13.  
 
In some Asian countries, CAM is the primary source of healthcare for up to 80% of the 
populations, such as China, North and South Korea and Viet Nam, and has been incorporated 
into the health system (Bagozzi, 1998). Meanwhile, CAM is also getting popular in the 
western countries in recent decades (Eisenberg et al., 1998, Eisenberg et al., 1993, Barnes et 
al., 2004, Thomas et al., 2003, Thomas et al., 2001, Yamashita et al., 2002). Recent surveys 
from United States in 1990 and 1997 found increased use of CAM therapies during the 
previous year from 33.8% to 42.1% (Eisenberg et al., 1998, Eisenberg et al., 1993). The 
national population health surveys in United States in 2002 found 62% of the interviewers had 
been used some forms of CAM (Barnes et al., 2004). Similar trends of the popularity of the 
use of CAM have been revealed in surveys from other countries, including United Kingdom 
(Thomas et al., 2003, Thomas et al., 2001), Canada (Ramsay et al., 1999) and Japan 
(Yamashita et al., 2002). In Australia, the population used the CAM in last 12 months, 
increased from 48.5% in 1993 (MacLennan et al., 1996) to approximately 52% in 2000 
(MacLennan et al., 2002) and 2004 (MacLennan et al., 2006), based on the Omnibus Health 
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Surveys conducted in the state of South Australia. Recent study also found more than 75% of 
general practitioners had recommended their patients to a CAM therapist in the state of 
Western Australia in 1998 (Hall and Giles-Corti, 2000). Due to the considerable increase of 
CAM usage, the global market of CAM has gained dramatically. For instance, in United 
States, US$21.2 billion has been spent on the CAM related market in 1997 (Eisenberg et al., 
1998). In Australia, the annual cost for CAM in 1993 was AU$621 millions (MacLennan et al., 
1996), which has been increased to AU$2.3 billions in 2000 (MacLennan et al., 2002). 
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Table 1.13 The major therapeutic approaches of CAM (NCCAM, 2002). 
Catalogues Therapies and techniques 
Alternative medical systems 
 Homeopathic medicine 
 Naturopathic medicine 
 Traditional Chinese Medicine 
 Chinese herbal medicine (CHM) 
 Acupuncture 
 Remedial massage 
 Qi gong  
 Ayurveda (Traditional Indian Medicine) 
 Diet and herbal remedies 
 Yoga 
Mind-body interventions  Patient support groups 
 Cognitive-behavioural therapy 
Dietary supplements 
 Vitamins 
 Minerals  
 Herbs or other botanicals 
 Amino acids 
 Other natural products 
Manipulative and body-based methods 
 Chiropractic  
 Osteopathic 
 Massage 
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1.2.1.2 Herbal medicine (HM) 
HM is one of the important therapeutical approaches of CAM. It includes western herbal 
medicine (WHM), Chinese herbal medicine (CHM), Ayurvedic and medicinal herbal 
materials and products from different countries (Wohlmuth et al., 2002). The application of 
HM has a long history in many eastern countries, such as China, India, Vietnam, Korea, and 
Japan, and it also gains popularity in many western countries, such as Australia, New Zealand 
and United States (MacLennan et al., 2006, Eisenberg et al., 1998, Barnes et al., 2004, 
Thomas et al., 2003, Thomas et al., 2001, Ramsay et al., 1999, Yamashita et al., 2002, 
Bagozzi, 1998). In Australia, a public survey found 26% of CAM users in South Australia in 
1993 had been prescribed HM (MacLennan et al., 1996). 
   
Western herbal medicine (WHM) 
WHM, including botanical sources of popular western herbs, which contain active ingredients 
or herbal drug preparations, has been used in Europe, U.S.A., Australia and other counties 
(EMEA, 2001).     
 
Chinese herbal medicine (CHM) 
CHM, including Chinese herbal materials and products of Chinese patent herbal medicines, 
has been used in China for more than 2000 years (Bensky and Gamble, 1993). More than 5000 
medicinal herbs have been documented (SATCM, 2000) and 992 herbs and herbal patent 
products are listed in the current Chinese Pharmacopoeia (The Pharmacopoeia Commission of 
People's Republic of China, 2005). 
 
Global growing of HM  
The global market of herbal medicines has increased dramatically, which is in the range of 
US$ 16-20 billion per year (Mahady, 2001). China, has a US$1.8 billion HM manufacturing 
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industry (Bagozzi, 1998). In UK, HM market represents an important share of the 
pharmaceutical market, with 57% of annual retails, which was in the range of £115 million in 
2000 (Barnes, 2003a). In 2000, Korea exported HM approximately about US$7.4 million and 
imported US$80.6 million (Choi et al., 2002). Meanwhile, the HM market of Japan in 2000 is 
worth about US$2.4 billions (Bagozzi, 1998). With the significant increase in the use of HM, 
more countries have committed to develop better access to HM with improved quality and 
efficacy.  
 
1.2.2 Complexity of CHM 
Herbs, as used in CHM, include barks, duramen, flowers, flower-buds, fruits, leaves, petals, 
roots, root-barks, seed and stems (The Pharmacopoeia Commission of People's Republic of 
China, 2005). They can contain a single herb, but more commonly several herbs in order to 
achieve complementary effects (Liang et al., 2004). Current herbal products are existed as the 
forms of raw herbs or herbal extracts that are often maintained after extracted with water, 
alcohol or other different solvents to achieve better therapeutic effects (Lu, 2003). The 
complexity of raw herbs and herbal products often cause the difficulties to identify or 
determine the bioactive components for clinical application (Rousseaux and Schachter, 2003). 
Alkaloids, coumarins, flavonoids, lignans, neolignans, terpenoids, fatty acids, sterols, 
glycosides, saponins, tannins and terpenens have been found as the bioactive components of 
herbal products (State Administration of Traditional Chinese Medicine "Chinese Materia 
Medica" Editorial Committee, 1998). A number of intrinsic as well as extrinsic factors have 
significant effects on the botanical quality, in terms of the yields of bioactive components and 
potencies of bioactivities (Figure 1.7).  
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Figure 1.7 The factors may affect the quality of CHM  
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1.2.2.1  Botanic sources  
1.2.2.1.1 Species and varieties differences 
More than 800 raw herbs, which are derived from thousand of botanic sources, can be found 
in the global CHM market (Li, 1996). Based on the existing evidences from academic and 
authoritative references, 522 herbal products have been included the authentic species and 
listed in the Chinese Pharmacopoeia (The Pharmacopoeia Commission of People's Republic 
of China, 2005). Moreover, British Herbal Pharmacopoeia (BHMAPublications, 2000) and 
American Herbal Pharmacopoeia (AHP, 2004) have been advocated the authentic botanic 
origins of 169 and 300 monographs, respectively. Frequently, more than one botanic species 
or varieties are named in a CHM scientific name (Latin name), which are commonly labelled 
for the herbal products in the global market. Such clinical practices of using different but 
related botanic species or varieties that have the same pharmaceutical names have created 
difficulties for CHM evaluation and identification.  
 
Firstly, the molecular profiles of different species and varieties are varying. Recent studies 
demonstrated that different Rhizoma Atractyloids (Cang-zhu) sources, which were found in 
the market, came from either the genuine source of plants Atractylodes lancea and A. 
chinenesis, or the three substitutes or adulterants (A. koreana, A. ovata and A. japonica), based 
on their DNA fingerprinting profiles (Ren et al., 2000, Mizukami et al., 2000, Kohjyouma et 
al., 1997). The significant genetic diversities also have been found with eight species in plants 
of Isodon (Schrad. Ex Benth.) Kudo (Xiang-cha-cai), a commonly used CHM (Fang et al., 
2003). Radix Astragali (Huang-qi), regarded as one of the most important CHM for Qi 
deficiency syndromes, has been used as CHM for more than 2000 year in China. The similar 
genetic relationships of four commonly used Astragalus species under the same CHM 
pharmaceutic name, Radix Astragali (Huang-qi), were recently sequenced and evaluated (Ma 
et al., 2000b) Fu et al (1999) reported the significant genetic differences between three 
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Codonopsis spp., including C. tangshen, C. modesta, and C. nervosa var. macrantha, which 
are known as the botanic sources of CHM Radix Codonopsis Pilosulae (Dang-shen). 
 
Furthermore, the bioactive chemical compositions of medicinal plants vary from species to 
species, varieties to varieties, within or without a genus as demonstrated by the presence of 
structurally different ephedrine alkaloids from two different species of Herba Ephedrae (Ma-
huang), Ephedrae sinica and E. aspera (Schaneberg et al., 2003). This significant variation in 
bioactive chemicals was also revealed in recent study on Magnesium tanshinoate B (MTB), 
Danshensu, Isotanshinon IIA, and Cryptotanshin I, after analysis of 57 batches of Radix 
Salviae Miltiorrhizae (Dan-shen) species or varieties, using a HPLC method (Zhang et al., 
2002a). Significant differences of the content of two anti-convulsive components, α-asarone 
and β-asarone, from three Rhizoma Acori (Shi-chang-pu) species, including Acori gramineus, 
A. calami and Anemone altaica, were investigated using RP-HPLC (Ke and Fang, 2004). The 
findings indicated that the contents of α-asarone and β-asarone of A. gramineus were 1.967% 
and 0.317%, respectively, while as 0.070% of α-asarone and 0.018% of β-asarone from A. 
calami, were detected. However, no α-asarone and β-asarone were detected from Anemone 
altaica, which was suggested as the adulterant of Rhizoma Acori (Shi-chang-pu). 
Phellodendron amurense and P. chinense have been recognised as the botanic sources of 
Cortex Phellodendri (Huang-bai), which was clinically applied for jaundice and morbid 
leucorrhoea caused damp-heat, urinary infection, oedema, consumptive fever, night sweating 
and skin infection (Bensky and Gamble, 1993). Ma et al (2006) reported that the content of 
major bioactive compound, obaculactone, was 0.269% from P. amurense and 0.154% from P. 
chinense using RP-HPLC method. Wang et al (2005) analysed the content of α-ligustilide 
from three Radix Angelicae Sinensis (Dang-gui) varieties from Gansu province, China. The 
range of the content of α-ligustilide from three Angelica sinensis was from 1.69% to 3.77%. 
Radix Ligustici Chuanxiong (Chuan-xiong), which has been used to invigorate the blood, has 
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also been found to contain α-ligustilide (Wang et al., 2006a). Recent study found that the 
content of α-ligustilide were varying between the Chinese species, Ligusticum chuanxiong 
(0.532 – 1.482 %), and the Japanese species Cnidium officiniale contained lower content of α-
ligustilide, ranged from 0.059 – 0.761% (Wang et al., 2006a). Furthermore, recent study 
demonstrated differences of the content of ferulic acid, another bioactive compound from 
Radix Ligustici Chuanxiong (Chuan-xiong) between the Chinese species (0.6530 – 1.3271%) 
and the Japanese species (0.7360 – 0.9507%) (Wang and Kuang, 2002). Flos Chrysanthemi 
Indici (Ye-ju-hua), one of the commonly used CHM for respiratory diseases, contained anti-
biotic compound cyclohexanecarboxylic acid. It has been elucidated differences of the content 
of cyclohexanecarboxylic acid in 14 Chrysanthemum indicum varieties in China (Tan et al., 
2004). Similar variation also appeared in protocatechuic acid in five Schisandra chinensis 
varieties, as the botanic sources of Fructus Schisandrae Chinensis (Wu-wei-zi) . The highest 
content of protocatechuic acid was 0.276% from the Korean variety, while as the lowest 
content was 0.099% from one of the Chinese varieties, grown in Hebei Province (Xu and 
Zhao, 2004). The previous study on selected 23 Radix Sophorae Flavescentis (Ku-shen) 
varieties from Sophora flavescens showed that oxymartine contents ranged from 1.25% to 
3.63% (Zhang et al., 2004). Oxymartine has been known as one of the bioactive compounds 
for anti-inflammatory, anti-arrhythmic and anti-fungal effects. Based on the Chinese 
pharmacopeia (The Pharmacopoeia Commission of People's Republic of China, 2005), one of 
the well-known CHM Radix Astragali (Huang-qi) are the dried roots from two species, 
Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) and A. membranaceus 
(Fisch.)Bge. The varying quantities of one of the key bioactive compounds, astragaloside IV, 
were demonstrated between two Radix Astragali (Huang-qi) species (Zhang et al., 2005c, Xu 
et al., 2005). Previous study on the quality of Radix et Rhizoma Rhei (Da-huang) species, 
including Rheum palmatum L., R. tanguticum and R. ficinale showed that content of aloe-
emodin ranged from 0.28% to 0.56%, content of rhein ranged from 0.32% to 0.84%, content 
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of emodin ranged from 0.16% to 0.61%, content of chrysophanol ranged from 0.44% to 
1.33%, and content of physcion ranged from 1.74% to 3.69% (Lin et al., 2005). Thus, to 
insure the chemical consistency of a CHM, it is necessary for establishment of the chemical 
profiles of the medicinal sources of different species and varieties.  
 
Although the evidences of differences of the pharmacological functions among the botanical 
sources of CHM are still lacking, the changes of chemical compositions, which are the 
foundation of pharmacological actions of CHM, suggest varying efficacies of their 
bioactivities. Due to the rapid development of isolation and separation techniques of bioactive 
constituents from CHM, there are increasing interests in the researches of the therapeutic 
effects of active components from various CHM species (Choi et al., 2002, Li, 2003). As 
mentioned before, the considerable diversity of the quality and the quantity of chemical 
compositions from various Flos Magnoliae species may cause differences of the 
pharmacological effects. However, such systematic research on evaluation of the 
pharmacological actions by Flos Magnoliae sources has not been established.  
 
1.2.2.1.2 Wild and domesticated populations 
Due to the elevated pressure on the protection of natural ecosystems, increased harvesting of 
domesticated population of CHM has been highly recommended and developed (Zou, 2000). 
Genetic variation occurred in the process of domesticated populations may alter the amount 
and structure of chemical compositions of CHM populations. This chemical variation of 
quantities and qualities was shown in previous studies, such as on artemisinin, the anti-
malarial agent, in Artemisia annua populations of CHM Herbal Artemisiae Annuae (Qing-hao) 
(Cao and Chen, 1996). The highest content of artemisinin in the domesticated Artemisia 
annua was 0.6%, which was higher than the content of artemsinin from the wide populations. 
In contrast, the quantitative chemical variations are superior in wild than in domesticated 
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populations in some CHM species, for instance, on ergosteral in Cordyceps (Dong-chong-xia-
cao) (Li et al., 2001b). Xie et al (2004) also revealed that the content of bioactive compound, 
gastrodin, was higher in the wild Rhizoma Gastrodiae (Tian-ma) species than the 
domesticated populations.  
 
1.2.2.1.3 Substitutes and adulterants 
When adverse effects from CHM products are reported, often they are the results of the 
occurrence of substitutions or adulterations (Ernst, 2004). The failure to sufficiently guarantee 
the correct botanical identity has been revealed as one of the most frequent limitations of 
botanical quality assurance (Leon et al., 2004). Even since Chinese started employing CHM to 
cure diseases two thousand years ago, choosing effective and safe botanic sources as herbal 
remedies had already been a big issue that appeared in some reputable CHM references (Yu et 
al., 1999).  
 
In some cases, the authorised CHM species may be substituted by an inferior species. A 
number of cases presented serious consequences of Aristolochia substitutions. Investigation of 
the 33 cases of nephropathy in Belgian revealed that Aristolochia westlandii, which contained 
a known nephrotoxin aritolochia acid, had been substituted for Radix Stephaniae Tetrandrae 
(Han-fang-ji), dried roots of Stephania tetrandra populations (Depierreux et al., 1994). Based 
on the Chinese Pharmacopoeia, Clematis armandii and C. montana are the authorised species 
for the CHM Caulis Clematidis Armandii (Chuan-mu-tong). A. manshuriensis, as the 
substitutes of Caulis Clematidis Armandii (Chuan-mu-tong), have been reported to cause 
terminal kidney failure in Canada (Health Canada, 2001b, Health Canada, 2001c, Health 
Canada, 2001d, Health Canada, 2001a). Recently, significant differences of the qualities and 
quantities of four bioactive compounds, including cinnamaldehyde, cinnamic acid, cinnamyl 
alcohol and coumarin, were elucidated in CHM Cortex Cinnamomi Cassiae (Rou-gui), from 
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13 authorised Cinnamomum cassia and 16 substitutes or adulterants including C. cassia, C. 
wilsonii, C. japonicum, C. burmannii, C. mairei and C. loureirii (He et al., 2005).  
 
1.2.2.2 Parts of plants 
Use different parts of plants may alter the quality of CHM, in which the site of biosynthesis, 
accumulation and storage are usually varying. An example of organ-specific accumulation as 
well as species specificity is that of the compounds considered responsible for the anti-
inflammatory effect of Radicis Angelicae Sinensis (Dang-gui). Different plant parts of 
Angelica sinensis are used for varying medical conditions. The entire root, Radicis Angelicae 
Sinensis, is usually prescribed for tonifying the blood and regulating the menses. The body of 
the herb, Corpus Radicis Agnelicae Sinensis (Dang-gui-shen), has effects on tonifying and 
invigorating the blood. The head of the herb, Caput Radicis Agnelicae Sinensis (Dang-gui-
tou), is suggested to be the most tonifying part, and worst in blood movements. On the other 
hand, the tail, Extremitas Radicis Agnelicae Sinenesis (Dang-gui-wei), is considered as the 
least tonifying part, but is most powerful in moving the blood. Previous studies indicated the 
different content of the bioactive compounds derived from four sites of the herb (Table 1.14) 
(Qiao and Xiang, 2005, Wu et al., 2004b). On the basis of the quantitative analysis, significant 
differences of the main flavonoids were demonstrated from five Herba Epimedii (Yin-yang-
huo) species, included Epimedium brevicornum, E. sagittatum, E. pubescens, E. wushanense 
and E. koreanum (Guo and Xiao, 1996, Li et al., 1996, Guo et al., 1996). The components of 
flavonoids between five sources of Herba Epimedii (Yin-yang-huo) had significant differences 
between rhizome and roots (Guo and Xiao, 1996).  
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Table 1.14 Quantitative analysis of the contents of the bioactive components from different 
Angelica sinensis sites (Qiao and Xiang, 2005, Wu et al., 2004b). 
The level of the compounds 
The sites of the herb 
Ferulic acid 
(%, w/w) α-pinene β-ocimene 
Radicis Angelicae Sinensis 0.1190 ** * 
Corpus Radicis Angelicae Sinensis 0.0813 *** ** 
Coput Radicis Angelicae Sinensis 0.1085 **** **** 
Extremitas Radicis Angelicae Sinensis 0.1262 * *** 
The levels of the compound are ****>***>**>*. 
 
Similar findings are also showed in volatile compositions of CHM, for instance, Fructus 
Alpiniae Oxyphyllae (Yi-zhi-ren), the fruits of Alpinia axyphylla. The content of volatile oil 
from the fruit was five times higher than it from the shell of the fruit, 1.77% and 0.38%, 
respectively (Yang and Xing, 2003). Asafum sieboldii, regarded as the botanic origin of Herba 
cum Radice Asari (Xi-xin), were used for clinical application of headache. The volatile 
composition accumulate and storage in the sites of roots and stems, where chemical 
biosynthesis usually takes place, the content of that was more than seven times higher than the 
content of the volatile oil in the leaves and fruits (Xia, 2005). Palmatic acid and linoleic acid 
are present in Caulis Lonicerae (Ren-dong-teng), the stems of Lonicera japonica, and Flos 
Lonicerae (Jin-yin-hua), the flowers of the same plant. Thirty-six volatile compounds were 
determined using GC-MS, whereas all 18 of them were both found in Caulis Lonicerae (Ren-
dong-teng) and Flos Lonicerae (Jin-yin-hua) (Li et al., 2003).  
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1.2.2.3 Diurnal and seasonal variations 
Due to the influences on accumulation and storage of the chemical synthesis, diurnal and 
seasonal variations are the other factors affecting the quality of CHM. Based on the different 
accumulation of bioactive compounds on the medicinal plants, the best harvesting and 
collecting time can occur at any time during the plants’ growth. The harvesting and collecting 
period usually takes place before or at the time of flower blossoming (Bensky and Gamble, 
1993). Previous studies elucidated that the diurnal and seasonal variations of harvesting and 
collecting can vary the quality of CHM. For example, the middle of April and the end of May, 
when stems have a purple hue, were considered as the best season for harvesting for Radix 
Ligustici Chuanxiong (Chuan-xiong), based on the content of bioactive compounds, 
senkyunolide A, coniferyl ferulate and Z-ligustilide (Li et al., 2006). The anti-oxidant 
compound luteolin-7-O-glycoside, derived from Dracocephalum rupestra (Yan-qing-lan), was 
reached highest level before blossoming (Ren et al., 2004). In other cases, medicinal plants are 
harvested immaturely, such as Pericarpium Citri Reticulatae Viride (Qing-pi), dried barks of 
Citrus spp., and Fructur Immaturus Citri Aurantii (Zhi-shi), dried fruits from Citrus aurantium 
(Bensky and Gamble, 1993).  
 
Thus, it is essential to establish the time for harvesting and collecting, when the highest 
amount of the bioactive compositions of CHM is achieved. However, the correlation of the 
content of the bioactive compounds and the seasons of harvesting and collecting are hardly 
available for most CHM. In such cases, the medicinal parts harvest traditionally, when the 
specific site reach its finest level of development (Bensky and Gamble, 1993). In the majority 
cases, roots and rhizomes are collected at the beginning of the spring or the end of the summer, 
barks are collected in spring, the leaves and whole plants are collected before or at the flower 
blossoming stage, and fruits and seeds are collected when they are fully ripe (Nanjing 
Botanical Garden, 2006). 
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1.2.2.4 Environmental factors 
Besides the intrinsic factors, the quality of CHM may affect by a number of extrinsic factors 
as well, such as the environmental factors during the cultivation process. Certain amount of 
sunlight and moisture, optimal soil conditions, appropriate climate and adequate nutrients are 
necessary for the medicinal plants to achieve the best quality. Existing classic and authorised 
CHM literatures have suggested the suitable area for the cultivation of the particular CHM, 
based on the differences in climate and geography. For instance, the high attitude mountain 
areas are the most suitable sites for the cultivation of Rhizoma Coptidis (Huang-lian) and 
Bulbus Fritullariae Cirrhosae (Chuan-bei-mu), where as the best quality of Herba Cistanches 
(Rou-cong-rong) and Herba Cynomorii Songarici (Suo-yang) from the desert. Furthermore, 
some of the CHM are suitable grown from damp areas, for example, Radix Rehmanniae 
Glutinosae (Sheng-di-huang) and Flos Carthami Tinctorii (Hong-hua) (Bensky and Gamble, 
1993, The Pharmacopoeia Commission of People's Republic of China, 2005, Yu et al., 1999). 
 
Resent researches studied on the relationship between the environmental conditions of growth 
and the quality of the chemical properties of soil for the cultivation of Panax notoginseng, 
medicinal sources of Radix Notoginseng (San-qi) in Yunan and Guangxi, China. The neutral 
weakly acidic soil with loam clay, and with carbonate was suggested as the most suitable soil 
conditions for Radix Notoginseng (San-qi) growing (Cui et al., 2005). The bioactive 
compound, berberine, was analysed for establishment of the most optimal environmental 
conditions for cultivation of Rhizoma Coptidis (Huang-lian), dried plant of Coptis chinensis. 
It was recommended that the low shading ratio was more suitable for Coptis chinensis, to 
obtain the better quality of Rhizoma Coptidis in the harvest (Guo et al., 2004b). It also has 
been reported that the proper shading method and the optimal level of fertilizer nitrogen was 
needed for achieving the highest content of the bioactive compounds, citronellol and geraniol, 
of Geranium (Tian-zhu-kui) (Ram et al., 2003). 
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1.2.2.5 Manufacturing factors  
Some manufacturing factors also affect the quality of CHM, such as post-harvest processing, 
shipping and storage. Those extrinsic factors can affect the morphological features and the 
chemical compositions of the medicinal plants.  
 
One of the reasons for processing the medicinal materials is to increase the potency. Proper 
processing is also aimed to minimize side effects or alter a substance’s properties to meet the 
particular clinical requirements. Dried roots and rhizomes of Polygonum cuspidatum is one of 
the commonly used CHM, Rhizoma Picrorhizae (Hu-zhang). Different manufacturing 
processes of Rhizoma Picrorhizae (Hu-zhang), including products fried with salt, vinegar or 
wine, have been found in the market and used for different clinical applications (Bensky and 
Gamble, 1993). Resent study found that among three processed products, the products 
processed by salt contained the highest level of piceid (1.114%), which has effects on 
reducing blood fat and thrombosis (Jiang et al., 2004a). The findings are in line with the 
suggestions appeared in the classic and authorised literatures. On the other hand, overheat 
process lead to the low quality of Fructus Arctii (Niu-bang-zi). Zhang (2004) indicated that 
crude Fructus Arctii (Niu-bang-zi) contained higher content of arctiin, as the anti-cancer and 
anti-biotic agent, than the products which have been boiled or burnt.  
 
Meanwhile, differences of the chemical contents of same CHM products from different 
marketing sources have been analysed by a number of studies. For instance, the contents of 
glycyrrhizin from five Radix Glycyrrhizae (Gan-cao) samples from different pharmaceutical 
suppliers were varying, ranged from 5.58% - 9.81% (Liu et al., 2003a). The poisonous 
compounds, aconitine and hypaconitine have been found in both Radix Aconiti Preparata 
(Chuan-wu) and Radix Aconiti Kusnezoffii (Cao-wu). The content of aconitine from three 
commercial suppliers ranged from 0 - 0.000233%, while the content of hypaconitine from 
 57 
Radix Aconiti Preparata (Chuan-wu) ranged from 0 – 0.007462% (Zhang and Feng, 2005). In 
the other hand, HPLC method was employed for determined the aconitine and hypaconitine, 
derived from Radix Aconiti Kusnezoffii (Cao-wu), from three suppliers in the market, ranged 
from 0 – 0.002100% and 0.010231% – 0 .028950%, respectively (Zhang and Feng, 2005). 
 
1.2.2.6 Contaminations  
It’s likely that unintentional or accidental substances may contaminate the CHM products. 
Potential contaminations include microbial and chemical agents (pesticides and herbicides) 
during any stage of CHM production. In addition, the heavy metal is also regarded as other 
major concerns, which may lead to poor quality and unsafe CHM application.  
 
1.2.2.6.1 Microbial  
Contamination of bacterial and fungal of CHM may cause health risk and financial loss. The 
improper sanitary conditions during post-harvesting process, storage, packaging and shipping 
usually result in the certain level of microbial contamination, which cannot meet the authorise 
standards. Some of the microbial contaminations, even at very low level, can induce server 
infections. A fluorescent staining method was employed for rapid assessment of total bacterial 
and esterase-active bacteria level of CHM (Nakajima et al., 2005). The outcomes indicated 
that the total bacterial from Radix Ginseng (Ren-shen) reached more than 107 cells/g and 
almost 106 cells/g of esterase-active bacteria.  
 
Furthermore, bacterial and fungal endotoxins can also cause harmful effects. For example, 
Aflatoxin, which is produced by a fungus, Aspergillus, is one of the most harmful substances 
for human being. Acute necrosis, cirrhosis and carcinoma of the liver exhibited by 
hemorrhage, acute liver damage, edema, alteration in digestion, absorption and metabolism of 
nutrition will be produced by exposure of high level of Aflatoxin, including Aflatoxin B1 and 
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B2, and Aflatoxin G1 and G2 (Smith et al., 1975). Recently, the contamination level of 
Aflatoxin in nine CHM patent product and 14 crude herbs were investigated using HPLC 
method (Zheng et al., 2005). Four patent products of nine were found contained Aflatoxin B1 
and B2, whose levels ranged from 0.48-1.21µg/kg and 0.49-2.43µg/kg, respectively. Only one 
of the 14 crude CHM herbs, was contained Aflatoxin B1 (1.54 µg/kg). 
 
1.2.2.6.2 Pesticide and herbicides 
Different pesticides and herbicides contamination of medicinal plants during the cultivation 
process is another safety concern. A pesticide can be used against pest, including insects, plant 
pathogens and microbes, and the herbicides are employed against weeds. Not only pesticides 
and herbicides are dangers to the environment, the pesticides and herbicides residue on CHM 
are also harmful to the health of general public. There are evidences that higher chances of 
brain cancer, leukaemia and birth defects after exposure to pesticides and herbicides 
(Hepworth et al., 2006, Lee et al., 2005, Miligi et al., 2006, Mahajan et al., 2006, Garry et al., 
2002). 
 
In China, a study employed multiresidue analytical method was applied for analysis of the 
organochlorine pesticides from CHM products (Hao and Xue, 2005). Thirteen organchloride 
pesticides from CHM products were examined by the SCF extraction followed by GC-MS 
confirmation method (Ling et al., 1999). CHM products, including Panax. notoginseng, 
botanical origins of Radix Notoginseng (San-qi); Panax. quinguefolium, botanical origins of 
Radix Panacis Quinquefolii (Xi-yang-shen); Paeonia lactiflora, botanical origins of Radix 
Paeoniae Alba (Bai-shao) and Angelica. sinensis, botanical origins of Radix Angelicae 
Sinensis (Dang-gui) were contained ranged from 0 - 3.6 × 10-10g of metalaxyl residues (Dong 
et al., 2004).  
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1.2.2.6.3 Heavy metals 
Heavy metal contamination can happen at any stages of the cultivation and manufacturing 
stages. Clinical consequences of heavy metal poisoning have been documented by a number 
of studies. 
 
Arsenic (As) 
Short-term exposure of As may cause neuropathy and megaloblastic anemia, and long-term 
exposure can lead to the development of cancer (Lerman et al., 1980, Tapio and Grosche, 
2006). In Singapore, 74 cases and 3 cases were reported for As poisoning, in 1975 and 1998, 
resulting to two patients died, after taking various CHM preparation, mainly for asthma 
treatment (Tay and Seah, 1975, Wong et al., 1998b, Wong et al., 1998a).  
 
Cadmium (Cd) 
Nephropathy and emphysema are usually seen after short-term exposure of Cd. Long-term 
exposure also can induce the development of cancer (Lee and White, 1980). In 1996, a 34-
year-old female patient was reported have permanent nephrogenic diabetes insipidus, caused 
by Cd poisoning, after three months CHM mixture treatment (Wu et al., 1996a). 
 
Mercury (Hg) 
The major symptoms and signs of Hg poisoning are depression, irritability, forgetfulness, 
confusion, tremor, sensory disturbances, visual deficits, hearing loss, movement disorders and 
cognitive disturbances (Magos and Clarkson, 2006). In Hong Kong, one case reported that a 
CHM mouth spray was responsible for the Hg poisoning for a five-year-old male patient, who 
recovered in two weeks (Li et al., 2000a). Unfortunately, it was reported that three Hg 
poisoning cases led to two death in United States (Kang-Yum and Oransky, 1992). 
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Lead (Pb) 
Pb poisoning leads to the gastrointestinal and neurologic symptoms for the adults, and lead 
encephalopathy, including lethargy, seizures, coma and death, for the children (Lidsky and 
Schneider, 2006, Toscano and Guilarte, 2005, Papanikolaou et al., 2005). A number of Pb 
poisoning cases, which caused by CHM, have been reported since 1977 (Lightfoote et al., 
1977, Chan et al., 1977, Levitt et al., 1984, Yu and Yeung, 1987, Markowitz et al., 1994, Wu 
et al., 1996b). Most of the patients were fully recovered, however, a two-months-old male 
infant was suffered by mildly delayed development (Yu and Yeung, 1987).  
 
Thallium (Tl) 
Gastrointestinal complaints can be initially caused by exposure of Tl, followed by sensory 
paresthesia (Jha et al., 2006, Meggs et al., 1994). Two middle-aged women, who had 
symptoms, including paresthesia, hair loss and vomiting, were diagnosed as Tl poisoning after 
being treated by CHM in 1992 (Schaumburg and Berger, 1992).  
 
1.2.2.7 Synthetic adulterants 
In addition to the adulteration by other medicinal plants, undeclared pharmaceuticals to CHM 
products are another quality concern. Commonly seen compounds includes a wide range of 
pharmaceuticals, such as analgesics, antibiotics, antidiabetics, antiepileptics, aphrodisiacs, 
hormones and anabolic drugs, psychotropic drugs, and weight reducer that have been found in 
CHM products.  
 
The chemical analysis of some CHM that led to the finding of nine adulteration, including 
sildenafil, famotidine, ibuprofen, promethazine, diazepam, nifedipine, captopril, amoxicillin 
and dextromethorphan, was performed using a robust LC-MS-MS method from over 200 
CHM products (Liang et al., 2006b). Recent study also showed that nine herbal products were 
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adulterated by pharmaceuticals, contained tadalafil, sildenafil, testosterone, decanoate, 
glibenclamide, fenfluramine, phentermine, caffeine, phyenylbutazone and dipyrone using 
HPLC-MS-MS (Bogusz et al., 2006). In Taiwan, 618 CHM samples from eight hospitals were 
found adulterated by pharmaceuticals, including caffeine, acetaminophen, indomethacin, 
hydrochlorothiazide, prednisolone, ethoxybenzamide, phenylbutazone, betamethasone, 
theophylline, dexamethasone, diazepam, bucetin, chlorpheniramine maleate, prednisone, 
oxyphenbutazone, diclofenac sodium, ibuprofen, cortisone, ketoprofen, phenobarbital, 
hydrocortisone acetate, niflumic acid, triamcinolone, diethylpropion, mefenamic acid, 
piroxicam and salicylamide (Huang et al., 1997). Moreover, 52.8% of the adulterated CHM 
products contained more than two synthetic therapeutic agents (Huang et al., 1997).  
 
1.2.3 Regulation and quality control of CHM 
Although the majority of CHM has a safe record, some still carry potential risk. 
Standardisation by most of manufacturers may help to maintain consistently high level of 
active ingredients of CHM products (Corns, 2003).  
 
This situation leads WHO and other authorities in many countries to address the issues of 
regulation and evaluation of quality, safety and efficacy of CHM. In China, CHM is fully 
covered in the health system. The Chinese Pharmacopoeia (The Pharmacopoeia Commission 
of People's Republic of China, 2005) described 920 monographs of CHM as therapeutic 
substances, which include details of Chinese materia medica and traditional Chinese patent 
medicines. Surveillance and legislation have been required to control the use of these herbal 
products (Akerele, 1984). In Korea, the authorities have regulated and evaluated herbal 
material medica by the Korean Pharmaceutical Affairs Law; directed manufacturers to 
conform to the Korean Good Manufacturing Practice (GMP) standard; and developed 
researches of new herbal therapeutic products by the Korean Food and Drug administration 
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(KFDA) (Choi et al., 2002, Corns, 2003). In Japan, Pharmaceutical Affairs Law ensures the 
quality standards of herbal therapeutical goods, regulated by Pharmaceutical administration. 
More than 90% of the products have been announced in the Japanese Pharmacopoeia (Saito, 
2000). In Australia, phytomedicines, including CHM, are regulated under the Therapeutic 
Goods Act 1989, which is administered by TGA (Drew and Myers, 1997, Briggs, 2002). To 
ensure better access to safe and proven CHM to the public, TGA has jurisdiction over 
licensing of manufacturers, pre-market assessment and post-market regulatory activity 
(Briggs, 2002).  
 
Nevertheless, harmonisation of regulation and evidence-based data for quality control are the 
biggest challenges in most countries. The good agricultural practices (GAP) can be maintained 
the quality production of medicinal plant during the commercial cultivation (Leung et al., 
2006). Based on the GMP guideline, the medicinal materials have to be processed to ensure 
the quality, efficacy and safety (Leung et al., 2006). The WHO has published general 
guidelines for the GMP production of botanic therapeutic products (WHO, 2004a). Moreover, 
regulatory authorities must employ the surveillance of post-marketing quality guarantees. 
Further steps are needed to institute and develop rapid, sensitive and reliable assessment 
methods to screen the quality of CHM products, including botanical taxonomic identification, 
morphological and histological analysis, analytical procedures of molecular profiles and 
chemical compositions and pharmacological and clinical evaluation.  
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1.3 Techniques for identification and authentication of CHM 
The quality of CHM products has been constantly acknowledged as a priority issue in the 
development of CHM (WHO, 2004b). Thus, establishing selective and efficient analytical 
methods are important not only for authentication of the origins of medicinal plant materials, 
but also for the quality control and safety assurance of CHM (Xue et al., 2004, Barnes, 2003a, 
Barnes, 2003b).   
 
There is an extraordinary history for CHM clinical application in China. Since early 220-225 
B.C., organoleptic identification was introduced in the first classic CHM literature, 
“Shennong’s Classic of Materia Medica” (Yu et al., 1999). In 420-479 A.D., ‘Leigong’s 
Discussion of Processing of Materia Medica’ was published, which firstly recorded a number 
of identification methods for assurance the quality of CHM (Yu et al., 1999). In 1500 years 
ago, the famous CHM practitioner, Tao, Hongjing firstly addressed in his publication 
‘Collection of Commentaries on the Classic of Materia Medica’ that the misidentification, 
adulteration and substitution were found in the market, which might lead to the unsafe clinical 
application of CHM (Yu et al., 1999). The first Pharmacopoeia was issued in order to 
regulating the CHM, in 659 A.D. Since then, numerous classic literatures have emphasised on 
quality and safety of CHM, and attempted to develop the sensitive and reliable methods for 
the identification and authentication of CHM.  
  
With the development of biology, chemistry and physics in the early 19th century, the 
Austrian physician, Schmidt firstly introduced pharmacognosy, which was used for dealing 
with crude or unprepared phytomedicines. Researchers started drawing attention to the 
bioactive components from plants. In 1803, French Derosne discovered the alkaloid from 
plants, and German Sertüner isolated morphine from opium in 1806 (Huxtable and Schwarz, 
2001). Therefore, modern techniques were used to assure and assess the quality, efficacy and 
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safety of herbal therapeutic agents. Microscopes have been extensively applied for the 
identification of herbal materials since 18th century (Techen et al., 2004). Until middle of last 
century, chromatographic and spectrophotometric techniques have been employed widely 
(Akerele, 1984). In 1985, Kary Mullis developed the PCR technique (Mullis, 1993). In recent 
decades, PCR-based molecular markers have been become one of the most accepted 
techniques for CHM identification and authentication.  
 
1.3.1 Traditional techniques  
Macroscopic and microscopic examinations of morphological and histological characteristics 
of CHM are regarded as the first step to authenticate CHM (Li, 1996). The quality parameters 
for botanicals continued are mainly based upon macroscopic and microscopic visual 
evaluations of herbal materials (Techen et al., 2004). For raw botanicals, above examinations 
of the characteristics of medicinal plants are usually very quick and inexpensive. However, a 
requirement of experienced and competent personnel to produce accurate assessment is the 
disadvantages of these approaches. 
 
1.3.1.1 Morphological identification  
The macroscopic description of CHM appeared in ‘Shennong’s Classic of Materia Medica’ 
two thousand years ago (Yu et al., 1999).  Until now, description of organoleptic markers 
such as shape, colour, texture and odour of CHM is still an important part in the botanic 
monographs from most of the authorised literatures and guidelines (Akerele, 1984, Bensky 
and Gamble, 1993, The Pharmacopoeia Commission of People's Republic of China, 2005, 
WHO, 1998, Yu et al., 1999).  
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1.3.1.2 Histological identification 
The introduction of microscopic technique to CHM identification resulted in the distinct 
improvement in CHM quality. Microscopic identification involves examination of internal 
structures of different botanic sources, for instances, skin, phloem, cambium, vessels, fibres, 
crystals, and calcium oxalate (Li, 1996). Optical microscopes and electron microscopes are 
two most commonly used instruments for CHM identification.  
 
1.3.2 DNA-based molecular markers 
Based on molecular cloning and PCR techniques, DNA-based molecular markers have been 
widely used for identification and authentication of plant and animal species (Joshi et al., 
2004). Moreover, since the mid-1990s, DNA fingerprinting techniques have been considered 
as an independent approach to identify and authenticate the medicinal plants (Cheung et al., 
1994). Various types of DNA-based techniques, includes PCR-based markers, hybridisation-
based markers and sequencing-based markers, have been employed to reveal the molecular 
information from CHM (Fowler et al., 1994). The various methods involved in DNA-based 
markers are shown in Table 1.15. 
 
Compared with other identification methods, DNA-based molecular marker techniques are 
much less affected by some factors, such as age, physiological circumstance, environments, 
climates and other issues. As the most basic signature of an organism, DNA sequences, even a 
few molecular DNA, could be the powerful evidence contributing to the quality control of 
CHM (Joshi et al., 2004). Furthermore, in most organisms, the DNA is an extended double-
stranded polymer, which institutes and keeps the cellular and biochemical functions of 
organisms (Glick and Pasternak, 2003). DNA-based markers are DNA-specific, not tissue-
specific, that can be identified at any stage of the organism progress. These markers have non-
restrictive physical forms and requiring only small quantities of testing samples (Fan et al., 
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2004). Therefore, they are particularly applicable for identification and authentication of the 
CHM. 
 
Table 1.15 Classification of diverse arrays of DNA-based markers (Fowler et al., 1994) 
Types Representative 
Random Amplified Polymorphic DNA (RAPD) 
Arbitrarily-primed PCR (AP-PCR) 
Simple Sequence Repeat (SSR) 
Amplified Fragment Length Polymorphism  (AFLP) 
Direct Amplification of Length Polymorphism (DALP) 
PCR-Based Markers 
PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) 
RFLP  Hybridisation-Based 
Markers Minisatellite / microstatellite 
Assessed the differentiation directly and obtained information by a 
defined locus Sequencing-Based 
Markers Internal transcribed spacers (ITS) of ribosomal DNA (rDNA) or 
chloroplast gene (trnK) 
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1.3.2.1 PCR-based markers 
PCR 
In 1944, Avery, Macleod and McCarty announced the revolution of genetics by DNA, which 
started and founded the molecular genetic science (Lederberg, 1994). In 1953, the structure of 
DNA was published by Watson and Crick (Watson and Crick, 2003). Since the successful 
development of PCR in 1988, (White et al., 1989), it has been considered as a valuable 
approach for producing large quantities of a specific DNA sequence that is useful for the 
molecular genetic analysis of plant, animals and other organisms, as three-step cycling 
procedure accomplishes the amplification of a specific DNA sequence that can be more than a 
million fold (Fowler et al., 1994). 
 
Components for PCR amplification  
Several crucial components are involved in PCR amplification (Table 1.16):  (1) primers that 
are harmonising to regions on opposite strands that flank the target DNA sequence; (2) a 
DNA template, which contains a target sequence from 100 to 35,000 base pairs (bp) in length; 
(3) a heat-stable DNA polymerase, which would synthesize DNA at elevated temperatures 
from single-stranded templates in the presence of a primer; and (4) four 2’-
deoxyribonucleotide-5’ triphosphates (dNTP) (including dAPT, dCTP, dGTP and dTTP). 
 
As a critical issue in any PCR to obtain high and specific amplification products, the 
optimisation of the combination of the constituents is essential, for instances, the balance of 
dNTPs and magnesium ion, the concentration of the PCR buffer, quantity of template DNA 
and Taq DNA polymerase, amount of primers and the quality and quantity of DNA templates 
(Markoulatos et al., 2002). 
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Table 1.16 Typical reaction set-up of routine PCR (Glick and Pasternak, 2003) 
PCR buffer 
Containing the cations in the buffer, which neutralise the negatively charge phosphate 
groups on the DNA backbone and decline the repulsive, and obliging the annealing 
process between the primer and the template.  
Magnesium chloride (MgCl2) 
The magnesium ion, which influences on primer annealing, the melting temperature of the 
PCR products and products specificity, not only bound by the template DNA, the 
nucleotides and the primer, but Taq DNA polymerase requires free magnesium ions as 
well.   
dNTPs 
The concentration of deoxyribonucleotides depends on the concentrations of primers and 
magnesium ions, thus decreasing the concentration of dNTPs results in a significant 
improvement in PCR amplification, but reduction of the PCR products.  
PCR Master Mix 
Taq DNA polymerase Heat-stable DNA polymerase from Thermus aquaticus, synthesizing DNA at specific 
temperatures from single-stranded templates in the presence of a primer. 
Primers  The proportion of the primer is critical for the generation of PCR products.  
DNA template  The amount, purity and integrity of the DNA template can be critical.  
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Steps of PCR amplification 
On the basis of denaturation, annealing and extension, a PCR is a relatively simple technique 
by which a DNA template is amplified many thousand or million fold quickly and reliably, 
generating sufficient material for subsequent analysis. The basic PCR reactions take place in a 
thermal cycler that has been preheated to 95°C (initial denaturation) for approximately 2min 
to ensure that the target DNA is completely denatured.  This is followed by a number of 
cycles for amplifying a specific DNA sequence, with each cycle having three steps: 
denaturation (maintaining at 95°C), annealing (at a lower temperature which should be 
optimised for each primer set based on the primer melting temperature), and extension 
(maintaining at 72°C, a step catalysed by the Taq DNA polymerase), followed by the final 
extension at 72°C. Finally the reaction is maintained at 4°C. Repeating the denaturation-
annealing-extension cycles multiplies an exponential accumulation of the DNA fragment of 
the defined sequence (McPherson and Moller, 2000) (Figure 1.8). The presence of primers, 
single-stranded polynucleotides that recognise and bind to the complementary DNA sequence 
on template DNA attributed to the specific duplication. The annealing primer, initiating from 
the 3’ hydroxyl end of each primer sequence, is extended by a thermostable DNA polymerase 
and persists though the region of the template DNA strand that is complementary for the next 
PCR cycle. The amplified PCR products are fractionated by electrophoresis on agarose or 
polyacrylamide gel and illuminated under UV after ethidium bromide (EtBr) staining. Due to 
the capacity to amplify DNA from a small quantity of materials in vitro, a range of PCR-
derived techniques have been established.  
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‘                  ’, represents primers. The primer used may be a specific target sequence (e.g. in 
PCR-RFLP) or an arbitrarily sequence (e.g. in RAPD). 
 
Figure 1.8 Schematic diagram of PCR 
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1.3.2.1.1 Random amplified polymorphic DNA (RAPD) 
General principles of RAPD 
In 1990, Williams reported the development of PCR-based genetic screening technique, 
RAPD (Williams et al., 1990). The method processes PCR amplification by only a single 
arbitrary oligonucleotide (oligo) primer, as both the forward and reverse primer in a PCR 
reaction. At a comparable low annealing temperature, a single random oligo, generally 10 
nucleotides long, can be bound to the chromosomal DNA (cDNA) templates, when two 
multiple copies of the oligo on opposite strands are oriented facing one another (Williams et 
al., 1990). Sequences between these positions will be amplified by PCR (Figure 1.9). 
 
 
 
 
‘        ’, represent multiple copies of a primer (all primers have the same sequence). 
 
Figure 1.9 The phenomenon of RAPD 
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RAPD analysis, which is simple and rapid, can be employed to identify entire genomic 
information, individual chromosomes, and unusually specific genes (Williams et al., 1990). 
The advantages of RAPD include: (1) smaller quantity of DNA is required compared to other 
PCR-based techniques; (2) a universal set of primers, even the same primer can be conducted 
and displayed in a short period of time, and samples from various plants, animals or microbes 
can be tested; (3) there is no requirements for isolation of cloned DNA probes, genomic 
libraries, radioactivities, southern transfers or preparation of hybridisation filers; (4) it is 
amenable to automation; and (5) low cost involved (Hadrys et al., 1992). 
 
However, RAPD technique is sensitive to contaminants in DNA and pre-PCR preparation and 
slight alteration during experiment, due to its low stringency of the annealing step (Sun and 
Yu, 2000). Apart from precautions to avoid contamination, there are few disadvantages: (1) 
purified, high molecular weight DNA is compulsory; (2) band profiles can not be translated in 
terms of loci and alleles; (3) low reproducibility; and (4) similar sized fragments may not be 
homologous (Sun and Yu, 2000).  
 
The arbitrary primers 
PCR is used to amplify a known sequence of DNA, while RAPD reactions amplify segments 
of DNA, which are essentially unknown. In other words, a ten-oligo sequence is simply made 
by experimenters or is generated by a computer randomly, then used to synthesise the primer. 
The replacement of a single oligo in a primer can cause a whole change in the RAPD 
products. Furthermore, the same sets of primers can be used to perform the RAPD 
fingerprints of different plants. However, it is still necessary to carry out the RAPD procedure 
with a number of different arbitrary primers until differences are exposed. The random 
primers that were used in this study are from RAPD 10-mer Kits specifically developed for 
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RAPD analysis from Operon (German). Operon manufactures 26 kits, each containing 20 
different arbitrary primers, which are currently available in the market.  
 
Application of RAPD approach 
RAPD technique can be used in molecular ecology to establish taxonomic characteristics, 
review association relationships, analyse varied genome samples and generate specific probes 
(Hadrys et al., 1992). The RAPD technique has been commonly applied for the analysis and 
identification of the fingerprinting genomes from plants, animals or microbes (Williams et al., 
1990). A number of studies assessing the phylogenetic relationships of organisms have been 
reported using RAPD. For instances, the genetic maps of tea, grapes, bush mango and 
strawberries have been screened by RAPD method (Wachira et al., 1995, Siles et al., 2000, 
Lowe et al., 2000, Congiu et al., 2000). RAPD has also been employed to generate the genetic 
maps from animals, such as fish, cattle and sheep (Kantanen et al., 1995, Asensio et al., 2002, 
Bardakci and Skibinski, 1994).  In addition, this technique has been popularly employed in 
bacterial and fungal pathology (Satokari et al., 2003, Cohen et al., 2001, Rychlik and Pavlik, 
1997, Sullivan et al., 1996). 
 
RAPD for identification and authentication of CHM 
Genomic fingerprinting assays using RPAD have already been shown to be useful for the 
differentiation of Radix Ginseng (Ren-shen) and Radix Panacis Quinquefolii (Xi-yang-shen). 
Different random decamer primers were selected to reveal the genetic diversity of Panax spp. 
among different species and cultivation regions (Ma et al., 2000a, Jiang et al., 1998). Various 
primers were used as to their applicability in establishing RAPD assays as a rapid 
identification system for CHM, for instance, Rhizoma Atractyloids (Cang-zhu), from either 
the genuine source of plants Atractylodes lancea and A. chinenesis, or other three substitutes 
or adulterants (A. koreana, A. ovata and A. japonica) (Ren et al., 2000, Mizukami et al., 2000, 
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Kohjyouma et al., 1997). RAPD analysis also has been used for the identification and 
authentication of Radix Angelicae Sinensis (Dang-gui), Flos Lonicerae (Jin-yin-hua) and 
Fructus Lycii (Gou-qi-zi) (Gao et al., 2001, Yu and Shi, 2000, Zhang et al., 2001). In addition 
to single herb identifications, RPAD was also employed to identify the CHM components in 
herbal formula, Yu-Ping-Feng San, which contained Rhizoma Atractylodis Macrocephalae 
(Bai-zhu), Radix Saposhnikoviae (Fang-feng) and Radix Astragali (Huang-qi) (Cheng et al., 
1998).  
 
1.3.2.1.2 Arbitrarily-primed PCR (AP-PCR) 
Almost the same year as RAPD technique invented, another group reported the establishment 
of another method, AP-PCR (Welsh and McClelland, 1990). The general principles and the 
procedures of AP-PCR are similar to RAPD that is the technique processes PCR amplification 
by only a single arbitrary oligo primer. Compared to a 10-oligo primer used in RAPD, AP-
PCR amplification used a 20-30 necleotides long primer (Welsh and McClelland, 1990). The 
identity of CHM samples can be determined, and the substitutions of CHM can be detected by 
this method. For example, the authentic Radix Ginseng (Ren-shen) and Radix Panacis 
Quinquefolii (Xi-yang-shen) species and their adulterants were identified and authenticated 
using AP-PCR (Shaw and But, 1995).  
 
1.3.2.1.3 Simple sequence repeat (SSR) 
SSR, also known as microsatellites, is repeated in tandem, and spread throughout eucaryotic 
genomes (Grist et al., 1993). The PCR amplified fragments were obtained using a unique pair 
of primers, followed by detection on high-resolution gels. These days, SSR has been 
commonly used for genetic mapping with populations of plants species (Garnica et al., 2006). 
SSR also has been successfully revealed the genetic characteristics of CHM, including 
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Rhizoma Gastrodiae (Tian-ma) and Radix Ginseng (Ren-shen) (Xu et al., 2006, Kim and Lee, 
2004).  
 
1.3.2.1.4 Amplified fragment length polymorphism (AFLP) 
AFLP is a highly sensitive technique used in the study of genomic fingerprints (Thomas et al., 
1995). Three stages are involved in AFLP procedures, including digestion of the genomic 
DNA with one or more restriction enzymes, amplification of some restriction fragments using 
two PCR primers that represent adaptor and restriction site sequences, and followed by 
electrophoresis on high-resolution polyacrylamide gel. Since its discovery, AFLP has been 
used for the identification of species, molecular evolution and biological diversity, the 
comparison of the differential expression of genes, and gene mapping for bacteria, fungi, 
plans, and human (Latorra and Schanfield, 1996, Lin et al., 1996, Meksem et al., 1995, 
Mueller et al., 1996).  
 
AFLP has been employed for the identification and authentication of CHM. For instances, 
Radix Ginseng (Ren-shen) and Radix Panacis Quinquefolii (Xi-yang-shen), from different 
growing locations in China or Korea (Ha et al., 2002). AFLP was also used for studying the 
complexity of application of CHM in Singapore market that included Randix Quinquefolii 
(Xi-yang-sheng), Radix Astragli (Huang-qi), Radix Notoginseng (San-qi), Cortex 
Cinnamomum (Gui-pi), Radix Isatidis (Ban-lan-gen), Radix Codonopsis (Dang-shen) and 
Radix Rehmannia (Sheng-di) (Yuan and Hong, 2003).  
 
Compared to other PCR-based technologies, ALFP is more reproducible due to the inflexible 
condition by used specific primers. However, the requirements of the genetic knowledge of 
the samples and high quality of DNA become the barriers for application of SSR for CHM 
identification and authentication (Glick and Pasternak, 2003). 
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1.3.2.1.5 Direct amplification of length polymorphism (DALP) 
This method resembles AP-PCR to produce DNA fingerprinting and sequence of the 
polymorphic loci (Desmarais et al., 1998). It has been employed for detection of the 
polymorphism of virus, plants and animals (Desmarais et al., 1998, Langar et al., 2003, Hu et 
al., 1999).  
 
The method has been adapted for analysis of the genomic diversity between Radix Ginseng 
(Ren-shen) and Radix Panacis Quinquefolii (Xi-yang-shen). A 636-bp DALP band was 
generated from Panax. ginseng, the botanic sources of Radix Ginseng (Ren-shen) sample, 
which may contribute to authenticate the Radix Ginseng (Ren-shen) products (Ha et al., 2001). 
 
High resolution of genomic profiles and high efficiency in isolation of large number of 
polymorphic fragments are regarded as the advantages of DALP. Moreover, no prior 
knowledge of the amplified site is required. However, the considerable requirements of time 
for sequencing the polymorphic DALP fragments is assuming as the disadvantage of this 
technique (Glick and Pasternak, 2003).  
 
1.3.2.1.6 PCR – restriction fragment length polymorphism (PCR-RFLP) 
General principles of PCR-RFLP 
PCR-RFLP technique is based on a distinct DNA fragment, which is amplified by PCR, using 
a pair of universal primers, including forward and reversed primers. The selected restriction 
endonuclease is applied for digestion, followed by gel electrophoresis and illumination under 
UV (Maeda et al., 1989). A specific recognition region for a particular restriction 
endonuclease is present or absent in one DNA template so that differences of the DNA 
fragments of different sizes are produced (Glick and Pasternak, 2003).  
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PCR-RFLP is one of the most commonly used approaches for genetic testing, due to its: (1) 
small amount DNA templates needed for analysis; (2) more loci and exclusive alleles to 
perform valuable linkage studies; (3) better repetition; and (4) sensitive and efficient 
amplification of DNA from organisms (Glick and Pasternak, 2003, Arens, 1999). However, 
there are still some shortcomings involved in PCR-RFLP. For instances, the RFLP loci are not 
allocated consistently from every chromosome, and the maintenance of the protocols can be 
inconvenient and cumbersome (Glick and Pasternak, 2003). 
 
Primers selection for PCR-RFLP 
As the basic requirements of PCR amplification, the region for PCR analysis flanking the 
target sequence is known (McPherson et al., 1991). Due to the preservation of specific region, 
this region can be willingly amplified from many species by a ‘universal primer’(Glick and 
Pasternak, 2003). Universal primers, which are designed to provide a ‘universal specificity’, 
can anneal to the preserved region of the target sequence and amplify DNA section in a wide 
range of taxa (Baker et al., 2003). Some candidates for ‘universal primers’ have been applied 
for PCR-RFLP analysis. The PCR-RFLP of rDNA (Carvalho et al., 2004, Abliz et al., 2004, 
Rachman et al., 2004) and the ribulose-1, 5-bisphosphate carboxylase L (rbcL) region (Van 
Droogenbroeck et al., 2004) have been successfully used to differentiate and identify the 
genetic profiles of organisms.  
 
Application of PCR-RFLP 
PCR-RFLP technique has been well established for genetic mapping study and evaluation of 
taxonomic relationship. It has been applied for a number of studies in various areas, such as 
ecology, virology, epidemiology, zoology and phytobiology (Glick and Pasternak, 2003). 
Botstein et al (1980) established a structure for reorganisation of polymorphic single-base-
pair probes, and using them as a ‘DNA marker loci’, they have contributed to map human 
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chromosomes. Over more than two decades, PCR-RFLP has been used as one of the powerful 
methods to validate reference strains of different phytogenic organisms, such as beech 
(Vettori et al., 2004), papaya (Van Droogenbroeck et al., 2004), ananas (Duval et al., 2003), 
etc. Furthermore, PCR-RFLP used in human genetic mapping contributes to the clinical 
microbiology, for instances, the identification of Burkhoderia spp. (van Pelt et al., 1999), 
dermatomycoses (Machouart-Dubach et al., 2001), TNF (Keso et al., 2001), etc.  
 
PCR-RFLP for identification and authentication of CHM 
The PCR-RFLP of the 18s ribosomal ribonucleic acid (rRNA) gene has been proposed to 
distinguish Panax spp., whose dried roots are recognised as Radix Ginseng (Ren-shen) (Um 
et al., 2001). The approach has also been suggested conveniently to identify Rhizoma 
Menispermi (Ban-xia), the dried roots from Pinellia ternate (Chung et al., 2002). Furthermore, 
it can be applied to the authentication of morphologically similar medicinal Codonopsis 
species for a CHM Radix Codonopsis (Dang-shen) (Fu et al., 1999).  
 
1.3.2.2 Hybridization-based markers 
A DNA fragment or synthetic oligo is used as a probe, which is labelled with radioisotopes or 
with conjugated enzymes that catalyse a colored reaction, to hybridise DNA (Huang and 
Kochert, 1994, Meyer et al., 1993). RFLP and minisatellite/microsatellite markers are 
representative of this technology and are employed in gene mapping and systematic and 
evolution studies in a wide range of organisms, plants, animals, and humans (Cheng et al., 
2003, Haberfeld et al., 1991, Iwasaki et al., 1992).  
 
Difficult to find the DNA probe may cause the failure to differentiate the genetic diversity 
between different Glehnia littoralis varieties of CHM Radix Glehniae (Bei-sha-shen) that 
 79 
cultivated in different geographic conditions (Mizukami et al., 1993). In addition, the high 
quantity and quality of DNA from CHM are necessary for using RFLP techniques.  
 
1.3.2.3 Sequencing-based markers 
Sequencing-based markers focus on a defined locus, and the variation can be compared, based 
on the PCR techniques (Gillespie et al., 2006). The nuclear (5S, 18S and 28S) and 
mitochondrial (12S and 16S) sequences encoding rRNA (rDNA), related internally 
transcribed spacer (ITS) from nuclear ribosomal DNA (nrDNA), transfer RNA for lysine 
(trnK), rubisco large subunit (rbcL) from chloroplast DNA (cp DNA) are the locus frequently 
used as molecular markers (Gillespie et al., 2006, Bena et al., 1998, Cao and Komatsu, 2003, 
Soltis et al., 1992). Although the requirements of the genetic knowledge of the target genome 
may affect the application of sequencing-based markers for CHM identification, the reliability 
and reproducibility are the significant advantages of this approach over other molecular 
markers. 
 
Recently, the spacer region of 5S rRNA was sequenced to verify that the crude CHM Radix 
Adenophorae (Sha-shen) was derived from roots of Adenophora stricta rather than A. 
tetraphylla, A. hunanensis and Glihnia littorlis (Zhao et al., 2003a). A sequence of 250bp 
amplified fragment from the conserved sequences of the 5S rRNA gene was used to identify 
the Adenophora spp. The sequence of 5S rRNA has also been used to authenticate Radix 
Notoginseng (San-qi), Radix Astragali (Huang-qi) and Radix Angelica (Dang-gui) (Cui et al., 
2003, Ma et al., 2000b, Zhao et al., 2003b).  The ITS of rDNA was selected for authentication 
of Herba Dendrobii (Shi-hu) (Lau et al., 2001). 18S rRNA has been used for verifying several 
Panax species, medicinal plants for Radix Ginseng (Ren-shen) and Radix Panacis 
Quinquefolii (Xi-yang-shen) (Fushimi et al., 1996). For Curcuma species, the 18S rRNA and 
trnK have been used to authenticate several related herbal medicines (Sasaki et al., 2002, Cao 
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et al., 2001). The molecular markers of 11 Curcuma spp., including C. longa and C. 
chuanhuangjiang for Rhizoma Curcumae Longae (Jiang-huang), C. phaeocaulis, C. wenyujin, 
C. aromatica, C. sichuanensis and C. chuanujin for Radix Curumae (Yu-jin), and C. zedoaria, 
C. kwangsiensis, C. chuanezhu and C. yunnanensis for Rhizoma Curcumae (E-zhu) were 
revealed. Furthermore, based on the sequence analysis of 18S rRNA and trnK genes, 25 CHM 
formulations contained Curcuma species were identified as well (Sasaki et al., 2002).  
 
1.3.3 Spectrophotometric and chromatographic techniques 
With the development of chemical and physical sciences, and analytical instruments, 
analytical chemistry is now widely used in the quality and quantity analysis of chemical 
compounds (Chun, 2003). Compared to the classic electroanalytical methods, a number of 
instrumental approaches have been employed as powerful analytical tools including 
spectrophotometry, atomic spectroscopy, MS, NMR, X-ray spectroscopy and chromatography 
(Banasal et al., 2004). The brief principles and classifications of various analytical methods 
are presented in Table 1.17.  
 
Analytical chemistry deals with the identification of quantity and quality of various chemical 
compositions that contributes to different areas, which involve pharmaceuticals, food industry, 
and environmental improvement (ACS, 2003). Recently, chemical analytical techniques have 
become a valid approaches to identify marker compounds of CHM, and have been contributed 
to qualitative and quantitative analysis of the bioactive constituents and quality evaluation of 
CHM (Mahady, 2001). In current CHM regulatory requirements in pharmacopoeias and 
authorised guidelines, UV spectrophotometry, atomic absorption (AA) spectrophotometry, 
TLC, HPLC, gas liquid chromatography (GLC), MS, GC-MS and LC-MS are commonly 
quoted techniques (AHP, 2004, BHMAPublications, 2000, Akerele, 1984, The 
Pharmacopoeia Commission of People's Republic of China, 2005).  
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Nevertheless, there are limitations in chemical analysis. Physiological circumstances, 
cultivation period, drying conditions and preparation circumstances could affect the 
variability and quantity of the active compositions of CHM. In addition, the similarities of 
chemical components among related medicinal species and varieties as well as the high cost 
of the advanced instruments, for instances HPLC, GC-MS and NMR, are also considered 
(Joshi et al., 2004). 
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Table 1.17 The classifications and brief principles of the commonly used analytical approaches (Kwak, 1997, Skoog et al., 2004) 
Method Brief principles Common types of instruments 
Electroanalytical chemistry  
Based on the Redox reaction and inter-relationship between electrical and 
chemical energy 
Potentiometer 
Coulometer 
Electrogravimeter  
Voltammeter 
Spectroscopy 
Electromagnetic radiation, treated as photons, is absorbed by analytical 
samples that associated with wavelength, frequency and wavenumber. 
X-ray spectroscopy 
Spectrophotometry 
 NMR spectroscopy 
Spectrophotometry More specific than general spectroscopy that is the study of spectra. 
UV spectrophotometers 
Visible spectrophotometers 
IR spectrophotometers 
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Continued Table 1.17 The classifications and brief principles of the commonly used analytical approaches (Kwak, 1997, Skoog et al., 2004) 
Method Brief principles Common types of instruments 
Atomic spectroscopy 
The amount of radiation absorbed by ground-state atoms created in a 
flame or a minifurnace is measured.  
Atomic emission spectroscopy 
 AA spectroscopy 
Atomic fluoresecne spectorcopy  
Mass spectrometry  
(MS) 
Small molecular is converted to ions so that they can be operated by 
external electric and magnetic fields 
Tandem MS 
Chromatography – MS  
Chromatography   
Based on the differences in separating characteristics between a 
mobile phase and a stationary phase, separate the compounds. 
TLC, LC, HPLC, GC 
Ion-exchange chromatography (IEC) 
Gel permeation chromatography (GPC) 
Affinity chromatography (AC) 
Electrophoresis 
Based on the movement of ions, which have various migration rate, 
separate the compound  
Paper / gel electrophoresis 
Capillary electrophoresis (CE) 
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1.3.3.1 Spectroscopy  
Spectroscopy is production, measurement and analysis of matter and its properties by 
investigating light, sound or particles as a result of the emission, absorption or scattering. 
Common types of spectroscopy, including flame spectroscopy, visible spectroscopy, UV 
spectroscopy, IR spectroscopy, thermal IR spectroscopy, NMR, photoemission spectroscopy 
are used for different measurement processes (Skoog et al., 2004). Recently, with the 
employment of the electromagnetic and non-electromagnetic radiations, such as microwaves, 
radiowaves, x-rays and other spectroscopy is broadly used in physical and analytical analysis 
(Skoog et al., 2004). X-ray spectroscopy, NMR and spectrophotometry are the most 
commonly used categories of spectroscopy for study the chemical profiles of CHM.  
 
1.3.3.1.1 X-ray spectroscopy 
X-ray spectroscopy technology has been employed in the Chinese Pharmacopoeia to identify 
the CHM products (The Pharmacopoeia Commission of People's Republic of China, 2005). 
X-ray spectroscopic fingerprinting has been applied for the identification of CHM, including 
Radix Gentianae Macrophyllae (Qin-jiao), Herba Oldenlandia (Bai-hua-she-she-cao), 
Rhizoma Ligusticum Chanxiong (Chuan-xiong), Radix Rehmanniae Preparata (Shu-di), 
Radix Paeoniae Alba (Bai-shao) and Radix Glycyrrhizae (Gan-cao) (Zhang and Gong, 2004, 
Liu et al., 2003b, Jia et al., 2003, Wang and Li, 2002, Wu and Wang, 2002b, Wu and Wang, 
2002a). 
 
1.3.3.1.2 NMR spectroscopy 
NMR is a powerful technique to maintain physical, chemical and electronic information on 
the three-dimensional structural of molecules, based on the magnetic properties of an atom's 
nucleus (Skoog et al., 2004). NMR spectroscopy is widely used for medical diagnosis and 
chemical analysis of biological samples, including nucleic acid (RNA and DNA) or protein.  
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Proton NMR and carbon-13 NMR are the most commonly used techniques for revealing the 
chemical compositions of CHM. The methods have been employed to establish the 
fingerprinting profiles of Radix Ginseng (Ren-shen), Randix Quinquefolii (Xi-yang-sheng) 
and Radix Notoginseng (San-qi), which may contribute to standardise the herbal products 
contained Panax spp. (Qin and Zhao, 1999). NMR also has been applied for revealing the 
chemical compositions of Radix Rhapontici (Lou-lu), Semen Cuscutae (Tu-si-zi) and Aloe 
vera (Wang and Fang, 2001, Cheng and Zhang, 2002, Zhang and Sun, 2000). Furthermore, 
NMR-MS has been used for isolation of new chemical components from CHM. Seven 
saponins from Astraglus memkranaceus, as one of the botanic sources of Radix Astragali 
(Huang-qi), were isolated using NMR-MS (Cao, 2002). 
 
1.3.3.2 Spectrophotometry 
Spectrophotometry is more specific than the general spectroscopy. Different types of 
spectrophotometers are available for measuring the wavelength of light (Banasal et al., 2004, 
Skoog et al., 2004). Three major classes of spectrophotometry are visible-region 
spectrophotometers, UV spectrophotometers and IR spectrophotometers, which are 
commonly used for CHM identification and authentication.  
 
1.3.3.2.1 Ultraviolet (UV) spectrophotometers 
UV spectrophotmeter uses light in the visible and adjacent near UV and near infrared (NIR) 
ranges (Skoog et al., 2004). UV spectrophotometry is routinely used in the quantitative 
determination of organic compounds, with a high degree of conjugation. Due to the organic 
solvents may have signifiant UV absorption, water usually is used for water soluble 
compounds, while ethanol is used for organic soluble compounds. UV spectrophotometer is 
also recognised as one of the most commonly seen detectors for HPLC system (Toussaint et 
al., 2000).  
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As the basic part of a UV spectrophotometer, an incandescent bulb for visible wavelengths, or 
a deuterium arc lamp for the UV wavelenth is applied with a holder for the sample. Testing 
samples are placed in cuvette, which made from high quality quartz, sometimes galss and 
plastics are also employed. A photodiode and a change couple devide (CCD) are two 
commonly used UV spectrometer detectors (Skoog et al., 2004).  
 
UV spectrophotometry has been applied for the identification of CHM, including Radix 
Puerariae (Ge-gen), Pericarpium Trichosanthis (Gua-lou-pi), Flos Buddlejae (Mi-meng-hua) 
and Rhizoma Cyperi (Xiang-fu) (Yu et al., 2005a, Li and Cao, 2005, Tu, 2005 , Xun and 
Chen, 2000). With the rapid development of UV spectrophotometry, this approach is 
becoming one of the main techniques to establish CHM fingerprinting profiles.  
 
1.3.3.2.2. Infrared (IR) spectrophotometers 
IR spectrophotmeter uses light in the near-, mid- and far- IR ranges to measure the wavelenth 
and intensity of the absorption of IR light (Skoog et al., 2004). The IR region is devided into 
three sections, incluidng, far-IR (400 – 10 cm-1), mid-IR (4000 - 400 cm-1) and near-IR 
(14000 - 4000 cm-1). In the 1970s, Fourier transform IR spectrometer (FTIR) was developed 
as a single-beam instrument (Lopez-Avila et al., 1993). It becomes widely used in both 
research and industry for quality control and dynamic measurement. In order to make the 
assessment quicker and more accurate, advanced technologies, such as specular reflection, 
diffuse reflection, attenuated total reflectance and photoacoustic spectroscopy have also been 
developed (Drozd et al., 2006, Smith et al., 2003, Hutson et al., 1988, Graves and Luo, 1994).  
 
IR spectrometer has been used for the identification of a number of CHM, including Radix et 
Rhizoma Rhei (Da-huang), Rhizoma Coptidis (Huang-lian) and Cornu Cervi (Lu-rong) (Tian 
and He, 1992, Zheng and Zhou, 1996, Fan et al., 2005). The approach has also been applied to 
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differentiate Cyathula officinalis, authentic species for CHM Radix Cyathulae seu 
Achyranthis (Niu-xi), from its adulterant (Arctium tappa) (Li et al., 2000b).  
 
1.3.3.3 Mass spectroscopy (MS) 
MS is an analytical technique used to measure the molecular mass of the analytes (Kwak, 
1997). In early 19th century, English scientist J. J. Thomson created the first mass 
spectrograph. A. J. Dempster and F. W. Aston devised the modern version of MS in 1918-
1919 (Skoog et al., 2004). Three basic parts involve in a typical MS, including an ion source, 
a mass analysor and a detector.  
 
MS has been applied for the determination of isotopic composition of elements (Danesi et al., 
2003), trace gas analysis (Fontanals et al., 2006), pharmacokinetics (Liang et al., 2006a) and 
the characterisation, identification and quantitation of protein (Areces et al., 2004). In resent 
decade, hyphenated MS has been used in a wide range, for instances, GC-MS, LC-MS and 
CE-MS. These technologies have been intensively employed for CHM identification and 
authentication, which will be reviewed in the following sections.  
 
1.3.3.4 Chromatography 
In 1906, the term “chromatographic experiments” firstly appeared in Mikhail Semenovich 
Tswett’s paper that established chromatography as a technique for the analysis of chlorophyll 
(Zolotov, 2003, UMICH, 2005). Since then, chromatography has been applied in various 
research areas, such as organic and inorganic chemistry, biochemistry and analytical 
chemistry, in the fields of medicine, food, cosmetics, and environmental industries (Skoog et 
al., 2004).  
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Chromatography is classified in two types: column chromatography and planar 
chromatography (IUPAC, 1993a). Planar chromatography includes paper chromatography 
and TLC (IUPAC, 1993b). Based on the various types of mobile phase, the sub-classification 
of column chromatography involves LC, GC and supercritical fluid chromatography (SFC) 
(Skoog et al., 2004). The differences of mobile phase, stationary phase, and column between 
different types of chromatography are shown in Table 1.18. 
 
The past century has been a vast undertaking in the development of chromatographic 
techniques. By comparison, TLC and HPLC provide rapid and reliable chemical approaches 
for ensuring botanical identity for most of CHM. However, GC procedures are more suitable 
for evaluating the volatile components (Li et al., 1998). In the current Chinese 
pharmacopoeia, TLC method has been adopted for the identification in 602 monographs, and 
HPLC method appeared in 105 monographs (The Pharmacopoeia Commission of People's 
Republic of China, 2005).  
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Table 1.18 Classification of column chromatographies  
Classification Application Mobile phase Stationary phase Specific methods 
Solids Adsorption chromatography  (APC) 
Ionic groups on a resin Ion-exchange chromatography (IEC) 
Liquids on an insert solid support Partitioning chromatography  (PC) 
Porous insert particles Size-exclusion chromatography (SEC) 
Liquid 
chromatography 
(LC) 
Organic or inorganic 
molecular dissolved 
in the solvent 
Liquid 
Immobilised solids Affinity chromatography (AC) 
Immobilised liquid Gas liquid chromatography (GLC) Gas chromatography 
(GC) 
Organic volatile 
components 
Gaseous 
Solid Gas solid chromatography (GSC) 
Supercritical fluid 
chromatography 
(SFC) 
Thermally unstable 
components 
Supercritical fluid 
chromatography 
A highly viscous liquid  
on a solid surface 
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1.3.3.4.1 Thin layer chromatography (TLC) 
Principles and application of TLC   
In 1951, American scientist J. G. Kirchner firstly reported a new chromatographic technique, 
and he called it ‘chromatostrip’ (Kirchner et al., 1951). In 1954, R. H. Reitsema applied 
similar approach to separate the essential oil that was named as ‘chromatoplate’ (Reitsema, 
1954). In the 1960s, E. Stahl contributed to the optimisation and standardisation of TLC 
technology (Ettre, 2005). High performance TLC (HPTLC) was born in late 1970s, which 
significantly increase the performance capacity, compared to the classic TLC technique 
(Kaiser and Rieder, 1977).  
 
The TLC technique involves using a solid fixed or stationary phase (the thin-layer), which is 
usually made from adsorbent material (silica gel, aluminium oxide, or cellulose) applied to a 
glass or a plastic plate, and a liquid mobile phase (elute solvent) that is applied to separate the 
analytes, via capillary action. The experimental solution is placed above the bottom of the 
TLC plate. After placed the plate in a developing chamber, in which the test solvent will 
either remain with the solid phase or dissolve in the elute solvent (Skoog et al., 2004).  
  
The TLC technique has been widely used for the determination and identification of 
biological and toxic samples (Raharjo and Verpoorte, 2004, Matsumura and Mori, 1998), 
analysis environmental hazardous pollutant (LeBlanc et al., 2003), and chemical compounds 
of food, cosmetic and pharmaceutical (Komsta and Misztal, 2005, Simko, 2002, Biju et al., 
2005).  
 
Stationary phase and mobile phase 
The stationary phase for TLC divides into two categories: self-coating preparation and pre-
coated TLC layers. A wide range of absorbents can be obtained that are used for preparation 
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of TLC plates, mainly including silica gel, aluminium oxide and cellulose. Self-coating plates 
need to be activated before sample application. Therefore, the pre-coated TLC plates are 
utilised due to its high quality and convenience to that of self-coating layers. TLC/HPTLC 
silica gel plates, TLC/HPTLC aluminium oxide plates and TLC/HPTLC cellulose plates are 
generally available in the market. The commonly sizes of plates are 10cm x 10cm, 10cm x 
20cm, 20cm x 10cm and 20cm x 20cm. Based on the polarity of the each solvent, the mobile 
phase has its own solvent strength. To maintain the best separation results, the optimal mobile 
phase is crucial.  
 
TLC system 
Basic TLC kit includes capillary pipettes for sampling, a developing chamber, a UV cabinet 
for detection and sprayer for colour developing reagents. In order to achieve the best test 
conditions, more and more new components have been invented (CAMAG, 2006a). Auto-
sampler has been employed to minimize the size of sample application on the plate, while 
maximum the volume of sample application. Automated developing chamber (ADC) was 
invented to keep the development fully automatic and reproducible. The automated multiple 
development system (AMD) has lead gradient elution and multiple development firstly 
appeared in TLC technology. High-resolution camera with the documentation system and the 
advanced scanner for densitometric evaluation were developed for measurements of refection 
and documentation of images. In addition, the computer technology has been hyphenated with 
TLC system. For instance, the planar chromatography manager, such as winCATs from 
CAMAG, now is popularly used for automatical information analysis.  
 
Application of TLC in identification and authentication of CHM 
TLC has been widely used for the identification and authentication of CHM. Rhaponticin, the 
toxic compounds, which were found in the adulterants of Radix et Rhizoma Rhei (Da-huang), 
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was determined on silica gel plates with mobile phase composed of ethyl acetate : methanol 
(8:2) (Yue et al., 1986). Bioactive compounds, matrine and oxymatrine, from Radix Sophorae 
Tonkinensis (Shan-dou-gen) were successfully separated on silica gel using chloroform : 
methanol : aminoprophyl (NH2) (4:1:0.1) (Zhang and Gu, 2002). Moreover, TLC has been 
applied for quantitative and qualitative analysis of chemical compositions of CHM. Four 
saponins from Radix Notoginseng (San-qi) were determined on methanol extraction using 
silica gel with the mobile phase composition of 1,2-dichloroethane : 1-butanol : methanol : 
water (30:40:15:25) (Zhou et al., 1981). Berberine, from Rhizoma Coptidis (Huang-lian), was 
quantitatively determined on silica gel using ethyl acetate : 2-butanol : formic acid : water 
(10:7:1:1) (Zang, 1986). TLC method has also been employed to assess the quality of 
particular species in order to indicate the clinical preference of CHM. Three Radix Bupleuri 
(Chai-hu) species, including Bupleurum polyclonum. B. kunmingense and B. luxiense, in 
Yunan Province, China, were found to contain high content of bioactive saponins using TLC 
(Pan et al., 1983). Although those species are not listed in the authorised literatures, the 
findings suggested that those species might be considered for clinical application in certain 
regions. With the development of TLC system, such as CAMAG TLC system coupled with 
the winCATs software, the method for determination of trigonelline hydrochloride from 
Semen Juglandis (Hu-lu-ba) was validated with the good linearity, precision and recovery 
(Chopra et al., 2006). 
 
1.3.3.4.2 High performance liquid chromatography (HPLC) 
Principles and application of HPLC   
In the 1960s, one of the modern analysis methods, HPLC started to evolve in the development 
of modern chemical analysis (Horvath, 1980). During the early stage of development of LC, 
low plate heights and low flow rates were major obstacles to increase the efficiency of 
separation (Skoog et al., 2004). Since then, the diameter of packing materials that 
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dramatically decreased to several micrometer, and the development of high pressure pump 
system, have been recognised as the evolution of the column chromatography (Michaelis et al., 
1973). Therefore, C. Horváth built the first HPLC instrument to separate the biological 
substances in Professor S. R. Lipsky’s laboratory at Yale University (Guttmán, 2004). Now, a 
HPLC system involves a reservoir of mobile phase, a sample injection system, a high-
pressure pumping system, a separation column and detectors. 
 
Stationary phase and mobile phase 
The selection of stationary phase and mobile phase is critical for development of a HPLC 
method. The commonly used stationary phase is considered as porous particles that are made 
from high purity silica and permeable to solvent (ASRG, 2004). Particles consideration 
dictates a wide selection, for instances, hydrophobic groups bonded to a silica support 
commonly used for reversed-phase chromatography (RPC), unbonded silica or bonded amino 
or cyano group regularly applied for normal phase chromatography (NPC) and bonded ionic 
groups utilized for IEC (Agilent, 2004). In HPLC system, mobile phase carries the analytes 
through the stationary phase, and then on account of the their polarity, produces separation 
(Skoog et al., 2004). Different HPLC separation modes are shown in Table 1.19. 
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Table 1.19 Various HPLC separation modes (Agilent, 2004, Skoog et al., 2004, Phenomenex, 2003). 
Stationary phase Columns Mobile Phase Separation mode 
Silica 
Luna Silica (Phenomenex, U.S.A); 
ZORBAX Rx-SIL (Agilent, U.S.A). 
Hexane, alcohols AC, NPC 
Octadecylsilyl and 
Octylsilane 
Gemini C8 and C18; Luna C8 and C18 (Phenomenex, U.S.A); 
ZORBAX Eclipse XDB C8 and C18 (Agilent, U.S.A) 
Water, methanol, 
acetonitrile 
RPC 
Cyanoprophyl (CN) 
 Luna CN, Capcell CN (Phenomenex, U.S.A); 
ZORBAX Eclipse XDB-CN (Agilent, U.S.A) 
Water, alcohol for RPC 
Hexane, ether for NPC 
NPC 
Aminopropyl (NH2) 
Capcell NH2 (Phenomenex, U.S.A); 
ZORBAX NH2  (Agilent, U.S.A) 
Water, alcohol  RPC 
Other polymers  
SHODEX (Phenomenex, U.S.A); 
Ultron chiral column, ZORBAX PSM, ZORBAX SAX 
and ZORBAX SCX (Agilent, U.S.A)  
Modifiers  
 IEC, NPC, AC, 
RPC, SEC 
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Detectors 
HPLC requires high sensitive detectors to detect the eluted analytes and consequently indicate 
a peak on the chromatogram (Ho and Stuart, 2003). Examples of detectors include UV 
detectors, refractive index detectors (RID), fluorescence, low temperature evaporative light 
scattering detectors (ELSD), chemiluminescence, electrochemical, MS, NMR, etc (Wu et al., 
2004a, Sato et al., 1990, Li et al., 2004b, Henderson et al., 1999, Ikarashi et al., 2001b). 
 
The UV detector has been considered as one of the most commonly used HPLC detectors 
(Toussaint et al., 2000). Based on the UV absorption by analytes passing through a flow cell, 
the voltage changes are illustrated as a peak and recorded at the retention time for the peak as 
area in a chromatogram (Ho and Stuart, 2003). Compared to the measurements of only one 
single wavelength by fixed wavelength detectors or one wavelength a time over specific range 
of wavelengths by variable wavelength detectors, diode array detectors (DAD) measure a 
wide range of wavelengths simultaneously (Valentao et al., 1999).  
 
Development of HPLC  evolution of reversed phase chromatography and gradient elution 
In the early stage of LC, a polar stationary phase and a relatively non-polar mobile phase such 
as hexane were focused, thus named NPC (Skoog et al., 2004). However, RPC, a relatively 
polar mobile phase and non-polar stationary phase, becomes the most popular separation 
mode (Hagan, 1994). The RPC is prevalently used for analysis of organic components, most 
of which can be dissolve in the modified mobile phase, containing aqueous soluble substances 
mixed with various concentrations of organic solvent, such as methanol, ethanol, acetonitrile, 
etc. (Ho and Stuart, 2003). RPC has been popularly applied for the chemical fingerprints of 
the botanics (Arnoldi et al., 2004, Schaneberg et al., 2003). 
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Obtaining the balance of sufficient separation and satisfactory retention time for each analytes 
is not easy for the optimisation of HPLC. The isocratic elution mode, which means the 
composition of the mobile phase kept constant during the whole analysis, often causes poor 
isolation of early peaks, expansion the later peaks, or prolonging the whole analytical 
procedure (Lee and Row, 2004). The new gradient elution chromatography opens a new era. 
Progressively increasing the proportion of organic solvent and the ionic strength of the mobile 
phase with time during the analysis is called gradient elution (Snyder, 1980). Gradient elution 
has been suggested as a solution to problems, which can be found in the usage of isocratic 
elution system, by improving the early eluting peaks, limiting the broadening of the later 
peaks and decreasing the time of analysis (Kress et al., 2002, Purcell et al., 1999).  
 
Application of HPLC in identification and authentication for CHM 
During past decades, HPLC has been applied for the isolation and purification of organic 
compounds, and the identification and quantification of chemical components (Horvath, 
1980). As one of the main approaches of chemical analysis, HPLC provides a reliable, 
sensitive and reproducible technique (Li et al., 1998). 
 
The application of HPLC to the quantitative and qualitative analysis of herbal medicines has 
been listed in the WHO guideline for regulation of the herbal medicine, the Chinese 
Pharmacopeia, the American herbal pharmacopeia and the British herbal Pharmacopeia 
(WHO, 2003, WHO, 2004a, AHP, 2004, BHMAPublications, 2000, The Pharmacopoeia 
Commission of People's Republic of China, 2005). HPLC method has been employed for the 
determination, identification, and evaluation of CHM. Moreover, it is recognised that modern 
HPLC method can be one of the main approaches to generate fingerprints of numerous 
compounds that are found in analysis of high complex CHM (Gong et al., 2003). Numbers of 
studies reported that the identification and authentication of CHM using HPLC (Table 1.20). 
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HPLC has also been used to isolated the bioactive components from CHM, including MTB, 
Danshensu, isotanshione IIA and cryptotanshinone in Salvia Miltiorrhizae (Dan-shen); rutin, 
quercitrin, quercetin, kaempferol and isorhamnetin in Ginkgo biloba, saponins in Radix 
Ginseng (Ren-shen); and andrographolide and neoandrographolide in Herba Andrographis 
(Chuan-xin-lian) (Zhang et al., 2002a, Zhang et al., 2005a, Dubber and Kanfer, 2004, 
Samukawa et al., 1995, Srivastava et al., 2004). Furthermore, detection of the declared drugs 
in CHM has been regarded as another potential advantage of HPLC (Liu et al., 2001a, Liu et 
al., 2000).                        
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Table 1.20 Recent studies on the identification and authentication of CHM using HPLC  
Name of CHM Standard compounds Column Mobile phase 
UV 
wavelength  
Reference 
Radix Paeoniae Alba 
(Bai-shao) 
Paeoniflorin 
Supelco Discovery  
(150mm x 4.6mm, 5µm) 
Methanol : potassium 
phosphate: isopropanol : 
acetic acid (67:173:4:4) 
230nm (Liu et al., 2001b) 
Cordyceps 
(Dong-chong-xia-cao) 
Ergosterol  Allsphere ODS-II, 5µm Methanol : water (95:5) 275nm (Li et al., 2001b) 
Fructus Chinensis 
(Wu-wei-zi) 
Schizandrin 
 Gomisin, 
Deoxyschizandrin    
γ-schizandrin 
 Gomisin 
 Wuweizisu C 
Nucleosil 100 C18, 5µm 
Acetonitrile : water  
(50:50 – 70:30) 
Methanol : water  
(70:30 – 95:5) 
254nm (Bartlova et al., 
2002) 
Rhizoma Ligusticum 
Chuanxiong (Chuan-xiong) 
Ferulic acid 
ODS C18  
(250mm x 4.6mm) 
Methanol : water : acetic 
acid (30:67:3) 
322nm (Wang and Kuang, 
2002) 
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Continued Table 1.20 Recent studies on the identification and authentication of CHM using HPLC 
Name of CHM Standard compounds Column Mobile phase 
UV 
wavelength  
Reference 
Radix Salviae Miltiorrhizae 
(Dan-shen) 
MTB 
Danshensu 
Isotanshinone IIA 
Eryptotanshinone  
Discovery RP – Amide C18 
(250mm x 4.6mm, 5µm) 
Methanol : water  
(85:15) 
270nm (Zhang et al., 
2002b) 
Radix Astragali 
 (Huang-qi) 
Astragaloside IV 
Phenomenex ODS 
 (250mm x 4.6mm) 
Acetonitrile : water 
(32:68) 
203nm (Zhang, 2003) 
Fructus Arctii  
(Niu-bang-zi) 
Arctiin  
Bondapak C18  
(250mm x 4.6mm, 5µm) 
Methanol : water  
(1:1.1) 
280nm (Zhang, 2004) 
Flos Chrysanthemi Indici  
(Ye-ju-hua) 
Cyclohexanecarboxylic 
acid 
DiamonsilTM C18  
(250mm x 4.6mm, 5µm) 
Acetonitrile : water : 
phosphoric acid 
(12:88:0.04) 
327nm (Tan et al., 2004) 
Radix Sophorae Flavescentis 
(Ku-shen) 
Martine  
Oxymartine  
Hypersil ODSII  
(200mm x 4.6mm, 5µm) 
Methanol: acetonitrile : 
water : phosphoric acid 
(10:30:65:0.05) 
210nm (Zhang et al., 2004) 
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Continued Table 1.20 Recent studies on the identification and authentication of CHM using HPLC 
Name of CHM Standard compounds Column Mobile phase 
UV 
wavelength  
Reference 
Herba Andrographis 
(Chuan-xin-lian) 
Andrographolide 
Neoandrographolide  
Merck RP18c  
(100mm x 4.6mm) 
Acetonitrile : water 
(50:50) 
220nm (Srivastava et al., 
2004) 
Radix et Rhizoma Rhei 
 (Da-huang) 
Aloe-emodin  
Rhien 
Emodin 
Chrysophanol  
Kromasil ODSII-1  
(200mm x 4.6mm, 5µm) 
Methanol : water : acetic 
acid (92:8:0.4) 254nm 
(Li, 2005) 
Semen Astragali Complanati 
(Sha-yuan-zi) 
Complanatuside 
VP-ODS  
(150mm x 4.6mm, 5µm) 
Acetonitrile : 1% HAC 
solvent (18:82)  
266nm (Liu et al., 2005) 
Radix Angelicae Sinensis 
(Dang-gui) 
Ligustilide 
Diamonsil C18  
(250mm x 4.6mm, 5µm) 
Methanol : water (70:30) 324nm (Wang et al., 2005) 
Cortex Phellodendri 
 (Huang-bai) 
Obaculactone 
Diamonsil C18  
(250mm x 4.6mm, 5µm) 
Acetonitrile : water : 
phosphoric acid 
(50:50:0.2) 
210nm (Ma et al., 2006) 
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Identification and authentication of CHM using LC-MS 
LC-MS is the technology that combines the separation capabilities of LC with the mass 
analysis capabilities of MS. Compared to other identification techniques, LC-MS not only 
isolate and detects the chemicals, but also potentially identifies the chemical structures of 
these chemicals. LC/MS is very commonly used in pharmacokinetic and proteomic studies 
(Liu et al., 2007, Shen et al., 2006). LC-MS has been used for the identification and 
authentication of CHM dealing with a complex mixture of chemicals. Moreover, the 
technology contributes to the discovery of the new bioactive compounds of CHM and 
revealing the chemical structures of these compounds. LC-MS has been used to identify the 
glycyrrhizin in Radix Glycyrrhizae (Gan-cao), andrographllide and 14-deoxy-11,12-
didehydroandrographolide in Herba Andrographis (Chuan-xin-lian), lipophilic and 
hydrophilic components in Radix Salivae Miltirorrhizae (Dan-shen), and flavonol glycosides 
and aglycones in Ginkgo biloba (Yin-xing) (Dubber et al., 2005, Liu et al., Li and Wang, 
2002).  
 
1.3.3.4.3 Gas chromatography (GC) 
Principles and GC systems 
In 1945, Germen scientist F. Prior devloped the world first solid state GC (Bobleter, 1996).  
Based on the thermal stability and volatility of the chemical compounds, the anayltes are 
seperated and analysed (Skoog et al., 2004). In GC, the mobile phase is a carrier gas, which 
usually is helium or nitrogen, and the stationary phase is high bioling liquid, which is packed 
in a long narrow glass or metal column (Kwak, 1997). Based on the different staitionary 
phases, solid state GC and liquid state GC are the two types of GC. GC is commonly used for 
separation of volatile components and even some involatile compounds, such as amino acids, 
steroids, and high molecular fatty acides (Haiyan et al., 2007, Hope et al., 2005, Crook, 1972).  
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A basic GC system involves a gas source, a flower controller, a sampe injector, a column and 
its oven and a detector (Kwak, 1997). As one of the commonly used gas source, hydrogen is 
suggested given the best efficiency and best serperation (Ray, 1958). However, helium as a 
non-flammable gas, has wide flowrates and is suitable for most of detectors (Ray, 1958). Split, 
splitless, or cool on column intel system is generally applied (Garrett, 1998). Recently, purge 
and trap system and solid phase microextraction (SPME) have been introduced to GC 
technique that offered a conventient and low-cost pre-concentration and purification steps 
(Rosell et al., 2006, Motlagh and Pawliszyn, 1993). Generally, a 1.5–10m long stainless steel 
or glass column, packed with solide support material coated with a liquid or solid stationary 
phase (Kwak, 1997). For instance, the capillary columns are usually made of fused-silica with 
a polyimide outer coating in order to allowing the components remaining longer and better 
seperation (Skoog et al., 2004). The flame ionization detector (FID) and the thermal 
conductivity detector (TCD) are the most commonly used detectors (Tvrzicka et al., 2002). 
TCD is less sensitive than FID towards organic molecules, but TCD is non-destructive for 
preparative applications. Other detectors include discharge ionization detector (DID) (May et 
al., 2003), electron capture detector (ECD) (Bigdeli and Collins, 1975), flame photometric 
detector (FPD) (Hoshika, 1982), hall electrolytic conductivity detector (ElCD) (Dynes and 
Thorburn Burns, 1987), helium ionization detector (HID) (Roberge et al., 2004), nitrogen 
phosphorus detector (NPD) (Beljean-Leymarie and Bruna, 1988), mass selective detector 
(MSD) (Doyle et al., 1990), photoionization detector (PID) (Hill and Baim, 1982) and pulsed 
discharge detector (PDD) (Forsyth, 2004).  
 
GC-MS  
In 1959, Holmes and Morrel invented the first GC-MS system (Gohlke and McLafferty, 
1993), based on the chemical properties of the components, GC separates the molecular, and 
followed by MS identify them based on their specific fragment spectrum, with the connection 
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of the database of standard references (Skoog et al., 2004). The most universal database 
NIST/EPA/NIH mass spectral library is maintained by the National Institute of Standards and 
Technology (NIST), the United States Environmental Protection Agency (EPA) and the 
National Institutes of Health (NIT) (NIST, 2005). GC-MS has been commonly used in 
medicines, evironmental analysis, forensics and astrochemistry (Panteghini and Forest, 2005, 
Betty and Karasek, 1978, Lachenmeier et al., 2006, Nuevo et al.).  
 
Application in identification and authentication of CHM 
A number of CHMs, mainly containing high content of volatile components, have been 
identified using GC-MS, such as 27 chemical compounds from Folium Perillae (Zi-su-ye) 
(Cui et al., 2002), and 20 volatile components from Herba Menthae (Bo-he) (Li et al., 2001a). 
Fifty volatile components from Rhizoma Curcumae Longae (Jiang-huang) were separated and 
13 of them were identified using GC-MS system (Chen, 2001). Qin et al (2001) reported that 
65 volatile compounds from Pericarpium Zanthoxyli (Hua-jiao) were identified from 80 
separated components. Moreover, the approach was also used to separate and identify other 
CHMs, including Rhizoma Ligusticum Chuanxiong (Chuan-xiong) (Yang et al., 2002), 
Cacumen Platycladi (Ce-bai-ye) (Wei and Wang, 2001), Cortex Cinnamomi (Rou-gui) (Li 
and Yuan, 2000) and Herbal Artemisiae Anuae (Qing-hao) (Guo et al., 2004a).  
 
1.3.3.5 Capillary electrophoresis (CE) 
CE is the method based on the conflicting electrophoretic mobility, in a conductive buffer and 
narrow capillary. The CE instrument consists of a sample vial, source and destination vials, a 
capillary, electrodes, a high-voltage power supply, a detector and a data analysor (e.g. a 
computer). CE technology has been applied for the basic researches of pharmaceuticals 
(Macia et al.),  proteins (Laing et al., 2006), forensics (Cengiz et al., 2004), toxicology 
(Thormann et al., 1998), etc. 
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Recently, CE or CE-MS have been used for the identification and authentication of CHM, for 
example, three active compounds, cryptotanshinone, tanshinone I and tanshinone IIA in Radix 
Salivae Miltiorrhizae (Dan-shen) (Gu et al., 2004). The procedure was also used for the 
chemical electrophoregrams of Ginkgo biloba (Yin-xing) using CE with DAD (Ji et al., 2006). 
Three bioactive components, baicalin, baicalein and wogonin in Radix Scutellariae (Huang-
qin), were successfully separated by CE (Yu et al., 2007). The active components, magnolol 
and honokiol from Cortex Magnoliae Officinalis (Ho-pu), were separated under the optimised 
CE conditions (Tian and Chen, 2006). 
 
1.3.4 Fingerprinting techniques  
Fingerprints are chromatograms, electrophotograms and/or other illustrative grams that 
represent the unique characteristics of CHM by various analysing techniques. The application 
of fingerprinting techniques offers consistent and reproducible approach in studying 
pharmaceuticals (Welsh et al., 1996, Collantes et al., 1997, Aksenova et al., 1999), 
environmental substances identification (Wang et al., 2004f), classification of food products 
(Berente et al., 2000), forensic drug samples (Klemenc, 2001), etc.  
 
In 1996, fingerprints were introduced to quality control and standardise the CHM products by 
WHO (WHO, 1996). Food and Drug Administration (FDA) issued that the chromatographic 
fingerprints of herbal products were sufficed if the identities of the active constituents or 
characteristic markers in drug substance was unknown (CDER, 2004).  The European Anency 
for the Evaluation of Medicinal Products (EMEA) also addressed that the chemical 
fingerprints of herbal products as a whole would be reflected the quality of the drug 
substances (The European Anency for the Evaluation of Medicinal Products, 2002).  
 
 105 
Fingerprints of CHM need to be exclusive and with unique features. Furthermore, stability is 
also required from CHM fingerprints, and especially in the main common peaks and the 
characterised peaks is relatively constant. Moreover, the well-established CHM fingerprints 
are also reproducible within a limit error. Although the fingerprinting technique is considered 
as an efficient and reliable quality control approach, there are some limitations. The intrinsic 
and extrinsic factors, including confusion of usage of medicinal plants, various environmental 
factors, different harvesting seasons, post-manufacture factors, which are detailed in Section 
1.2.2, are the main encountered obstacles for establishment of CHM fingerprints. Therefore, 
high quality and reliable herbal sources are essential for this technique. In some cases, the 
lack of correlation between the fingerprints and pharmacological actions is another major 
concern. Generally, the fingerprints of CHM products can represent the consistence and 
content of their molecular and chemical characteristics, regardless if the bioactivities of these 
chemical compositions are unknown.   
 
1.3.4.1 Main techniques 
There are two categories for CHM fingerprints: chemical fingerprints (eg. TLC, HPLC) and 
molecular fingerprints (eg. RAPD, PCR-RFLP). Chromatographic approaches are commonly 
reported for a chemical fingerprint of CHM (Li et al., 2004a). TLC fingerprints has been 
recognised as a fast, economic and widely used technique (Cai et al., 2000b). However, the 
lack of sensitivity and difficulty to detect the microconstituents are the limitations for TLC 
fingerprints (Cai et al., 2000b). HPLC and GC, which may coupled with MS, have been 
applied to identify and authenticate the CHM products sensitively and reliably, to make them 
becoming the most commonly used methods (Fan et al., 2006). Spectrophotometric 
technologies, including UV and IR, have also been used to reveal the chemical fingerprints 
for a wide range of CHM. However, poor resolution of these techniques is discouraged 
application for similar botanic origins (Jiang et al., 2004b). Other techniques, for instances, 
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CE and NMR, have been commonly employed for CHM fingerprints (Han et al., 2004). With 
the rapid development of molecular sciences, more and more DNA-based markers, which 
were described in Section 1.3.2, become widely used for CHM fingerprints (Shaw et al., 
2002).   
 
1.3.4.2 Application in CHM 
There are a number of chromatographic fingerprinting studies on CHM, such as, Radix 
Scutellariae (Huang-qin) (Yu et al., 2007), Radicis Angelicae Sinensis (Dang-gui) (Wang et 
al., Wang et al., 2006b), Fructus Xanthii (Cang-er-zi) (Ruan and Li), Rhizoma et Radix 
Notopterygii (Qiang-huo) (Jiang et al.), Ginkgo biloba (Yin-xing) (Ji et al., 2005), Ganoderma 
(Ling-zhi) (Di et al., 2003), Radix Slaviae Miltiorrhizae (Dan-shen) (Liang et al., 2005), 
Radix Astragli (Huang-qi) (Hu et al., 2004), Herba Ephedrae (Ma-huang) (Schaneberg et al., 
2003), etc.  
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1.4 Aims of This Thesis 
Flos Magnoliae is an important CHM used in the clinical application for rhinitis, sinusitis and 
headache (The Pharmacopoeia Commission of People's Republic of China, 2005). As 
mentioned through this chapter, molecular and chemical profiles, and pharmacological actions 
of different Flos Magnoliae species may vary, which may cause the confusion of its clinical 
application. In addition, there is little information about the locally grown Flos Magnoliae 
species, in terms of their genetic and chemical data, and pharmacological actions. Therefore, a 
systematic evaluation for different species and varieties is essential for developing quality 
control procedures for Flos Magnoliae. Furthermore, some intrinsic and extrinsic factors may 
contribute to the influences of the quality of Flos Magnoliae. Firstly, six Flos Magnoliae 
species and six M. biondii varieties were employed in the present study. Secondly, the Flos 
Magnoliae products from different herbal suppliers were included as well. At last, the qualities 
of the different M. biondii and M. sprengeri samples, collected from different cultivation sites 
in China or Australia, were used in this thesis. 
 
The major aim of this thesis was to develop systematic quality profiles of different Flos 
Magnoliae sources. The specific aims include: (1) identification of six Flos Magnoliae species 
from Australia and China using DNA-based markers; (2) qualitative identification of different 
Flos Magnoliae samples using TLC/HPTLC, while magnolin and fargesin were regarded as 
the marker compounds; (3) simultaneous determination of content of the bioactive lignans, 
magnolin and fargesin, in different Flos Magnoliae samples; (4) identification of Flos 
Magnoliae samples using HPLC fingerprinting techniques; (5) evaluation of the 
pharmacological actions of Flos Magnoliae and its active components, including the volatile 
oil and the lignans (magnolin and fargesin), on compound 48/80 induced histamine release 
from rat peritoneal mast cells (RPMC). 
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Five major methods were used in this study, including: DNA fingerprinting using RAPD and 
PCR-RFLP techniques; qualitative identification of the herbal extracts using TLC/HPTLC; 
determination of contents of the bioactive compounds using HPLC; identification of the 
herbal extracts using HPLC and pharmacological studies on compound 48/80 induced 
histamine release in RPMC. 
 
2.1 Sample collection  
2.1.1 Sample collection from China 
2.1.1.1 Flos Magnoliae species from Henan Province 
Eleven M. biondii samples from six varieties were collected in Nanzhao, Henan Province, 
China in February 2006. Four M. biondii samples were collected from four different locations 
of the cultivation sites in Nanzhao, Henan Province, China. A packed Flos Magnoliae product 
from Hualong Magnolia Development Co. Ltd. was employed in this study. Furthermore, the 
essential oil from Flos Magnoliae was used for testing. The samples were donated by Hualong 
Magnolia Development Co. Ltd. The altitude of the cultivation site is 300 – 1000m. The mean 
annual temperatures are 13˚C-15˚C and the mean annual precipitations are around 600 – 
1000mm. The cultivation site and collection procedures of M. biondii are shown in Figure 2.1 
and the morphological figures of the samples are illustrated in Figure 2.2.  
 
 
2.1.1.2 Flos Magnoliae species from Sichuan Province 
Two M. sprengeri samples and M. sargentiana were collected from two different locations 
(Jiangyou and Mabian) of Sichuan Province, China (Figure 2.3). The samples were supplied 
and identified by Prof. Zhongzhen Zhao from School of Chinese Medicine, Hong Kong 
Baptist University (HKBU), Kowloon Tong, Hong Kong Special Administrative Region 
(SAR), China in June 2005. 
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2.1.1.3 Flos Magnoliae species from Hong Kong SAR 
The Flos Magnolia products were from three herbal suppliers, including Tung Fong Hung 
Medicine Co. Ltd., Tsang Fook Kee Medicine Co., and Eu Yan Sang International Ltd., from 
Hong Kong SAR, China (Figure 2.4). The samples were supplied and identified by Prof. 
Zhongzhen Zhao from School of Chinese Medicine, HKBU in June 2004.  
 
2.1.2 Sample collection from Australia  
2.1.2.1 Magnolia spp. from Royal Botanic Garden (RBG), Melbourne 
The fresh buds of M. kobus were kindly supplied by RBG, Melbourne, Australia (Figure 2.5). 
With the assistance from Izabella Meraviglia-Crivelli, the curator of the Magnolia garden, 
RBG, Melbourne, the samples were collected in June 2003.  
 
2.1.2.2 Magnolia spp. from Ferny Creek Nursery, Mt. Dandenong, Victoria 
The fresh samples of M. campbellii, M. denudata, M. liliflora and M. sprengeri were 
purchased from the Ferny Creek Nursery, Mt. Dandenong, Victoria in June 2003 (Figure 2.6). 
All the tax invoices were kept in the RMIT Chinese Medicine Research Group. All the 
purchased specimens were planted in the Herbarium, RMIT.  
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Figure 2.1 The process of the Flos Magnoliae samples, collected from Nanzhao, Henan Province, China
Cultivation sites 
Medicinal plant 
Harvesting 
Processing  Dried herb Essential oil 
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Figure 2.2 The images of different varieties of M. biondii, collected from Nanzhao, Henan 
Province, China
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Huang Geng Chuan Yu 
 
Er Mao Tao 
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Biao Zhun Chuan Yu 
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Figure 2.3 The images of M. sprengeri and M. sargentiana colleted from Sichuan Province, China 
 
 
 
 
 
 
 
 
 
Figure 2.4 The images of three different Flos Magnoliae products from Hong Kong SAR, China
Tung Fong Hung  
Medicine Co. Ltd. 
Tsang Fook Kee 
Medicine Co. 
Eu Yan Sang  
International Ltd. 
M. sprengeri M. sargentiana M. sprengeri M. sargentiana 
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Figure 2.5 The images of M. kobus, collected from RBG, Melbourne, Australia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 The images of M. denudata and M. liliflora, from Ferny Creek Nursery, Mt. 
Dandenong, Victoria, Australia 
 
 
 
RBG, Melbourne M. kobus M. kobus 
M. liliflora M. denudata 
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2.2 Plant materials  
2.2.1 Flos Magnoliae samples for DNA fingerprinting  
The plant materials used in this study were five fresh Magnolia spp. and six dried Flos 
Magnoliae species (Table 2.1). The five fresh samples sourced locally from Ferny Creek 
Nursery, Mt. Dandenong, Victoria, Australia and Royal Botanic Garden (RBG), Melbourne, 
Victoria, Australia. Schisandra chinensis, as the positive control, was obtained from White 
Cottage Nursery, Victoria, Australia.  
 
For the dried samples, five above samples, except M. kobus, were dried in RMIT plant 
biotechnology laboratory under room temperature and in darkness condition for one month 
after collection. The other two dried samples, M. biondii and M. sargentiana were supplied 
and identified by Prof. Zhongzhen Zhao from School of Chinese Medicine, HKBU.  
 
Studies on PCR of 5S rRNA region were only conducted for five Flos Magnoliae species, 
except M. sargentiana.  
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Table 2.1 Fresh and dried Flos Magnoliae samples used in RAPD and PCR-RFLP analysis 
Section Species Nature Source of material 
Yulania M. campbellii Fresh Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
Yulania M. denudata Fresh/dried Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
Yulania M. liliflora Fresh/dried Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
Tulipastrum M. sprengeri Fresh/dried Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
Buergeria M. kobus Fresh/dried Royal Botanic Garden (RBG) Melbourne, Victoria, Australia 
Schisandra Schisandra chinensis Fresh White Cottage Nursery, Victoria, Australia 
Buergeria M. biondii Dried Nanzhao, Henan Province, China 
Yulania M. sargentiana Dried Mabian, Sichuan Province, China 
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2.2.2 Flos Magnoliae samples for chemical determination and identification 
Different Flos Magnoliae samples from six different Magnolia spp. (Table 2.2) were 
employed, including M. sargentiana and M. biondii from China. M. sprengeri, M. denudata 
and M. liliflora were purchased from Ferny Creek Garden, Victoria, Australia. M. kobus was 
kindly donated by RBG, Melbourne, Victoria, Australia.  
 
Moreover, 11 batches of M. biondii from six varieties were used in this study (Table 2.3). 
Five different Flos Magnoliae products were obtained from different herbal suppliers, namely, 
Hualong Magnolia Development Co. Ltd. in Henan Province, China, Tung Fong Hung 
Medicine Co. Ltd., Tsang Fook Kee Medicine Co. and Eu Yan Sang International Ltd. in 
Hong Kong SAR, China, and KODA International in Australia (Table 2.4). Four M. biondii 
samples were collected from different growing locations, in Nanzhao, Henan Province, China 
(Table 2.5). 
 
Two of three M. sprengeri samples were collected from Jiangyou and Mabian, Sichuan 
Province, China.  Another M. sprengeri sample was purchased from Ferny Creek Garden, 
Victoria, Australia (Table 4.6).  
 
The identities of all samples from China were confirmed by Prof. Zhongzhen Zhao, School of 
Chinese Medicine, HKBU, Hong Kong SAR, China. All Flos Magnoliae samples collected 
from Australia were identified by Dr. Edwin C. K. Pang, School of Applied Sciences, RMIT.  
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Table 2.2 Different species of Flos Magnoliae, collected from Australia and China 
Species Name Sources 
M. biondii Nanzhao, Henan Province, China 
M. denudata  Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
M. kobus RBG, Melbourne, Victoria, Australia 
M. liliflora Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
M. sargentiana Mabian, Sichuan Province, China 
M. sprengeri Ferny Creek Nursery, Mt. Dandenong, Victoria, Australia 
 
 
Table 2.3 Different varieties of M. biondii, collected from Nanzhao, Henan Province, China. 
Variety Name 
No 
Sample Name English Name Chinese Name 
1  HLWH Hua Long Wu Hao 华龙五号 
2 EMT Er Mao Tao 二毛桃 
3 EMT Er Mao Tao 二毛桃 
4 XMT Xiao Mao Tao 小毛桃 
5 HGCY Huang Geng Chuan Yu 黄梗串鱼 
6 CY Chuan Yu 串鱼 
7 CY Chuan Yu 串鱼 
8 CY Chuan Yu 串鱼 
9 EMT Er Mao Tao  二毛桃 
10 HLWH Huang Long Wu Hao 华龙五号 
11 BZCY Biao Zhun Chuan Yu 标准串鱼 
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Table 2.4 Different Flos Magnoliae products from five herbal suppliers  
Sample Name Herbal Suppliers  
HL 
Hualong Magnolia Development Co. Ltd., Henan Province, 
China 
TFH Tung Fong Hung Medicine Co. Ltd., Hong Kong SAR, China 
TFK Tsang Fook Kee Medicine Co., Hong Kong SAR, China 
EYS Eu Yan Sang International Ltd., Hong Kong SAR, China 
KODA KODA International, Australia 
 
Table 2.5 Different M. biondii samples, collected from different cultivation sites in China 
Sample Name Cultivation sites 
DHY Eastern Garden, Nanzhao, Henan Province, China 
XHY Western Garden, Nanzhao, Henan Province, China 
YYS Mt. Yanyi, Nanzhao, Henan Province, China 
TQ Tian Bridge, Nanzhao, Henan Province, China 
 
Table 2.6 Different M. sprengeri samples, collected from different cultivations sites in China 
and Australia 
Sample Name Cultivation sites 
JY Jiangyou, Sichuan Province, China 
MB Mabian, Sichuan Province, China 
MD 
Ferny Creek Nursery, Mt. Dandenong, Victoria, 
Australia 
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2.2.3 Flos Magnoliae samples for pharmacological study  
The Flos Magnoliae samples used for anti-histamine release studies were previously identified 
using TLC and HPLC in this thesis. Furthermore, the volatile oil of Flos Magnoliae, which 
was supplied by Hualong Magnolia Development Co. Ltd., was employed for anti-histamine 
release test. The anti-histamine release effects of two isolated compounds, magnolin and 
fargesin were purchased from National Institute for the Control of Pharmaceutical and 
Biological Products (NICPBP) of China. 
 
2.3 Reagents and chemicals  
2.3.1 Reagents and chemicals for DNA fingerprinting  
DNeasy Plant Mini Kit and DNeasy Plant Maxi Kit were purchased from Qiagen (Victoria, 
Australia). Tris-base, boric acid and ethylenediaminetetraacetic acid (EDTA) were obtained 
from Sigma-Aldrich (New South Wales, Australia). GeneRuler 1kb DNA Ladders and 
GeneRuler 100bp DNA Ladders Plus were acquired from Fermentas (Queensland, Australia). 
dNTPs kits (dATP, dCTP, dTTP and dGTP), 10×PCR buffer, 50mM MgCl2 and Taq 
polymerase were purchased from Invitrogen (Victoria, Australia). EtBr was acquired from 
BioRad (New South Wales, Australia). Ten-mer oligo primers (GeneWorks, South Australia, 
Australia) were used for RAPD analysis. A pair of 5S rRNA primers was purchased from 
Invitrogen, Australia.  
 
2.3.2 Reagents and chemicals for TLC analysis  
Diethyl ether for TLC / HPTLC analysis was HPLC grade (Merck, New South Wales, 
Australia); and chloroform for TLC / HPTLC analysis was HPLC grade (Sigma-Aldrich, New 
South Wales, Australia) also. HPLC grade methanol was purchased from Merck New South 
Wales, (New South Wales, Australia). The marker compounds magnolin and fargesin were 
purchased from the NICPBP of China.  
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2.3.3 Reagents and chemicals for HPLC analysis  
Acetonitrile for HPLC analysis was HPLC grade (Sigma-Aldrich, New South Wales, 
Australia); and water for HPLC analysis was purified by a Milli-Q water purification system 
(Millipore, New South Wales, Australia). ACS grade ethanol was purchased from Ajax 
Finechem (New South Wales, Australia). The marker compounds magnolin and fargesin were 
purchased from the NICPBP of China.  
 
2.3.4 Reagents and chemicals for histamine release determination 
Compound 48/80, spermidine trihydrochloride, o-phthalaldehide (OPA), histamine, toluidine 
blue, N-2-hydroxyethylpiperazine-N’-ethanesulfonic acid (HEPES), sodium chloride (NaCl), 
potassium chloride (KCl), MgCl2, L-(+)-tartaric acid, sodium tartrate dihydrate, 1-
octanesulfonic acid sodium salt, boric acid and sodium hydroxide (NaOH) were obtained 
from Sigma-Aldrich (New South Wales, Australia). Calcium chloride (CaCl2), di-sodium 
hydrogen orthophosphate (NaH2PO4) and D-glucose anhydrous were acquired from Ajax 
Chemicals (New South Wales, Australia). Heparin sodium injection was obtained from BDL 
(Australia). HPLC grade methanol was purchased from Merck (New South Wales, Australia). 
The marker compounds magnolin and fargesin were purchased from the NICPBP of China.  
 
2.4 Identification of different Flos Magnoliae species using DNA 
fingerprinting  
2.4.1 DNA extraction  
DNAs from fresh samples were extracted using the DNeasy Plant Mini Kit (Qiagen, Victoria, 
Australia), and DNA templates from dried medicinal materials were extracted using the 
DNeasy Plant Maxi Kit (Qiagen, Victoria, Australia). The extraction procedures were based 
on the protocols provided by the supplier. Briefly, 100mg of fresh plant tissues or 500mg of 
dried buds were ground to a fine powder in liquid nitrogen. After adding specific buffers at 
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various stages to lyse the cells and precipitate the detergent, proteins and polysaccharides, the 
debris and precipitates were retained in the filter of either QIAshredder Mini or Maxi Spin 
Column. The DNA that was bound on the membrane of either DNeasy Mini or Maxi Spin 
Column was then washed by the washing buffer, followed by an elution step.  
 
Aliquots of 5µl or 10µl of DNA templates were analysed using 1.5% DNA grade agarose gel 
electrophoresis in the 1× TBE (10.8g of Tris-base, 5.5g of boric acid and 0.93g of EDTA 
dissolved in 1L distilled water) buffer system. The 1kb GeneRuler™ DNA Ladders was used 
as a molecular weight marker. The electrophoretic gel plate was stained in a 10µg/ml solution 
of EtBr and visualised under UV illumination. The Discovery Series Quantity One 1-D 
Analysis Software (BioRad, New South Wales, Australia) was used for imaging the 
electrophoresis gels. The remaining DNA was kept at -20°C for further analysis. The DNA 
stocks were adjusted to a concentration of about 10ng/µl for PCR amplification. 
 
2.4.2 RAPD  
Fifteen 10-mer oligo primers (GeneWorks, South AustraliaAustralia) were used for RAPD 
analysis of fresh samples, and ten 10-mer oligo primers (Operon, Cologne, Germany) were 
employed for analysis of dried herbal materials (Table 2.7). The RAPD method was modified 
from previous studies (Shaw and But, 1995, Cui et al., 2003). Briefly, 40ng of plant DNA was 
amplified in a 25µl PCR mixture consisting of 2.5µl of 10×PCR buffer (100mM Tris-HCl, 
500mM KCl, 0.01% gelatin), 0.75µl of 50mM MgCl2, 6µl of 1mM dNTPs, 1µl of 10µM 
primer and 1U Taq polymerase. The amplified reaction took place in a P×2 Thermal Cycler 
(Thermal Electron Corporation, Waltham, MA, United States) and PCR was performed using 
the following cycles: initial 1 cycle of 3min at 94°C, followed by 15s denaturing at 94°C, 
1min annealing at 36°C and 1min elongation at 72°C for 38 cycles and 1 cycle of 5min 
extension at 72°C. The RAPD fragments were separated on 1.5% DNA grade agarose gel 
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electrophoresis. The Discovery Series Quantity One 1-D Analysis Software (BioRad, New 
South Wales, Australia) was used for imaging the electrophoresis gels. 
 
Table 2.7 Decamer oligo primers used for RAPD analysis 
Oligo Name Sequence (5’ → 3’) 
Suggested annealing 
temperature  
Usage 
OPA-07 GAA ACG GGT G 35°C Dried samples 
OPA-11 CAA TCG CCG T 32°C Fresh / Dried samples 
OPA-14 TCT GTG CTG G 35°C Dried samples 
OPB-03 CAT CCC CCT G 32°C Fresh / Dried samples 
OPB-04 GGA CTG GAG T 35°C Fresh / Dried samples 
OPB-06 TGC TCT GCC C 32°C Fresh / Dried samples 
OPB-07 GGT GAC GCA G 35°C Fresh / Dried samples 
OPB-08 GTC CAC ACG G 32°C Fresh samples 
OPB-12 CCT TGA CGC A 35°C Dried samples 
OPB-16 TTT GCC CGG A 35°C Dried samples 
OPB-17 AGG GAA CGA G 35°C Dried samples 
OPC-19 GTT GCC AGC C 32°C Fresh samples 
OPG-13 CTC TCC GCC A 32°C Fresh samples 
OPM-04 GGC GGT TGT C 32°C Fresh samples 
OPN-04 GAC CGA CCC A 32°C Fresh samples 
OPP-10 TCC CGC CTA C 32°C Fresh samples 
OPU-03 CTA TGC CGA C 32°C Fresh samples 
OPV-06 ACG CCC AGG T 32°C Fresh samples 
OPW-04 CAG AAG CGG A 32°C Fresh samples 
OPW-09 GTG ACC GAG T 32°C Fresh samples 
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2.4.3 PCR-RFLP  
A pair of PCR-primers (GeneWorks, South Australia, Australia), 5SP1=5’ GTG CTT GGG 
CGA GAG TAG TA 3’ (forward) and 5SP2=5’ TTA GTG CTG GTA TGA TCG CA 3’ 
(reverse), was used for PCR-RFLP. They were designed to amplify the 5S ribosomal RNA (5s 
rRNA) spacer (Wolters and Erdmann, 1988). A 25µl PCR mixture contained the following 
40ng plant DNA, 2.5µl of 10×PCR buffer, 0.75µl of 50mM MgCl2, 6µl of 1mM dNTPs, 1µl 
of 10µM forward primer, 1µl of 10µM reverse primer and 1 units Taq polymerase. PCR was 
performed using the following cycles: initial 3min at 94°C, followed by 1min denaturing at 
94°C, 1min annealing at 62°C and 1min elongation at 72°C repeated for 38 cycles and with 
10min extension at 72°C. The RFLP fragments were separated on 1.5% agarose gel by 
electrophoresis in 1×TBE buffer system and stained with EtBr (Lin et al., 2001). 
 
The PCR products were digested by restriction enzymes AflIII, ApoI, DdeI, EcoRI, EcoRV, 
HaeIII, HhaI, HinfI, MnlI, NcoI, NlaIV, PmlI, PstI, RsaI and SmaI (Table 2.8). Briefly, 4µl of 
PCR products was digested for 2hr at 37°C with 5 units of restriction enzymes (10 units/µl), 
1µl RE 10×buffer and 0.1µl of acetylated bovine serum albumin (BSA) (10µg/µl) in a 10µl 
total volume (Lin et al., 2001). The digested fragments were separated on 1.5% agarose gel, 
stained with EtBr and visualised under UV illumination. The Discovery Series Quantity One 
1-D Analysis Software (BioRad, New South Wales, Australia) was used for imaging the 
electrophoresis gels. 
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Table 2.8 The details of 15 restrictions enzymes for PCR-RFLP analysis  
Restriction 
Enzymes 
Sequence (5’ → 3’) 
Suppliers 
AflIII A▼CRYGT New England Biolabs, Ipswich, MA, USA 
ApoI R▼AATTY New England Biolabs, Ipswich, MA, USA 
DdeI C▼TNAG Promega, New South Wales, Australia 
EcoRI G▼AATT C Promega, New South Wales, Australia 
EcoRV GAT▼TAC  Promega, New South Wales, Australia 
HaeIII GG▼CC Promega, New South Wales, Australia 
HhaI  GCG▼C  Promega, New South Wales, Australia 
HinfI G▼ANTC Promega, New South Wales, Australia 
MnlI CCTC(N)7▼ New England Biolabs, Ipswich, MA, USA 
NcoI C▼CATG G Promega, New South Wales, Australia 
NlaIV GGN▼NCC New England Biolabs, Ipswich, MA, USA 
PmlI CAC▼GTG New England Biolabs, Ipswich, MA,  USA 
PstI CTGCA▼G Promega, New South Wales, Australia 
RsaI GT▼AC Promega, New South Wales, Australia 
SmaI CCC▼GGG Promega, New South Wales, Australia 
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2.5 Identification of different Flos Magnoliae species and varieties 
using TLC/HPTLC 
2.5.1 Herbal extraction and preparation 
Samples were crushed into powder with a mortar and pestle. Precisely, 1g of fine powder of 
each sample was extracted with 60ml of absolute ethanol using an Accelerated Solvent 
Extraction machine (ASE-100, Dionex, Sunnyvale, CA, U.S.A.). The herb was extracted three 
times at a temperature of 100°C and under the pressure of 1500psi. The static time was 5 min 
and the flush volume was 60% of the 33ml cell. After filtered by Whatman No1. paper filter 
(150mm Dia) (Crownscientific, Victoria, Australia), the combined extract was evaporated at 
60°C under vacuum to 20ml approximately. The concentrated extract was then diluted by 
HPLC grade ethanol to the final volume as 25ml using a volumetric flask. The ethanol extract 
was filtered with PTFE syringe filters (25mm, 0.45µm) (Alltech Associates, New South 
Wales, Australia) and stored at -20°C for further analysis. Before the TLC application, the test 
samples were sonicated for 15min.  
 
2.5.2 Preparation of standard references, magnolin and fargesin 
A stock solution of the standard was prepared by weighing 1.5mg each of magnolin and 
fargesin into a 1.5ml Eppendorf tube. Precisely 1.5ml of ethanol was added to each tube and 
the solution was sonicated for 15min. After the solution had cooled to the room temperature, 
it was diluted from the stock solution to the concentrations of 2.5mg/ml for magnolin and 
1mg/ml for fargesin.  
 
2.5.3 Chromatographic conditions 
2.5.3.1 TLC/HPTLC plates preparation  
TLC silica gel 60 F254 plates (20cm x 10cm, E. Merck, Darmstadt, Germany) and HPTLC 
silica gel 60 F254 plates (10cm x 10cm, E. Merck, Darmstadt, Germany) were employed. The 
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plates were pre-washed with HPLC grade methanol, and then dried for 30min at 105°C before 
sample application.  
 
2.5.3.2 Sample application  
Test solution of the reagent blank (methanol, 5µl), reference standard and samples were 
applied on the plates with a TLC system (CAMAG, Muttenz, Switzerland) (Figure 2.7 and 
Table 2.9). With Linomat 5, maximum of 18 tracks were applied. Band width was required at 
the minimum of 8mm. Varying amount of analytes were applied of 8mm space from the 
lower edge of the plates. The distances from the side of the plates were at least 15mm, while 
the space between two bands were at least 10mm.  The spraying rates for the samples were 
20µl. 
 
2.5.3.3 Chromatographic conditions 
The TLC plates and HPTLC plates were then developed in a 20cm x 10cm and a 10cm x 
10cm horizontal developing chambers with glass lids, respectively. The twin-trough chamber 
was pre-equilibrated for 30min with the filter paper soaked with 10ml developing solvent. For 
TLC/HPTLC separation, chloroform – ether (5:1) was used as the developing solvent. The 
migration distance was 7cm from lower edge. Subsequent to the development, TLC/HPTLC 
plates were dried in a current of air.  
 
2.5.3.4 Documentation  
After developing, densitometric scanning was performed by CAMAG TLC scanner III in the 
absorbance mode at 254nm. The source of radiation utilized was a deuterium lamp.  
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Figure 2.7 CAMAG TLC system (CAMAG, Switzerland) 
Linomat 5 
(semi-automatic sample application) 
10cm x 10cm plates 
Horizontal developing chamber 
20cm x 10cm plates 
DigiStore 2 documentation system with high-
resolution 12-bit CCD camera (HV-C20A, Hitachi, 
Japan) 
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Table 2.9 The compositions of CAMAG system 
Components Model 
Sample application  Linomat 5 (semi-automatic sample application) 
Chromatogram 
development 
Horizontal developing chamber 20cm x 10cm plates (for 
TLC) 
Horizontal developing chamber 10cm x 10cm plates (for 
HPTLC) 
Evaluation: detection  TLC scanner III 
Evaluation: 
documentation  
DigiStore 2 documentation system with high resolution 12 
bit CCD camera (HV-C20A, Hitachi, Japan) 
UV cabinet dural wavelength, 254/366nm 
Chromatographic layer 
Merck, TLC plates silica gel 60F 254 20 x 10cm 
Merck, HPTLC plates silica gel 60F 254 10 x 10cm 
Software  winCATS (Version: 1.2.5) 
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2.6 Quantitative determination of Magnolin and Fargesin from 
different Flos Magnoliae species and varieties using HPLC  
2.6.1 Herbal extraction and preparation 
The procedure for extraction and preparation are described in Section 2.5.1. Briefly, the fine 
powder of each sample was extracted with absolute ethanol using an Accelerated Solvent 
Extraction machine (ASE-100, Dionex, Sunnyvale, CA, U.S.A.). The concentrated ethanol 
extracts were filtered with PTFE syringe filters (25mm x 0.45µm, Alltech Associates, New 
South Wales, Australia) and stored at -20°C. After being sonicated for 15min, the 20 times 
ethanol (HPLC grade) dilution of the stock solution was used for HPLC injection.  
 
2.6.2 Preparation of standard references, magnolin and fargesin 
A stock solution of the standard was prepared by accurately weighing about 1.5mg each of 
magnolin and fargesin into a 1.5ml Eppendorf tube. Precisely 1.5ml of ethanol was added to 
each tube and the solution was sonicated for 15min. After the solution cooled to the room 
temperature, it was diluted from the stock solution to five concentrations, ranging from 10-
100 ng/ml for magnolin and 1-10 ng/ml for fargesin.  
 
2.6.3 Chromatographic conditions 
HPLC was performed on a Shimadzu Model SCL-10Avp HPLC system (Shimadzu, Japan) 
equipped with a Shimadzu Model SPD-M10Avp photodiode array detector (Figure 2.8 and 
Table 2.10). The separations were obtained with a RP-C18 column (ODSII, L 250 × 4.6 I.D. 
mm, 5µM, Phenomenex, Torrance, CA, U.S.A.) and a pre-column of the same packing 
material (Security Guide cartridge; 3.0mm; Phenomenex, Torrance, CA, U.S.A.) were used 
for analysis. A linear gradient elution of acetonitrile and water was used. The gradient 
program is presented in Table 2.11. Among of these, 20min for determination, and 10min for 
pre-equilibration. Detection wavelength was set at 278nm. The solvent flow rate was 1ml/min 
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and the column temperature was set at 30°C (Figueiredo et al., 1999, Xu et al., 2003).  The 
injection volume was 10µl of the prepared solution. Total running time was 30.50min.  
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Figure 2.8 Shimadzu Model SCL-10Avp HPLC system (Shimadzu, Japan) 
Durable pump A 
 
Auto-injector  
Flow line switching valve 
 
Four-line membrane degasser VP column oven  
System controller 
Photodiode array detector 
Fluorescence detector 
Durable pump B 
 
Fraction collector 
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Table 2.10 The compositions of Shimadzu system  
Components Model 
System controller SCL-10Avp 
Auto-injector SIL-10ADvp 
Durable pump LC-10ATvp 
Flow line switching value FCV-10ALvp 
Four-line membrane degasser DGU-14A 
VP column oven CTO-10Avp 
Photodiode array detector SPD-M10Avp 
Fluorescence detector RF-10Axl 
Software Class-vp5.0 
 
 
Table 2.11 A linear gradient solution for HPLC determination  
Time (min) Acetonitrile (%) Water (%) 
0.01 45 55 
10.00 65 35 
18.00 70 30 
20.00 45 55 
30.00 45 55 
30.50 Stop 
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2.6.4 Validation parameters 
2.6.4.1 Linearity 
Linear calibration curves were constructed by analysis of a mixture containing magnolin and 
fargesin at five levels and plotting peak area against the concentration of each reference 
standard. The standard solution (10µl) was used for HPLC injections. Calibration curves were 
constructed at the relevant wavelength of maximum absorption of each reference compound.  
 
2.6.4.2 Precision 
The Flos Magnoliae sample was prepared as described in Section 2.5.1. The intermediate 
precisions of injections were evaluated with the test sample five times on the same day. All of 
the measurements of precisions were expressed as relative standard deviations (R.S.D.s). 
 
2.6.4.3 Stability  
Same analyte, which was conducted the precision test, was employed for the stability test. The 
stability of injection was calculated with the test sample at the room temperature for five 
times.  The HPLC injections were taken during 48hr. All of the measurements of stabilities 
were expressed as R.S.D.s. 
 
2.6.4.4 Repeatability 
Five replicates analyses of the same Flos Magnoliae sample were carried out to sequentially 
evaluate the repeatability of the quantitative procedure. All of the measurements of 
repeatabilities were expressed as R.S.D. 
 
2.6.4.5 Recovery 
Standards of 200µg/ml of magnolin and 15µg/ml of fargesin in solutions were spiked to the 
Flos Magnoliae sample solution of which the content of magnolin and fargesin had been 
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determined before the addition of the two chemical standards. Then, two marker compounds 
in Flos Magnoliae sample solutions were extracted, processed and quantified in accordance 
with the established procedure, and finally the recovery rates were calculated.  
 
2.7 Identification of different Flos Magnoliae species and varieties 
using HPLC  
2.7.1 Herbal extraction and preparation 
The procedure for extraction and preparation of Flos Magnoliae samples were described in 
Section 2.5.1. After being sonicated for 15min, the stock solution was directly used for HPLC 
injection.  
 
2.7.2 Chromatographic conditions 
A Shimadzu Model SCL-10Avp HPLC system (Shimadzu, Japan) equipped with a Shimadzu 
Model SPD-M10Avp photodiode array detector was used to perform HPLC analysis (details 
see Figure 4.1 and Table 4.10). The HPLC fingerprint was carried out on a RP-C18 column 
(ODSII, L 250 × 4.6 I.D. mm, 5µM, Phenomenex, Torrance, CA, U.S.A.) and a pre-column 
of the same packing material (Security Guide cartridge; 3.0mm; Phenomenex, Torrance, CA, 
U.S.A.). A linear gradient mobile phase of acetonitrile and water was used. The gradient 
program is presented in Table 2.12. Among of these, 60min was used for determination, and 
15min was used for pre-equilibration. Detection wavelength was set at 278nm. The solvent 
flow rate was 1.0ml/min and the column temperature was set at 30°C. The injection volume 
was 10µl of the prepared solution. Total running time was 75.50min.  
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Table 2.12 A linear gradient solution for HPLC identification 
Time (min) Acetonitrile (%) Water (%) 
0.01 30 70 
15.00 30 70 
25.00 60 40 
35.00 70 30 
45.00 75 25 
60.00 75 25 
61.00 30 70 
75.00 30 70 
75.50 Stop 
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2.7.3 Validation parameters  
2.7.3.1 Precision 
The intra-day precisions of the HPLC-DAD method were validated with the analyte under the 
selected optimal conditions five times consistently. All measurements of precisions were 
expressed as R.S.D.s. 
 
2.7.3.2 Stability  
For stability, measurements on three consecutive days were conducted. All of the 
measurements of stabilities were expressed as R.S.D.s. 
 
2.7.3.3 Repeatability 
Five independently prepared sample solution of Flos Magnoliae with the same amount were 
analysed and the variations within five measurements were calculated for evaluation of the 
repeatability. All of the measurements of repeatabilities were expressed as R.S.D.s. 
 
2.8 Determination of compound 48/80 induced histamine release in 
RPMC 
2.8.1 Herbal extraction and preparation  
Samples were crushed into powder with a mortar and pestle. Precisely, 1g of fine powder of 
each sample was extracted with 60ml of absolute ethanol using an Accelerated Solvent 
Extraction machine (ASE-100, Dionex, Sunnyvale, CA, U.S.A.). The herb was extracted three 
times (i.e. three static cycles), at a temperature of 100°C and under a pressure of 1500psi. 
After filtered by Whatman No1. paper filter (Crownscientific, New South Wales, Australia), 
the combined extract was evaporated at 65°C under vacuum to 5ml approximately. Ather 
transferred to a tube, the concentrated extracts then were evaporated at 80°C to dryness using 
a multi-block heater. The dried concentrated powder were precisely weighed and followed by 
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diluted in absolute ethanol. The ethanol extract was filtered with PTFE syringe filters (25mm 
x 0.45µm, Alltech Associates, New South Wales, Australia) and stored at -20°C for further 
analysis.  
 
2.8.2 Animals  
Male Sprague Dawley (SD) rats at 10 – 12 weeks of age (250 – 350g) were used for 
experiments. All animals were purchased from Monash Animal Services, Victoria, Australia. 
All procedures involved in experimental animals had the prior approval from the Animal 
Experimentation Ethics Committee of RMIT University and conformed to the Australian 
National Health and Medical Research Council guidelines. Animals were housed in the RMIT 
Bundoora animal facility located in building 201, level 1, under controlled conditions. The 
temperature (19-22°C) and lighting (12 hour on and 12 hour off) conditions of the animal 
accommodation were controlled. Groups of 2-4 animals were placed in a standard rat box and 
were fed a diet consisting of adlib water and standard rat chow.  
 
2.8.3 Isolation and preparation of peritoneal mast cells from rats  
On the day of the experiment, the male SD rats (250 – 350g, Monash Animal Services, 
Victoria, Australia) were transferred to the treatment laboratory of Building 223, level 2, 
Module E, Room 46 where they were sacrificed by asphyxiation in a saturated carbon dioxide 
(CO2) atmosphere followed by decapitation.  
 
The peritoneal mast cells were prepared as described previously (Ikarashi et al., 2001b). 
Briefly, 20ml of Tyrode’s buffer (NaCl, 137.0mM; KCl, 1.0mM; MgCl2, 1.0mM; CaCl2, 
1.6mM; NaH2PO4·2H2O, 0.41mM; HEPES, 10mM and L-(-)-Glucose, 1%; pH 7.4) 
containing 0.3% BSA and 5.0 units/ml heparin sodium was injected intraperitoneally. The 
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abdomen was gently massaged for 2min, followed by collection of peritoneal solutions, which 
contained mast cells. The solution was then centrifuged at 1200rpm for 5min at 4°C. 
 
The pellet containing RPMC was washed three times with 15ml of Tyrode’s solution and 
resuspended in 10ml Tyrode’s buffer, PH 7.4, containing 0.1% BSA. Fifty microliter of 
0.05% toluidine blue in saline was added to an equal volume of the cell suspension. This 
solution was employed to determine the number of mast cells in the suspension to stain mast 
cells by counting microscopically using a Burker-Turk counting chamber. Finally, the number 
of RPMC in the suspension was adjusted to 5×105 cells/ml for further experiments. 
 
2.8.4 Effects of herbal extraction on compound 48/80 induced histamine release in 
RPMC  
To study the effects of herbal extracts on mast cell-derived histamine release, 10µl of various 
concentrations of herbal extracts (final concentrations, 0.01, 0.05, 0.1, and 0.5 µg/ml) or an 
equal volume of absolute ethanol (vehicle controls) was added to the cell suspension (5×105 
cells/ml, pre-incubated in the water bath at 37°C for 10 min) to a final volume of 500µl and 
incubated in the water bath at 37°C for 10min (Ikarashi et al., 2001a, Ikarashi et al., 2001b).  
 
Histamine release in RPMC was then elicited by the addition of 25µl of compound 48/80 
(final concentration of 0.5 µg/ml) into the cell suspension. After further incubation at 37°C 
for 10min, the suspension was chilled in ice for 10min to stop the reaction of histamine 
release in RPMC. Residual histamine in the cells was released by disrupting the cells with 
30% HClO4 and centrifugation at 12000rpm for further 2min. Then, 50µl of aqueous 
spermidine trihydrochloride (1.0 mg/ml) was then added as an internal standard into the 
supernatant. The basal and total levels of histamine release were determined using Tyrode’s 
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buffer (10 mM) or 30% HClO4, respectively, as previously described (Ikarashi et al., 2001b). 
Ca2+ chelating agent EDTA (100 µM) was used as a positive control. 
 
2.8.5 HPLC system for determination of compound 48/80 induced histamine 
release in RPMC  
The level of histamine released in RPMC was determined by HPLC using a Shimadzu HPLC 
instrument SCL-10Avp (Shimadzu, Japan) with the following conditions (details see Figure 
2.1 and Table 2.10): a fluorescent detector (RF-10Axl, Shimadzu, Japan), a STR reverse-
phase column (ODS-II; L 150 × 4.6 I.D. mm; 5µM; Shimadzu, Japan.) and an attached post-
column for derivatization with the OPA, which is a reaction coil (5.0×0.5mm stainless steel 
tubing). Mobile phase to the main column was made up of a mixture of 100mM sodium 
tartaric acid buffer (pH 4.4), containing 25mM L-(+)-tartaric acid, 75mM sodium tartrate 
dihydrate and 10mM 1-octanesulfonic acid sodium salt, and HPLC grade methanol (2:1), and 
the flow-rate was maintained at 1.0ml/min (Table 2.13). The post column solution for 
derivatization contained a mixture of 400mM sodium borate buffer (pH 9.2), containing 
400mM boric acid and 200mM NaOH, and 10mM OPA in HPLC grade methanol (2:1) 
(Table 2.14). The post column flow-rate was 0.5ml/min. The column temperature was set at 
50°C and the injection volume was 10µl. The wavelengths for excitation and emission were 
360nm and 440nm, respectively. Under these conditions, the retention time of histamine was 
3.5 min, while that of the internal standard (spermidine) was 6.0 min. 
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Table 2.13 The constituents of the mobile phase for determination of histamine release. 
Consisted a mixture A:B = 2:1. 
 Buffer  Gradients 
A 
100mM Sodium tartaric acid buffer with 
10mM 1-octanesulfonic acid sodium salt, 
dissolved in distilled water, (pH 4.4) 
25mM L-(+)-Tartaric acid  
75mM Sodium tartrate dihydrate 
10mM 1-octanesulfonic acid sodium salt 
B Methanol (HPLC Grade) 
 
 
 
Table 2.14 The constituents of the post column solution for determination of histamine 
release. Consisted a mixture C:D = 2:1. 
 Buffer  Gradients 
C 
400mM Sodium borate buffer dissolved 
in distilled water, (pH 9.2) 
400mM Boric acid 
200mM NaOH 
D 
OPA dissolved in Methanol 
 (HPLC Grade) 
10mM   OPA 
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2.9 Data analysis and statistics  
2.9.1 Analysis of genetic distances  
Only clear, coherent and consistent banding patterns were scored. RAPD and PCR-RFLP 
bands were scored as present (1) or absent (0) for each genotype. A matrix of genetic 
distances estimation between different Magnolia spp., based on dissimilarity (D=1-SXY) 
indices was obtained by POPGENE v 1.31, a Microsoft Window-based free software for 
population genetic analysis (Yeh et al., 1999). On the basis of Nei’s coefficient, the genetic 
similarity indices were calculated as SXY=2nXY/(nX+nY), where nX and nY represent the 
numbers of fragments in individuals X and Y, respectively, and nXY represents the number of 
the fragments shared between individuals X and Y. 
 
The free software package Molecular Evolutionary Genetics Analysis 2 (MEGA 2) was used 
for reconstruction which for comparison the genetic distances between all individuals by an 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) method (Kumar et al., 
2001, Kumar and Tamura, 2000). The linearised tree was expressed as percentage of the 
dissimilarity indices. 
   
2.9.2 Data analysis of identification using TLC/HPTLC 
The chromatograms were imaged and analysed by winCATs (CAMAG, Muttenz, 
Switzerland). The Rf values of the resolved bands were recorded. Furthermore, testing 
samples were in quadruplicates and all of the measurements were expressed as R.S.D. 
 
2.9.3 Data analysis of quantitative determination of magnolin and fargesin using 
HPLC   
Based on the liner regression models from the calibrations of standards, magnolin and 
fargesin, the linear relationships were established between the measured peak area and the 
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known concentration. According to the equation Y=a × X + b, a represents the intercept value 
of the axis of the measured peak area (Y), and b represents the slope of the line. The 
concentration of the test sample (X) was calculated as the area under the peak as compared to 
the reference area. Testing samples were in triplicates and were represented as mean ± 
standard deviation (S.D.). Furthermore, all of the measurements were expressed as R.S.D. 
 
2.9.4 Data analysis of identification using HPLC  
The HPLC chromatograms were documented by Class-vp5.0 (Shimadzu, Japan). The 
retention time, relative retention time, peak area and relative peak area of each characteristic 
peak were also calculated in the chromatograms. Testing samples were in triplicates and all 
measurements were expressed as R.S.D. 
 
2.9.5 Data analysis and statistics for determination of histamine release  
The effect of Flos Magnoliae species on compound 48/80-induced histamine release in RPMC 
was calculated using the following formula: Percentage (%) inhibition = (level of compound 
48/80 induced histamine release in the present of equal volume of ethanol – level of 
compound 48/80 induced histamine release in the presence herbal ethanol extract) / (level of 
total histamine release – basal level of histamine release). The effect of EDTA was calculated 
use the same formula except using Tyrode’s buffer as the vehicle. 
 
Data were presented as mean ± standard error of measurement (S.E.M.). Statistics of 
comparisons between groups were carried out by one-way analysis of variance (one-way 
ANOVA) followed by Tukey’s test using the Prism 4.03 (GraphicPad Software, Inc., San 
Diego, CA, U.S.A.). Values of p < 0.05 indicated significant difference.  
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 Chapter Three 
Identification of Different Flos Magnoliae Species Using 
 DNA-Based Fingerprinting Markers 
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3.1 Background 
As described in Section 1.3.2, DNA based markers have been considered as one of the 
commonly used methods to identify and authenticate medicinal species (Joshi et al., 2004). 
DNA-based markers are more distinct, standard, and definite means of CHM authentication 
and authentication, including PCR-based markers, hybridisation-based markers and 
sequencing-based markers (Fowler et al., 1994, Fan et al., 2004).  
 
As one of the commonly used DNA-based molecular markers, RAPD has been extensively 
applied to study the genetic diversities and authenticate different species and varieties of 
CHM. The main principles and the application of CHM identification and authentication 
using RAPD are described in Section 1.3.2.1.1. RAPD fingerprints of a number of CHMs, 
including Radix Ginseng (Ren-shen) and Radix Panacis Quinquefolii (Xi-yang-shen) (Ma et 
al., 2000a, Jiang et al., 1998), Rhizoma Atractyloids (Cang-zhu) (Ren et al., 2000, Mizukami 
et al., 2000, Kohjyouma et al., 1997), Radix Angelicae Sinensis (Dang-gui) (Gao et al., 2001), 
Flos Lonicerae (Jin-yin-hua) (Yu and Shi, 2000), and Fructus Lycii (Gou-qi-zi) (Zhang et al., 
2001), have been revealed.  
 
Compared to RAPD, PCR-RFLP provides better reproducibility and sensitivity of DNA 
amplification from organisms (Glick and Pasternak, 2003, Arens, 1999). PCR-RFLP analysis 
of the 18S rRNA region has been used for the identification of various species of Radix 
Ginseng (Ren-shen) (Fushimi et al., 1997, Um et al., 2001). The rDNA ITS regions have been 
employed to differentiate the various sources of Radix Codonopsis (Dang-shen) (Fu et al., 
1999). Nakai et al (1996) reported the genetic fingerprints of different Herba Epimedii (Ying-
yang-huo) in Japan using PCR-RFLP of the rbcL region.  
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5S rRNA is a cellular protein synthesis apparatus that can be found in prokaryotes and 
eukaryotes (Barciszewska et al., 2001). The gene encoding 5S rRNA occurs in eukaryotes in 
tandem repeating units, possessing a coding region of 120bp (Figure 3.1) (Barciszewska et al., 
2001, Ma et al., 2000b). The structure and the function of 5S rRNA have been detailed based 
on the electronic information from URL: http://biobases.ibch.Poznan.pl/5Sdata/ and 
http://rose.man.poznan.pl/5Sdata/ (Ma et al., 2000b). Recent studies indicated that the 
nucleotide sequence of 5S rRNA could be useful in resolving the phylogenetic relationships 
between related CHM species, including Radix Notoginseng (San-qi) (Cui et al., 2003), Radix 
Astragli (Huang-qi) (Ma et al., 2000b) and Radix Angelicae Pubescentis (Du-huo) 
(Mizukami, 1995). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Basic structures of 5S rRNA gene clusters 
 
 
 
 
GTG CTT GGG CGA GAG TAG TA TTA GTG CTG GTA TGA TCG CA 
5SP1 primer 
(forward) 
5SP2 primer 
(reverse) 
Coding region Coding region 
Non-transcribed spacer 
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Aim of this study 
Although DNA fingerprinting technique has been used to determine the taxonomic 
relationship of Magnolia spp., there is no report of the genetic identification of various 
medicinal Flos Magnoliae species. Therefore, the aim of this study was to develop DNA 
fingerprinting profiles of different Flos Magnoliae species, namely M. biondii, M. denudata, 
M. sprengeri, M. kobus, M. liliflora and M. sargentiana that were collected in Australia or 
China, which may contribute to the identification and authentication of Flos Magnoliae 
species.  
 
Thus, the present DNA fingerprinting study was divided into three components.  Firstly, the 
DNA fingerprinting profiles of fresh materials from various Magnolia spp. in Australia were 
established using RAPD analysis, in order to confirm the phylogenetic relationships. 
Secondly, the DNA fingerprints of six dried medicinal Magnolia spp. in Australia or China 
were generated for the identification of different Flos Magnoliae species using RAPD. Finally, 
in addition of RAPD analysis, another fingerprinting technique, PCR-RFLP of the 5S rRNA 
region was employed to identify the six dried medicinal Magnolia spp. for establishment of 
DNA fingerprints of six Flos Magnoliae species. In additional, Schisandra chinensis, which 
was in genus Schisandra, tribe Shisandreae, family Magnoliaceae, was introduced as a 
standard to identify the genetic similarity among analytical species. 
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3.2 Method 
3.2.1 Collection of plant materials 
3.2.1.1 Fresh samples from Magnolia spp. 
The fresh materials from five Magnolia spp., M. campbellii, M. denudata, M. kobus, M. 
liliflora and M. sprengeri, and Schisandra chinensis were collected in Australia (as described 
in Section 2.2.1). In addition, due to the difficulties of obtaining fresh materials from China, 
two species, M. biondii and M. sargentiana were not included in the present study.   
 
3.2.1.2 Dried medicinal Flos Magnoliae species 
The dried medicinal parts of Flos Magnoliae were from six Flos Magnoliae species, M. 
biondii, M. denudata, M. kobus, M. liliflora, M. sprengeri and M. sargentiana (as described in 
section 2.2.1).  
 
3.2.2 Reagents and chemicals 
The details of the reagents and chemicals are described in Section 2.3.1. 
 
3.2.3 DNA extraction 
DNA extraction from fresh samples was conducted using DNeasy Plant Mini Kit (Qiagen, 
Australia). DNA templates from dried medicinal materials were extracted using DNeasy Plant 
Maxi Kit (Qiagen, Australia). The protocol of the extraction are described in section 2.4.1. 
 
3.2.4 RAPD analysis of fresh samples from Magnolia spp. 
Fifteen 10-mer oligo primers (GeneWorks, Australia) (details see Table 2.7) were used for 
RAPD analysis of fresh samples. The PCR amplified reaction took place in a P×2 Thermal 
Cycler (Thermal Electron Corporation, UK). The details of method are described in Section 
2.4.2. RAPD marker has been previously demonstrated to establishment the DNA fingerprints 
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of Cicer arietinum (chickpea) (Sudupak et al., 2002). Thus, DNA extraction from Cicer 
arietinum was used for positive control and conducted in all PCRs. 
 
3.2.5 RAPD analysis of crude medicinal materials of Flos Magnoliae  
Ten 10-mer oligo primers (Operon, Germany) (details see Table 2.7) were used to identify the 
Flos Magnoliae sources. The protocol is described in Section 2.4.2. 
 
3.2.6 PCR-RFLP analysis of crude medicinal materials of Flos Magnoliae  
A set of 5S rRNA primers was applied for PCR-RFLP. For the details of the method, see 
Section 2.4.3.  
 
3.2.7 Data collection and analysis of genetic distances 
POPGENE v 1.31, and MEGA 2 software packages were used for analysis of the genetic 
diversities between different species (see Section 2.9.1). All PCRs were in triplicates. 
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3.3 Results 
3.3.1 DNA extracted from fresh and dried samples of different Flos Magnoliae 
species 
The average size of total DNAs from individual fresh materials of Magnolia spp. was ≥10 kb, 
as shown in Figure 3.2. The electrophoresis profiles of DNAs from dried buds of different 
Flos Magnoliae species showed the similar size of DNA fragments (≥10kb) for all species, 
except M. biondii, which DNA profiles was ranged from 0.25kb to 10kb, as shown in Figure 
3.3.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Total DNA extractions from five fresh Magnolia spp. and Schisandra chinensis 
(5µl of DNA extraction) 
La: GeneRuler 1kb DNA Ladder; Track 1: M. campbellii; Track 2: M. denudata; Track 3: M. 
kobus; Track 4: M. liliflora; Track 5: M. sprengeri; and Track 6: Schisandra chinensis.  
 
 
 
   La
  
                  1           2          3          4         5       6       La 
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Figure 3.3 Total DNA extractions from six dried Flos Magnoliae species  
La: GeneRuler 1kb DNA Ladder (Fermentas, U.S.A.); Track 1: M. biondii (5µl of DNA 
extraction); Track 2: M. biondii (10µl of DNA extraction); Track 3: M. denudata (5µl of DNA 
extraction); Track 4: M. liliflora (5µl of DNA extraction); Track 5: M. sargentiana (5µl of 
DNA extraction); Track 6: M. sprengeri (5µl of DNA extraction); and Track 7: M. kobus (5µl 
of DNA extraction). 
 
 
 
   3      La   
 
          4     5     La       6       7     La         La     1     1            2     2         La 
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3.3.2 Genetic divergence among five Magnolia spp. using fresh materials in 
Australia by RAPD 
Fifteen RAPD primers (details see Table 2.7) were chosen to measure the genetic distances 
among the five Magnolia spp. and Schisandra chinensis. There was a very high level of 
polymorphism amongst five species of Magnolia and Schisandra chinensis. Of the total of 
139 loci were scored, 98.6% were polymorphic. RAPD electrophoresis profiles of individual 
species demonstrated distinguishing DNA fingerprints of five Magnolia spp. and Schisandra 
chinensis, as shown in Figure 3.4 (a)-(o).  
 
Based on the Nei’s coefficient, the genetic identities and genetic distances among five 
Magnolia spp. and Schisandra chinensis, the specific plants that were grown in Australia, to 
RAPD data are presented in Table 3.1. The genetic distances among five Magnolia spp. and 
Schisandra chinensis ranged from 0.2160 to 0.7601. The maximum genetic distance was 
0.7601 between M. campbellii and Schisandra chinensis. The maximum genetic distance 
among five Magnolia spp. was 0.4918 between M. campbellii and M. sprengeri, and the 
minimum genetic distance was 0.2160 between M. campbellii and M. denudata. Schisandra 
chinensis had bigger genetic distance with other species. 
 
A dendrogram was constructed using MEGA 2 software using the UPGMA method (Figure 
3.5). Six species were grouped into two main clusters. Cluster I contains Schisandra chinensis, 
which was found to be the most distinct (34% of genetic dissimilarity) species among six 
species. Within another main cluster that contained five Magnolia spp., 11% of genetic 
dissimilarity indicated M. campbellii was closely related to M. denudata, and M. kobus was 
closely related to M. liliflora (13% of genetic dissimilarity). However, M. sprengeri was 
clustered more distantly than other four species within this cluster.  
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           (a) OPA-11                                                    (b) OPB-03 
 
 
 
 
 
 
 
 
 
              (c) OPB-04 
 
(c) OPB-04 
 
 
 
 
 
 
 
Figure 3.4 Gels of five Magnolia spp. and Schisandra chinensis (fresh materials) were tested 
by RAPD analysis using 15 random primers La: GeneRuler 1kb DNA Ladder or GeneRuler 
100bp DNA Ladder Plus (Fermentas, U.S.A.); N; negative control (distilled water); P: 
positive control (chickpea); Track 1: M. campbellii; Track 2: M. denudata; Track 3: M. kobus; 
Track 4: M. liliflora; Track 5: M. sprengeri and Track 6: Schisandra chinensis.   
 
La        N     P             1      2       3      4     5     6  
    N   P               1    2    3    4    5   6              La     P      N       1      2       3       4      5      6      La 
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(d) OPB-06      (e) OPB-07 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (f) OPB-08     (g) OPC-19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued Figure 3.4 Gels of five Magnolia spp. and Schisandra chinensis (fresh materials) 
were tested by RAPD analysis using 15 random primers  
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus (Fermentas, U.S.A.); 
N; negative control (distilled water); P: positive control (chickpea); Track 1: M. campbellii; 
Track 2: M. denudata; Track 3: M. kobus; Track 4: M. liliflora; Track 5: M. sprengeri and 
Track 6: Schisandra chinensis.   
             
    N    P               1     2      3       4      5      6     La      N   P                  1     2     3    4     5     6    La 
  La    N       P             1     2      3      4      5    6         La    N     P           1      2    3     4    5            6    
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(h) OPG-13     (i) OPM-04  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(j) OPN-04     (k) OPP-10  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued Figure 3.4 Gels of five Magnolia spp. and Schisandra chinensis (fresh materials) 
were tested by RAPD analysis using 15 random primers  
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus (Fermentas, U.S.A.); 
N; negative control (distilled water); P: positive control (chickpea); Track 1: M. campbellii; 
Track 2: M. denudata; Track 3: M. kobus; Track 4: M. liliflora; Track 5: M. sprengeri and 
Track 6: Schisandra chinensis.   
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(l) OPU-03      (m) OPV-06  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (n) OPW-4     (o) OPW-09  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued Figure 3.4 Gels of five Magnolia spp. and Schisandra chinensis (fresh materials) 
were tested by RAPD analysis using 15 random primers 
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus (Fermentas, U.S.A.); 
N; negative control (distilled water); P: positive control (chickpea); Track 1: M. campbellii; 
Track 2: M. denudata; Track 3: M. kobus; Track 4: M. liliflora; Track 5: M. sprengeri and 
Track 6: Schisandra chinensis.   
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Table 3.1 Matrix of genetic identity and genetic distance among five Magnolia spp. and Schisandra chinensis (fresh materials), based on Nei’s 
coefficient (Nei, 1972). The genetic identities (upper diagonal) and genetic distances (under diagonal) among six species, according to RAPD data.  
Species M. campbellii M. denudata M. kobus M. liliflora M. sprengeri Schisandra chinensis 
M. campbellii **** 0.8058 0.6978 0.6906 0.6115 0.4676 
M. denudata 0.2160 **** 0.6906 0.7410 0.6763 0.4748 
M. kobus 0.3598 0.3701 **** 0.7770 0.6978 0.5108 
M. liliflora 0.3701 0.2997 0.2523 **** 0.6619 0.4748 
M. sprengeri 0.4918 0.3912 0.3598 0.4127 **** 0.6259 
Schisandra chinensis 0.7601 0.7448 0.6718 0.7448 0.4689 **** 
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The scale bar represented genetic dissimilarity.  
 
Figure 3.5 The UPGMA dendrogram showed the estimated genetic distance among five Magnolia spp. and Schisandra chinensis (fresh materials) in 
Australia using RPAD.  
 M. campbellii
 M. denudata
 M. kobus
 M. liliflora
 M. sprengeri
 Schisandra chinensis
0.000.050.100.150.200.250.30
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3.3.3 Genetic divergence among six species of Flos Magnoliae using dried materials 
by RAPD analysis 
Dried buds of six commonly used medicinal Flos Magnoliae species were used in RAPD 
analysis. M. campbellii was not included, due to the absence of the buds of M. campbellii 
from grown plants at the time of the study. Ten 10-mer oligo primers were tested for the 
identification of the DNA fingerprints of six Flos Magnoliae species. Of a total 86 loci, 98.8% 
were polymorphic (85 polymorphic loci), among the six Flos Magnoliae species. Figure 3.6 
(a) – (i) show those RAPD electrophoresis profiles of six Flos Magnoliae species 
demonstrated unique DNA fingerprints. However, there is no amplification product for OPB-
03 from six Flos Magnoliae species (the electrophoresis gel did not show).  
 
The matrix (Table 3.2) based on Nei’s coefficient revealed the polymorphism among six Flos 
Magnoliae species. Genetic identities between six species varied from 0.5698 to 0.7907. 
Genetic distances among six species ranged from 0.2348 to 0.5625. The maximum genetic 
distance was 0.5625 between M. biondii and M. denudata, and the minimum genetic distance 
was 0.2348 between M. denudata and M. kobus. M. biondii and M. sargentiana, which were 
collected from China, had more genetically divergent from the other species. 
  
A dendrogram indicating the genetic relationships among six Flos Magnoliae species was 
constructed using MEGA 2 software (Figure 3.7). M. denudata was closely related to M. 
kobus with 12% of genetic dissimilarity. However, two preparations of Flos Magnoliae 
species, M. biondii and M. sargentiana were clustered more distantly than other four species.  
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                           (a) OPA-07                                                      (b) OPA-11  
 
 
 
 
 
 
 
 
                                                                    (c) OPA-14  
 
 
 
 
 
 
 
 
Figure 3.6 Gels of six dried Flos Magnoliae species (dried materials) were tested by RAPD 
analysis using nine random primers  
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus; N; negative control 
(distilled water); P: positive control (chickpea); Track 1: M. biondii; Track 2: M. denudata; 
Track 3: M. kobus; Track 4: M. liliflora; Track 5: M. sprengeri and Track 6: M. sargentiana.    
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                                  (d) OPB-04                                                   (e) OPB-06  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  (f) OPB-07                                               (g) OPB-12  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued Figure 3.6 Gels of six dried Flos Magnoliae species (dried materials) were tested 
by RAPD analysis using nine random primers  
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus; N; negative control 
(distilled water); P: positive control (chickpea); Track 1: M. biondii; Track 2: M. denudata; 
Track 3: M. kobus; Track 4: M. liliflora; Track 5: M. sprengeri and Track 6: M. sargentiana.    
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750bp 
690bp 
1600bp 
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                                OPB-17 (h)                                                    (i) OPB-18  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued Figure 3.6 Gels of six dried Flos Magnoliae species (dried materials) were tested 
by RAPD analysis using nine random primers  
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus; N; negative control 
(distilled water); P: positive control (chickpea); Track 1: M. biondii; Track 2: M. denudata; 
Track 3: M. kobus; Track 4: M. liliflora; Track 5: M. sprengeri and Track 6: M. sargentiana.    
 
 
 
 
         La    N      P     1             2     3     4      5     6      
1700bp  
1400bp 
850bp 
 N     P     1             2      3      4     5     6     La 
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Table 3.2 Matrix of genetic identity and genetic distance among six Flos Magnoliae species (dried materials), based on Nei’s coefficient (Nei, 
1972). The genetic identities (upper diagonal) and genetic distances (under diagonal) among six Flos Magnoliae species, according to RAPD 
data. 
Species M. biondii M. denudata M. kobus M. liliflora M. sprengeri M. sargentiana 
M. biondii **** 0.5698 0.6395 0.6047 0.5930 0.6512 
M. denudata 0.5625 **** 0.7907 0.7558 0.7442 0.6860 
M. kobus 0.4470 0.2348 **** 0.7558 0.7442 0.6628 
M. liliflora 0.5031 0.2800 0.2800 **** 0.6860 0.7442 
M. sprengeri 0.5225 0.2955 0.2955 0.3768 **** 0.6628 
M. sargentiana 0.4290 0.3768 0.4113 0.2955 0.4113 **** 
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The scale bar represented genetic dissimilarity. 
 
Figure 3.7 The UPGMA dendrogram showed the estimated genetic distance among six Flos Magnoliae species (dried materials) using RAPD  
 M. denudata
 M. kobus
 M. liliflora
 M. sprengeri
 M. sargentiana
 M. biondii
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3.3.4 Genetic divergence among five species of Flos Magnoliae using dried 
materials by PCR-RFLP analysis 
The PCR of 5S rRNA region was with five Flos Magnoliae species, except M. sargentiana. 
PCR products having a similar size of about 650bp were obtained from five Flos Magnoliae 
species, as shown in Figure 3.8. A DNA fragment of 500bp was also presented in M. liliflora 
after amplification.  
 
Fifteen different restriction enzymes were used. Only four of the 15 enzymes (HhaI, PmlI, 
SmaI and EcoRV) (New England Biolabs, USA and Promega, Australia) (details described in 
Table 2.8) were suitable for PCR-RFLP analysis. The DNA fingerprinting profiles from 
digestions generated clear, coherent banding patterns, which enabled to determine the 
differences between five Flos Magnoliae species [Figure 3.9 (a)-(d)]. 
 
According to the Nei’s coefficient, the genetic identities and genetic distances among five 
Flos Magnoliae species to PCR-RFLP data are presented in Table 3.3. The genetic identities 
among five Flos Magnoliae species ranged from 0.6400 to 0.9200. The genetic distances 
between five Flos Magnoliae species ranged from 0.0834 to 0.4463. The maximum genetic 
distance was 0.4463 between M. biondii and M. liliflora, and the minimum genetic distance 
was 0.0834 between M. denudata and M. sprengeri.  
 
A dendrogram indicating the genetic relationships among five Flos Magnoliae species was 
constructed using MEGA 2 software (Figure 3.10). The scale bar was inflated in order to 
clearly illustrate the branching patterns. There is little genetic distance among five Flos 
Magnoliae species, compared to the genetic distance, found in RPAD profiles. However, M. 
liliflora was clustered more distantly than other four species. 
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Figure 3.8   PCR products of five Flos Magnoliae species (dried materials) after amplified 
with 5S rRNA genes  
La: GeneRuler 1kb DNA ladder; N; negative control (distilled water); P: Positive control 
(chickpea); Track 1: M. biondii; Track 2: M. denudata; Track 3: M. kobus; Track 4: M. 
liliflora; and Track 5: M. sprengeri.   
 
 
 
 
 
 
350bp 
700bp 650bp 
500bp 
   La        N          P                     1         2          3         4         5  
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                                   (a) HhaI                                                            (b) PstI 
 
 
 
 
 
 
 
 
                                    (c) SmaI                                                         (d) EcoRV  
 
 
 
 
 
 
 
 
 
Figure 3.9   After amplified with 5S rRNA genes, DNA fingerprinting profiles of five Flos 
Magnoliae species (dried materials), digested by four restriction enzymes  
La: GeneRuler 1kb DNA Ladder or GeneRuler 100bp DNA Ladder Plus; N; negative control 
(distilled water); P: Positive control (chickpea); Track 1: M. biondii; Track 2: M. denudata; 
Track 3: M. kobus; Track 4: M. liliflora; and Track 5: M. sprengeri.   
     La   N     P            1      2     3     4     5            La    N    P             1      2     3     4     5 
    N   P             1     2     3     4      5    La     N     P            1      2     3      4     5    La 
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Table 3.3 Matrix of genetic identity and genetic distance among five Flos Magnoliae species (dried materials), based on Nei’s coefficient (Nei, 
1972). The genetic identities (upper diagonal) and genetic distances (under diagonal) among five Flos Magnoliae species, according to PCR-
RFLP data. 
Species M. biondii M. denudata M. kobus M. liliflora M. sprengeri 
M. biondii **** 0.8000 0.8400 0.6400 0.8000 
M. denudata 0.2231 **** 0.8800 0.8400 0.9200 
M. kobus 0.1744 0.1278 **** 0.7200 0.8800 
M. liliflora 0.4463 0.1744 0.3285 **** 0.8400 
M. sprengeri 0.2231 0.0834 0.1278 0.1744 **** 
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The scale bar represented genetic dissimilarity. 
 
Figure 3.10 The UPGMA dendrogram showed the estimated genetic distance among five Flos Magnoliae species (dried materials) using PCR-
RFLP of 5S rRNA region  
 M. denudata
 M. sprengeri
 M. kobus
 M. biondii
 M. liliflora
0.000.020.040.060.080.100.120.14
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3.4 Discussion 
Species of fresh Flos Magnoliae buds, collected in Australia, are from the family 
Magnoliaceae, tribe Magnolieae, subtribe Magnolieae, genus Magnolia subgenus Yulania, 
except Schisandra chinensis (Magnolia Society, 2003). M. campbellii, M. denudata and M. 
sprengeri are recognised under section Yulania (Magnolia Society, 2003, Pei and Chen, 
1991). M. kobus and M. liliflora are classified in the section Buergeria and section 
Tulipastrum, respectively. Schisandra chinensis (Family Magnoliaceae, tribe Schisandreae, 
genus Schisandra) was selected as an out-group genus, thereby providing a yardstick for 
comparisons within Magnolia spp. High-level genetic dissimilarity (34%) among Schisandra 
chinensis to other five Magnolia spp was in agreement with the taxonomy system.  
 
The finding of the close genetic distance between M. denudata and M. campbellii is in line 
with the classical taxonomy system (Magnolia Society, 2003). Although M. liliflora and M. 
kobus are under two different sections, Buergeria and Tulipastrum, respectively, dissimilarity 
as mentioned in this study was found very small. More species under these two sections need 
to be accurately analysed the genetic distances of the species from Buergeria and 
Tulipastrum. However, M. sprengeri has the highest genetic distance in this cluster compared 
to other species. This finding disagrees with the finding in previous studies that the genetic 
distances were 0.17 or 0.18 between M. sprengeri and M. denudate, (Wang et al., 2004c, 
Wang et al., 2004e) compared to the finding (genetic distance: 0.3912) of this study. In 
addition, Wang et al (2004c) also found larger genetic distance, 0.591, between M. kobus and 
M. sprengeri, compared to the findings (genetic distance: 0.3598) from present study. The 
samples used in the present study were locally collected, and the samples used in the previous 
studies were collected from China. Hybridization could be the factor causing the big genetic 
distance between the Australian M. sprengeri variety and the Chinese variety. Furthermore, 
these findings may be due to the misidentification of M. sprengeri by the local nursery. The 
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future study on investigation of the molecular profiles from different M. sprengeri varieties is 
necessary for a better understanding of the present existing findings.  
 
The RAPD analysis demonstrated a slight genetic dissimilarity among six Flos Magnolia 
species. For instance, the DNA fingerprinting profiles of M. biondii and M. sargentiana, from 
the Chinese market, have larger genetic distances compared to other species. These results are 
in disagreement with the previous studies (Wang et al., 2004e, Wang et al., 2004c) and 
Magnoliaceae taxonomy (Magnolia Society, 2003). However, due to the low concentration 
and poor quality of dried materials, present study was not able to investigate further to explain 
the present genetic data. The distinct DNA fingerprinting profiles, which were obtained after 
amplification by primers OPA-07, OPA-14 and OPB-07, may be used for distinguishing 
different Magnolia spp. in the future. A number of DNA fragments identified by OPA-11 
(950bp), OPB-04 (690bp and 750bp), OPB-06 (1600bp), OPB-12 (550bp and 2500bp), OPB-
17 (1400bp and 1700bp) and OPB-18 (850bp) (black arrows as shown in Figure 3.6), could 
be regarded as species-specific markers. Therefore, the shared RAPD fragments between 
species can be cloned, sequenced and then designed as probes to be used for the identification 
and authentication of Flos Magnoliae species.  
 
There were slight differences between the DNA fingerprinting profiles from fresh samples 
and crude buds in this study, although most of the DNA fragments are same between fresh 
and dried samples. For instance, no DNA fragments of dried Flos Magnoliae were visualised 
after amplification by primer OPB-03, compared to distinct DNA patterns in the fresh 
samples, that probably as a result of the physical conditions and individual characteristics of 
the DNA extraction from crude materials (Shaw et al., 2002).  
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PCR-RFLP analysis was also performed for the identification of the genetic profiles of Flos 
Magnoliae in this study. The extraction conditions of dried materials were optimised in this 
study, because the DNAs obtained from crude drugs were degraded. The low concentration 
and poor purity of DNA from M. sargentiana may cause the failure of the amplification by 5S 
rRNA, which may be due to over-heating of the preparation under high temperature by the 
herbal suppliers. This may indicate that the physical conditions of heat and dryness and the 
content of polysaccharides and polyphenolic could directly affect the accuracy and sensitivity 
of PCR amplification (Shaw et al., 2002).  
 
The distinct DNA fingerprints from PCR-RFLP of 5S rRNA region may contribute to the 
identification of Flos Magnoliae species. The closer genetic dissimilarity was demonstrated in 
the PCR-RFLP profiles, compared to the RAPD profiles. PCR-RFLP method, detected a 
single genomic locus in which recombination has been shown to occur, in present study the 
5S rRNA region (Glick and Pasternak, 2003). In the contrast, RAPD method explores genetic 
dissimilarity with the whole genomic DNA, resulting in the high degree of polymorphism 
among individuals (Lynch and Milligan, 1994).  
 
The molecular bases of the RAPD methods and PCR-RFLP analysis are different. The RAPD 
method explores genetic dissimilarity with the whole genomic DNA, which can detect greater 
genetic diversity, compared to PCR-RFLP method (Betancor et al., 2004). Such multi loci can 
be exploited in ways largely analogous to the uses of PCR-RFLP (Glick and Pasternak, 2003). 
RAPD does allow the better identification of different species, compared to PCR-RFLP 
(Yakoob et al., 2001). These factors are especially valuable for the identification of different 
Flos Magnoliae species. However, the low reproducibility and sensitivity were considered for 
RAPD method (Penner et al., 1993). Compared to RAPD, the PCR-RFLP of multi copy 
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genes, such as 5S rRNA, may estimate different medicinal sources with the high 
reproducibility and sensitivity (Shaw and But, 1995).  
 
In conclusion, the present study established the genetic profiles of different Flos Magnoliae 
species using RAPD and PCR-RFLP, which represents the first report on these particular 
species. The findings may be useful for the identification and authentication of different Flos 
Magnoliae species. Furthermore, the phylogenetic relationship of Magnolia spp. in Australia 
was confirmed, indicating locally grown Flos Magnoliae species may be used for medicinal 
application.  
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Chapter Four 
Qualitative Identification of Flos Magnoliae Using TLC 
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4.1 Background 
Since 1960s, optimal and standardised TLC technology has been widely applied for analysis 
of chemical compositions of food, cosmetics and pharmaceuticals (Ettre, 2005). The principle 
of the techniques has been described in Chapter 1 (see Section 1.3.4.4.1). Recently, with the 
rapid development of the HPTLC instrumentation and computer assistance, more advanced 
TLC systems, such as CAMAG, have been used for analysis of a numbers of CHM (CAMAG, 
2006b). TLC has now been frequently used for the identification and authentication of CHM 
and other herbal medicines. Various authorised references, for instances the Chinese 
Pharmacopoeia and the American Herbal Pharmacopoeia (The Pharmacopoeia Commission 
of People's Republic of China, 2005, AHP, 2004). Compared to other chromatographic 
techniques, it has been recognised with the characterisations of rapidity and simultaneousness 
(Kotiyan and Vavia, 2000).  
 
As one of the commonly used CHM, many substitutes and adulterants of Flos Magnoliae have 
been found in the market (Fu, 2000). According to the current Chinese Pharmacopoeia, TLC 
is used for the identification of Flos Magnoliae, in which magnolin as the marker compound 
(The Pharmacopoeia Commission of People's Republic of China, 2005). Recently, magnolin, 
pinoresinol dimethyl ether and lirioresinol-B dimethyl ether from the chloroform extracts of 
M. biondii, M. denudata and M. sprengeri, have been identified using TLC (Su et al., 2001). 
 
Amis of the study 
The aim of the present study is to establish the method to identify Flos Magnoliae species, in 
regard to qualitative analysis of two marker compounds, including magnolin and fargesin, in 
the ethanol extracts from different Flos Magnoliae species and varieties. Meanwhile, to use 
the technique as a quality control tool to identify the various batches of M. biondii from 
different suppliers and cultivation sites.  
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4.2 Method 
4.2.1 Samples extraction and preparation  
Dried Flos Magnoliae samples from six different Magnolia spp. (Table 2.2) were used, 
including M. biondii, M. denudata, M. kobus, M. liliflora, M. sprengeri and M. sargentiana. 
Twenty M. biondii samples, including 11 batches from six varieties (Table 2.3), five batches 
from different herbal suppliers (Table 2.4), and four batches from different cultivation sites 
(Table 2.5) were used in the present study.  
 
The protocol of samples extraction and preparation is described in Chapter 2 (Section 2.5.1). 
 
4.2.2. Reagents and chemicals 
The details of the reagents and chemicals are described in Chapter 2 (Section 2.3.2).  
 
4.2.3 Preparation of standard references, magnolin and fargesin 
Briefly, 1.5mg of marker compounds, magnolin and fargesin, were dissolved in 1.5ml of 
ethanol, and then sonicated for 15min (details see Section 2.5.2). The final concentrations of 
2.5mg/ml for magnolin and 1mg/ml for fargesin were used for standard solutions.  
 
4.2.4 Chromatographic conditions 
The TLC system (CAMAG, Switzerland) (Figure 2.7 and Table 2.9) consisted of the semi-
automatic sample application (Linomat 5), the horizontal developing chambers, the TLC 
scanner III, the documentation system with the camera (HV-C20A, Hitachi, Japan) and the 
workstation (winCATS, version: 1.2.5). TLC silica gel 60 F254 plates (20cm x 10cm, E. 
Merck, Germany) and HPTLC silica gel 60 F254 plates (10cm x 10cm, E. Merck, Germany) 
were used. The mobile phase was a mixture of chloroform – ether (5:1, %-v:v). The protocols 
of the chromatographic conditions are described in Section 2.5.3. 
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4.2.5 Data analysis  
Magnolin and fargesin from the testing samples were qualitatively determined based on the Rf 
values of the resolved bands. Testing samples were in quadruplicates and were represented as 
mean ± S.D. Furthermore, all measurements were expressed as R.S.D. 
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Figure 4.1 The repeatability of the method for TLC identification 
B: Blank (10µl, methanol); M: Magnolin standard (2.5mg/ml, 10µl); F: Fargesin standard 
(1mg/ml, 10µl); Track 1-5: M. biondii (50mg raw herb/ml, 30µl). 
4.3 Results 
4.3.1 Method optimisation 
The mixture of chloroform – ether (5:1) resolved magnolin and fargesin spots with a better 
peak shape. The combination of chloroform and ether was found to produce an optimal 
migration of magnolin and fargesin (Rf values of 0.41±0.01 for magnolin and 0.62±0.02 for 
fargesin). The repeatability of the method was tested by five applications of the same sample 
(M. biondii, Hualong Magnolia Development Co. Ltd) on the same TLC plates (Figure 4.1). 
The Rf value of magnolin was 0.41±0.00 and the Rf value of fargesin was 0.60±0.00.  
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4.3.2 Identification of different Flos Magnoliae species 
Six Flos Magnoliae species were studied, namely, M. biondii, M. denudata, M. kobus, M. 
liliflora, M. sprengeri and M. sargentiana (Figure 4.2). The chromatograms of two species, 
including M. biondii and M. kobus showed the bands that indicated magnolin and fargesin. 
Magnolin was detected from the ethanol extract of M. liliflora, although fargesin was not 
found. Table 4.1 showed the values of Rf  for magnolin and fargesin from the samples. For 
positive identification, the testing sample must exhibit bands with the Rf values (0.41 – 0.42 
for magnolin and 0.60 – 0.61 for fargesin), similar to those (% R.S.D. < 3%) to those of 
reference marker compounds. 
 
 
Table 4.1 The values of Rf for magnolin and fargesin in different Flos Magnoliae species. 
Data are presented as mean ± S.D. (n=4). ‘n/a’ indicated not detected.  
 M. biondii M. denudata M. kobus M. liliflora M. sargentiana M. sprengeri 
Rf 
(S.D.) 
0.41 
(0.00) 
n/a 
0.41  
(0.00) 
0.42 
(0.00) 
n/a n/a 
Magnolin 
% 
R.S.D. 
0.9 n/a 0.7 0.8 n/a n/a 
Rf 
(S.D.) 
0.60 
(0.00) 
n/a 
0.61 
(0.00) 
n/a n/a n/a 
Fargesin 
% 
R.S.D. 
0.7 n/a 0.9 n/a n/a n/a 
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Figure 4.2 TLC chromatograms of six Flos Magnoliae species 
B: Blank (10µl, methanol); M: Magnolin standard (2.5mg/ml, 10µl); F: Fargesin standard (1mg/ml, 10µl); Track 1: M. biondii (50mg raw 
herb/ml, 30µl); Track 2: M. denudata (50mg raw herb/ml, 30µl); Track 3: M. kobus (50mg raw herb/ml, 30µl); Track 4: M. sprengeri (50mg 
raw herb/ml, 30µl); Track 5: M. liliflora (50mg raw herb/ml, 30µl); Track 6: M. sargentiana (50mg raw herb/ml, 30µl). 
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4.3.3 Identification of different M. biondii varieties 
Eleven M. biondii samples were studied (details see Table 2.3). The bands of magnolin and 
fargesin were observed from all 11 samples in the TLC chromatogram (Figure 4.3). The 
HPTLC chromatogram has also identified that all the samples contained magnolin and 
fargesin (Figure 4.4). The Rf values of magnolin and fargesin are shown in Table 4.2. For 
positive identification, the testing sample must exhibit bands with the Rf values (0.37 – 0.43 
for magnolin and 0.60 – 0.64 for fargesin), similar to those (% R.S.D. < 3%) to those of 
reference marker compounds. 
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Figure 4.3 TLC chromatograms of 11 batches of M. biondii varieties 
B: Blank (10µl, methanol); M: Magnolin standard (2.5mg/ml, 10µl); F: Fargesin standard (1mg/ml, 10µl); Track 1: No1 (50mg raw herb/ml, 
30µl); Track 2: No2 (50mg raw herb/ml, 30µl); Track 3: No3 (50mg raw herb/ml, 30µl); Track 4: No4 (50mg raw herb/ml, 30µl); Track 5: No5 
(50mg raw herb/ml, 30µl); Track 6: No6 (50mg raw herb/ml, 30µl); Track 7: No7 (50mg raw herb/ml, 30µl); Track 8: No8 (50mg raw herb/ml, 
30µl); Track 9: No9 (50mg raw herb/ml, 30µl); Track 10: No10 (50mg raw herb/ml, 30µl); Track 11: No11 (50mg raw herb/ml, 30µl). 
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Figure 4.4 HPTLC chromatograms of 11 batches of M. biondii varieties 
B: Blank (10µl, methanol); M: Magnolin standard (2.5mg/ml, 10µl); F: Fargesin standard (1mg/ml, 10µl); Track 1: No1 (50mg raw 
herb/ml, 30µl); Track 2: No2 (50mg raw herb/ml, 30µl); Track 3: No3 (50mg raw herb/ml, 30µl); Track 4: No4 (50mg raw herb/ml, 
30µl); Track 5: No5 (50mg raw herb/ml, 30µl); Track 6: No6 (50mg raw herb/ml, 30µl); Track 7: No7 (50mg raw herb/ml, 30µl); Track 
8: No8 (50mg raw herb/ml, 30µl); Track 9: No9 (50mg raw herb/ml, 30µl); Track 10: No10 (50mg raw herb/ml, 30µl); Track 11: No11 
(50mg raw herb/ml, 30µl). 
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Table 4.2 The values of Rf for magnolin and fargesin in different M. biondii varieties. Data are presented as mean ± S.D. (n=4).  
 
 
 
1 
HLWH 
2 
EMT 
3 
EMT 
4 
XMT 
5 
HGCY 
6 
CY 
7 
CY 
8 
CY 
9 
EMT 
10 
HLWH 
11 
BZCY 
Rf 
(S.D.) 
0.40 
(0.00) 
0.41 
(0.00) 
0.41 
(0.01) 
0.42 
(0.00) 
0.42 
(0.00) 
0.39 
(0.00) 
0.40 
(0.00) 
0.40 
(0.00) 
0.39 
(0.00) 
0.37 
(0.00) 
0.43 
(0.01) 
Magnolin 
% R.S.D.  0.7 0.5 1.4 1.0 0.7 0.6 0.6 0.7 1.0 1.2 2.1 
Rf 
(S.D.) 
0.61 
(0.00) 
0.61 
(0.00) 
0.61 
(0.00) 
0.61  
(0.00) 
0.61 
(0.00) 
0.61 
(0.02) 
0.61  
(0.01) 
0.61 
(0.01) 
0.61 
(0.01) 
0.60 
(0.00) 
0.64 
(0.00) 
Fargesin 
% R.S.D. 0.5 0.3 0.5 0.3 0.3 2.5 1.3 1.0 1.5 0.7 0.6 
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4.3.4 Identification of Flos Magnoliae products from different herbal suppliers 
The chromatograms from five Flos Magnoliae herbal products from five herbal suppliers 
(details see Table 2.4) show similar chromatographic patterns (Figure 4.5). Magnolin and 
fargesin were observed from all five Flos Magnoliae products, based on the Rf values (Table 
4.3). For positive identification, the testing sample must exhibit bands with the Rf values 
(0.40 – 0.43 for magnolin and 0.61 – 0.65 for fargesin), similar to those (% R.S.D. < 3%) to 
those of reference marker compounds. 
 
4.3.5 Identification of M. biondii samples from different cultivation sites 
Four M. biondii samples, which were collected from different cultivation sites, were used in 
the present study (details see Table 2.5). The magnolin and fargesin were identified by the 
optimised TLC approach (Figure 4.5). The Rf values of magnolin and fargesin are shown in 
Table 4.4. For positive identification, the testing sample must exhibit bands with the Rf values 
(0.40 – 0.42 for magnolin and 0.62 – 0.63 for fargesin), similar to those (% R.S.D. < 3%) to 
those of reference marker compounds. 
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Figure 4.5 TLC chromatograms of five Flos Magnoliae products from different herbal suppliers and four M. biondii batches, collected from different 
cultivation sites 
B: Blank (10µl, methanol); M: Magnolin standard (2.5mg/ml, 10µl); F: Fargesin standard (1mg/ml, 10µl); Track 1: EYS (50mg raw herb/ml, 30µl); 
Track 2: KODA (50mg raw herb/ml, 30µl); Track 3: TFH (50mg raw herb/ml, 30µl); Track 4: TFK (50mg raw herb/ml, 30µl); Track 5: HL (50mg 
raw herb/ml, 30µl); Track 6: DHY (50mg raw herb/ml, 30µl); Track 7: XHY (50mg raw herb/ml, 30µl); Track 8: YYS (50mg raw herb/ml, 30µl); 
Track 9: TQ (50mg raw herb/ml, 30µl).  
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Table 4.3 The values of Rf for magnolin and fargesin in different Flos Magnoliae products 
from five herbal suppliers. Data are presented as mean ± S.D. (n=4).  
 HL TFH TFK EYS KODA 
Rf 
(S.D.) 
0.43 
(0.00) 
0.40 
(0.01) 
0.41 
(0.02) 
0.42 
(0.02) 
0.41 
(0.01) 
Magnolin 
% 
R.S.D. 
1.0 1.7 3.6  3.7 1.5 
Rf 
(S.D.) 
0.65 
(0.01) 
0.61 
(0.01) 
0.62 
(0.01) 
0.63 
(0.01) 
0.62 
(0.01) 
Fargesin 
% 
R.S.D. 
1.1 1.8 1.4 1.7 1.5 
 
 
Table 4.4 The values of Rf for magnolin and fargesin in different M. biondii samples, 
collected from four cultivation sites. Data are presented as mean ± S.D. (n=4).  
 DHY XHY YYS TQ 
Rf 
(S.D.) 
0.42 
(0.01) 
0.42 
(0.01) 
0.40 
(0.01) 
0.40 
(0.01) 
Magnolin 
% 
R.S.D. 
2.2 1.6 2.1 1.4 
Rf 
(S.D.) 
0.62 
(0.01) 
0.63 
(0.01) 
0.63 
(0.00) 
0.62 
(0.00) 
Fargesin 
% 
R.S.D. 
1.3 1.1 0.4 0.7 
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4.4 Discussion 
A simple, sensitive and robust TLC method for the identification of different Flos Magnoliae 
species has been developed in the present study using magnolin and fargesin as marker 
compounds. After initial experiments on selection of a suitable solvent system for the best 
separation of Flos Magnoliae samples, chloroform – ether in varying rations (1:1, 2:1, 4:1 and 
5:1) were used, and chloroform – ether (5:1) was found as the optimised mobile phase for the 
development of the chromatogram, for achieving the dense and compact bands of magnolin 
and fargesin. The present findings are in agreement with that suggested by a previous study 
(Su et al., 2001). It was also observed in the present study that well-defined spots of Flos 
Magnoliae samples were obtained when the chamber was pre-equilibrated with the mobile 
phase for a period of 30min. The percentage R.S.D. for repeatability of magnolin and fargesin 
from five samples application on the same plates were found to be 0.9% and 0.7%, 
respectively, indicating an excellent repeatability of the method developed.  
 
Six Flos Magnoliae species were studied using the optimised TLC method. Two species, M. 
biondii and M. kobus were found to contain magnolin and fargesin, based on the analysis by 
winCATS workstation (CAMAG, Switzerland). Locally grown M. liliflora, which was 
commonly used as the substitutes of Flos Magnoliae in China, was found to contain magnolin. 
All six species showed unique chromatographic fingerprints, which may be used to identify 
and authenticate different Flos Magnoliae species. The good separation of the chromatogram 
of M. biondii was achieved, compared to the chromatograms of other five Flos Magnoliae 
species. Moreover, 11 batches from six M. biondii varieties, five Flos Magnoliae herbal 
products and four M. biondii batches from different cultivation sites, were qualitatively 
analysed using the present TLC method. Magnolin and fargesin were detected in all samples. 
Five bands, whose Rf values ranged from 0.40 to 0.75, were well separated from all M. biondii 
varieties. So it seems the present TLC condition may be specific for the identification of M. 
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biondii. Furthermore, the existences of magnolin and fargesin from all five Flos Magnoliae 
products, purchased from different herbal suppliers in Australia and China, indicate that M. 
biondii may be the botanic sources of those marketed products.  
 
High opportunities of contaminations of the neighbouring analytes, which might be occurred 
during the promotion by the solvents, has been considered as one of the major limitations of 
TLC method (Hilaire et al., 1998). Furthermore, although TLC is a fast, economic and widely 
used technique, the lack of sensitivity and difficulty to detect the microconstitutes is another 
advantage of this approach (Cai et al., 2000a). Recently, the use of CAMAG video store 
system improved the sensitivity and reproducibility of the present method. Further research 
will be focused on the quantitative analysis of the bioactive compounds from Flos Magnoliae 
samples. The well-established and validated TLC or HPTLC method will be required with the 
help of image analysis and digitalized techniques with the CAMAG TLC system (Chopra et 
al., 2006, Sek et al., 2001).  
 
In summary, the well-established TLC method is rapid, specific and simultaneous for the 
qualitative analysis of magnolin and fargesin in ethanol extracts of different Flos Magnoliae 
species and varieties, and the authentication of the Flos Magnoliae products in the market.  
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Chapter Five 
Simultaneous Determination of Magnolin and Fargesin  
in Flos Magnoliae Using  HPLC 
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5.1 Background 
HPLC has been distinguished as the most commonly used approach for the identification and 
quantification of chemical components (Horvath, 1980).  Due to its high reliability, sensitivity 
and reproducibility, the technique has been frequently used in the quality control of CHM (Li 
et al., 1998). The applications of HPLC for determination of the active components from 
CHM and related chromatographic conditions are shown in Chapter 1 (Section 1.3.3.4.2). 
 
In 1936, Haworth named systematic compounds, the lignans that contained two β,β’-linked 
cinnamic acid residues (Moss, 2000). With more new lignans and neolignans revealed by the 
investigation of bioactive compounds from plants, they are categorised into eight subgroups 
of lignans, including furofurans (FF), furan (FR), dibenzylbutane (DB), 
dibenzylbutyrolactone (DBL) dibenzylbutyrolactol (DBLL), aryltetralin (AT), 
arylnaphthalene (AN) and dibenzocyclooctadiene (DCO) (Umezawa, 2003).  
 
Pharmacological and clinical investigations have demonstrated that FFs have anti-tumour and 
anti-allergic effects (Brown et al., 2001). One of the AT lignans, podophyllotoxin, has 
significant cytotoxic properties (Gordaliza et al., 2004, Chang et al., 1992). Although the 
toxic side effects of podophyllotoxin are recognised by clinical investigation, it has been 
regarded as one of the major parent component for the powerful anti-cancer agent, etoposide 
and related medicinal products (Arroo et al., 2002).  
 
The investigation of CHM has led to the discovery of the potent bioactive components, 
lignans and neolignans (Homma et al., 2000). The active lignans and neolignans, including 
forsythin and forsythoside in Fructus Forsythiae (Lian-qiao), arctiin and arctigenin in Fructus 
Arctii (Niu-bang-zai), schisandrene in Fructus Schisandrae (Wu-wei-zi), asarinin in Herba 
Asari (Xi-xin) and honokiol and magnolol in Cortex Magnoliae Officinalis (Ho-pu) have been 
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demonstrated to have potent pharmacological function and potential clinical effects (Ho et al., 
2001, Iwakami et al., 1992, Kim et al., 2004, Sun et al., 1992) 
 
Extracts of dried buds from different Magnolia spp. have been reported to contain different 
yield of bioactive lignans and neolignans (Kimura et al., 1991, Ma and Han, 1995). The 
chemical structures of these lignans and neolignans are shown in Figure 1.5 of Section 
1.1.4.1.2. The investigation of lignans and neolignans started with M. biondii. In the early 
stage, six different FF lignans, which were magnolin, fargesin, demethoxyaschantin, 
aschantin, pinoresinol dimethyl ether, and lirioresinol-B-dimethyl ether, were reported as the 
active components that were responsible for the anti-inflammatory and anti-allergic actions of 
Flos Magnoliae (Ma and Han, 1995, Brown et al., 2001, Mitsuo, 2001). With the development 
of isolation and separation techniques, more and more lignans from Flos Magnoliae have been 
identified, including biondinin A, fargesone A and B, magnone A and B, and denudatin B 
(Chen et al., 1988, Pan et al., 1987, Ma et al., 1996, Ma and Han, 1992, Jung et al., 1998). 
However, the pharmacological actions of these compounds are still unclear. In Japan, two 
neolignans, magnosalin and magnoshinin were reported as the major bioactive components of 
Flos Magnoliae (Magnolia salicifolia Maxim) (Kikuchi et al., 1983). The anti-inflammatory 
and anti-allergic effects of magnosalin and magnoshinin were demonstrated through 
inhibition of angiogenesis and proliferation of vascular endothelial cells by magnosalin and 
granuloma formation by magnoshinin in vivo and in vitro (Kobayashi et al., 1998, Kobayashi 
et al., 1996a, Kimura et al., 1992, Kimura et al., 1991, Kimura et al., 1990).  
 
HPLC has been applied to quantitatively and qualitatively analyse of the lignans and 
neolignans of different Flos Magnoliae species. Magnolin, pinoresinol dimethyl ether, and 
lirioresinol-B-dimethyl ether were qualitatively identified by RP-HPLC using a C8 column 
with the mobile phase containing acetonitril-tetrahydrogenfuran-water and at 278nm 
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wavelength (Fang et al., 2002). Different HPLC system was also employed to identify 
magnolin and fargesin using a C18 column, with the mobile phase of acetonitrile-water (50:50) 
mixture as mobile phase, at 278 nm wavelength (Xu et al., 2003). Xu et al (2003) also found 
that M. biondii contained significantly higher content of magnolin than M. denudata and M. 
sprengeri, while only M. biondii contained fargesin. 
 
Aims of this study 
The present study aimed to establish a HPLC system to simultaneously determine two 
bioactive compounds, magnolin and fargesin in different Flos Magnoliae sources. Magnolin 
has been listed as the marker compound in the current Chinese Pharmacopoeia (The 
Pharmacopoeia Commission of People's Republic of China, 2005). The qualities of different 
Flos Magnoliae species and varieties were used in the present study, including six Flos 
Magnoliae species, batches of M. biondii from different varieties, herbal suppliers and 
cultivation sites, and batches of M. sprengeri grown in different locations from Australia and 
China.  
 
5.2 Method 
5.2.1 Samples collection, extraction and preparation  
Six Flos Magnoliae species were used, including M. biondii, M. denudata, M. kobus, M. 
liliflora, M. sprengeri and M. sargentiana (Table 2.2). Meanwhile, 20 M. biondii samples, 
including 11 batches from six varieties (Table 2.3), five batches from different herbal 
suppliers (Table 2.4) and four batches collected from different cultivation sites (Table 2.5) 
were used in the present study. Furthermore, three M. sprengeri batches collected from China 
and Australia were employed as well (Table 2.6).  
 
The method of extraction and preparation are described in Chapter 2 (Section 2.6.1). 
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5.2.2 Reagents and chemicals 
The details of the reagents and chemicals are described in Chapter 2 (Section 2.3.3). 
 
5.2.3 Preparation of standard references, magnolin and fargesin 
A stock solution of the standard compounds was prepared by accurately weighing each of 
magnolin and fargesin. The protocols of the preparation of the standard compounds are 
described in Section 2.6.2.  
 
5.2.4 Chromatographic conditions 
The HPLC system (Shimadzu Model SCL-10Avp, Shimadzu, Japan) consisted of a 
photodiode array detector (Shimadzu Model SPD-M10Avp, Shimadzu, Japan). A RP-C18 
column (ODSII, L 250 × 4.6 I.D. mm, 5µM, Phenomenex, U.S.A.) and a pre-column of the 
same packing material (Security Guide cartridge; 3.0mm; Phenomenex, U.S.A.) were used for 
separation of magnolin and fargesin. The mobile phase was a mixture of acetonitrile and 
water. The protocols of the chromatographic conditions are described in Section 2.6.3. 
 
5.2.5 Validation parameters  
The calibration curves and the linearity relationships between peak areas and concentrations 
were established. Meanwhile, the intra-day precision, stability, reproducibility and recovery 
experiments are described in Section 2.6.4. 
 
5.2.6 Data analysis of quantitative determination of magnolin and fargesin 
The contents of magnolin and fargesin from the testing samples were analysed based on the 
linearity relationship between the peak area and the concentration. Details are described in 
Section 2.9.3. Testing samples were in triplicates and were represented as mean ± S.D.  
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5.3 Results 
5.3.1 Method optimisation 
The effectiveness of HPLC separation was tested using the ethanol extracts of M. biondii and 
the herbal products from Hualong Magnolia development Co. Ltd. in Henan Province, China. 
The gradient elution profile was optimised to obtain the highest resolution of magnolin and 
fargesin within a short analysis period. Different mobile phase compositions were tested. 
Acetonitrile and water (65:35) did not achieve a good separation of both compounds (Figure 
5.1). Then, the effect of acetonitrile and water composition of the mobile phase was studied as 
a gradient elution (Figure 5.2). The gradient elution program was 10% to 100% of acetonitrile 
(0 – 90min). The good separation of magnolin and fargesin were achieved when the 
concentrations of acetonitrile and water were 64% : 36% and 71% : 29%, respectively. As a 
result, the best resolution of the main peaks was achieved to use a gradient elution of the 
mobile phase consisting of acetonitrile and water within 20min (the elution program see Table 
2.11). The retention times of magnolin and fargesin are 11.038min and 14.297min, 
respectively (Figure 5.3). Furthermore, the detection of a mixture of magnolin and fargesin 
was tested at 250nm, 278nm and 290nm, under the above conditions. It was found that the 
best sensitivity was achieved when the detection wavelength was 278nm (Figure 5.4).  
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Figure 5.1 The chromatogram of M. biondii from the mobiles phase of a mixture of 
acetonitrile and water (65:35). 
 
 
 
 
 
 
 
Figure 5.2 The chromatogram of M. biondii from the mobiles phase of a mixture of 
acetonitrile and water with a gradient elution  
 
 
 
 
 
 
 
Figure 5.3 The chromatogram of M. biondii from the mobiles phase of the optimised gradient 
elution for 20min. The program details are described in Table 2.11. 
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Figure 5.4 The chromatograms of M. biondii, using optimised HPLC determination conditions with different detection wavelengths at 250nm, 
278nm and 290nm. 
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5.3.2 Method validation 
5.3.2.1 Linearity  
Appropriate dilutions of magnolin and fargesin dissolved in ethanol, were made to prepare the 
working solutions containing 10, 25, 50, 75, and 100 ng/ml, and 1, 2.5, 5, 7.5, and 10 ng/ml, 
respectively. The chromatogram of the standard solution is shown in Figure 5.5. Calibration 
curves were plotted by linear regression of peak area vs. concentration. The regression 
equations of magnolin and fargesin are shown in Figure 5.6. The linearity relationship 
between peak areas and concentrations were good, and the regression coefficients (γ) were 
0.9995 for the curves (Table 5.1).  
 
 
 
 
 
 
 
Figure 5.5 The chromatogram of the standard solution containing 100ng/ml of magnolin and 
10ng/ml of fargesin (20min) 
 
Table 5.1 The linear ranges and correlation coefficients of calibration curves of magnolin and 
fargesin 
Standard compound Range Retention time Standard curve γ 
Magnolin 10-100 ng/ml 11.038 min y=3114.4x-2011.8 0.9995 
Fargesin 1-10ng/ml 14.297 min y=5168.2x-141.8 0.9995 
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Figure 5.6 The standard curves of magnolin (A) and fargesin (B) 
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5.3.2.2 Precision  
Injection of five replicates of a M. biondii sample produced a consistent result (Table 5.2). 
The R.S.D.s for the determination of the magnolin and fargesin were 0.22% and 0.36%, 
respectively.   
 
 
Table 5.2 The precision test for HPLC determination method 
Magnolin Fargesin 
No Weight (g) 
Peak area % (w/w) Peak area % (w/w) 
1 652571 6.50 73468 0.40 
2 655172 6.53 73188 0.40 
3 654099 6.52 72788 0.39 
4 653565 6.51 73259 0.40 
5 
1.5559 
651350 6.49 72966 0.39 
Average 6.513 0.396 
SD 0.015 0.001 
% RSD 
 
0.22 
 
0.36 
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5.3.2.3 Stability 
Injection of a M. biondii sample was performed at room temperature for five times within 
48hrs (Table 5.3). The R.S.D.s for magnolin and fargesin were 1.09% and 1.75%, respectively. 
 
 
 
Table 5.3 The stability test for HPLC determination method 
Magnolin Fargesin 
Time  Weight (g) 
Peak area % (w/w) Peak area % (w/w) 
0hr 652571 6.50 73468 0.40 
2hr 653565 6.51 73259 0.40 
18hr 651308 6.50 74488 0.40 
24hr 649147 6.48 72483 0.39 
42hr 638792 6.34 72365 0.38 
48hr 
1.5559 
642414 6.38 72593 0.39 
Average  6.446  0.393 
SD  0.070  0.007 
% RSD  1.09  1.75 
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5.3.2.4 Repeatability 
Five replicates of one batch of M. biondii sample were extracted and determined to evaluate 
the repeatability of the quantitative procedure. All of the measurements of repeatabilities were 
expressed as R.S.D.s (Table 5.4). 
 
 
Table 5.4 The reproducibility test for HPLC determination method 
Magnolin Fargesin 
No Weight (g) 
Peak area % (w/w) Peak area % (w/w) 
653988 6.80 74163 0.42 
1 1.5946 
656151 6.82 75778 0.43 
648172 6.94 72941 0.43 
2 1.5466 
649104 6.95 73897 0.43 
649742 6.99 75064 0.44 
3 1.5389 
654432 7.04 75308 0.44 
635510 6.76 73832 0.43 
4 1.5558 
637324 6.78 74914 0.43 
664401 6.78 74610 0.41 
5 1.5559 
661880 6.75 74228 0.41 
Average  6.859  0.427 
SD  0.107  0.010 
% RSD  1.55  2.46 
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5.3.2.5 Recovery 
The recovery rates for magnolin and fargesin were evaluated by investigating maker 
compounds, 200µg/ml of magnolin and 15µg/ml of fargesin, which were added to a sample. 
Spiked samples were prepared in five duplicates. The results are shown in Table 5.5 and 5.6. 
The average recoveries for magnolin and fargesin were 98.373% and 94.226, respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
204 
 
Table 5.5 The recovery rate of magnolin and related experiment conditions  
No 
Weight 
 (g) 
Concentration 
 (µg/ml) 
Added standard 
 (µg/ml) 
Peak area 
Concentration 
(µg/ml)  
Recovery  
(%) 
216.75 200.00 627652 204.59 98.18 
1 1.5946 
217.47 200.00 636998 207.64 99.47 
214.82 200.00 620397 202.22 97.50 
2 1.5466 
215.13 200.00 617247 201.20 96.93 
215.34 200.00 628237 204.78 98.61 
3 1.5389 
216.90 200.00 636880 207.60 99.59 
210.63 200.00 637324 207.74 101.18 
4 1.5558 
211.23 200.00 618881 201.73 98.11 
210.88 200.00 620656 196.99 95.89 
5 1.5559 
210.08 200.00 634749 201.47 98.26 
Average  98.373 
SD  1.482 
% RSD  1.51 
 
 
205 
 
Table 5.6 The recovery rate of fargesin and related experiment conditions 
No 
Weight 
 (g) 
Concentration 
 (µg/ml) 
Added standard 
 (µg/ml) 
Peak area 
Concentration 
(µg/ml)  
Recovery 
 (%) 
13.41 15.00 75648 13.50 95.01 
1 1.5946 
13.70 15.00 75859 13.54 94.31 
13.19 15.00 74792 13.34 94.68 
2 1.5466 
13.36 15.00 73597 13.13 92.59 
13.57 15.00 75480 13.47 94.26 
3 1.5389 
13.62 15.00 76793 13.70 95.75 
13.35 15.00 74914 13.37 94.29 
4 1.5558 
13.55 15.00 75022 13.39 93.78 
12.84 15.00 75112 12.93 92.86 
5 1.5559 
12.77 15.00 76432 13.15 94.72 
Average  94.226 
SD  0.951 
% RSD  1.01 
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5.3.3 Determination of contents of magnolin and fargesin in different Flos 
Magnoliae species  
The content of magnolin and fargesin in six Flos Magnoliae species, M. biondii, M. denudata, 
M. kobus, M. liliflora, M. sargentiana and M. sprengeri were determined (Table 5.7). Among 
the six different species, only M. biondii and M. kobus contained magnolin and fargesin. 
Magnolin was also detected in the ethanol extract of M. liliflora. However, this sample did not 
contain fargesin. No magnolin and fargesin were detected from ethanol extract of other three 
species. There were great variations in the concentrations of magnolin and fargesin among 
different sources of Flos Magnoliae. M. biondii was found to possess the highest amount of 
magnolin and fargesin, as 6.513±0.015% and 0.396±0.001%, respectively. In addition, there 
were remarkable differences between the chromatographic profiles of six Flos Magnoliae 
species (Figure 5.7). 
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Figure 5.7 HPLC chromatograms of six Flos Magnoliae species. 
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Table 5.7 The contents of magnolin and fargesin in six Flos Magnoliae species. (n=3) 
 M. biondii M. denudata M. kobus M. liliflora M. sargentiana M. sprengeri 
Mean (%, w/w)  
(S.D.) 
6.513 
(0.015) 
- 
0.108 
(0.003) 
0.244 
 (0.014) 
- - 
Magnolin 
% R.S.D. 0.2 - 3.8 3.5 - - 
Mean (%, w/w)  
(S.D.) 
0.396 
(0.001) 
- 
0.210 
(0.002) 
- - - 
Fargesin 
% R.S.D. 0.4 - 1.3 - - - 
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5.3.4 Determination of contents of magnolin and fargesin in different M. biondii 
varieties 
Eleven batches of six M. biondii varieties were studied (details see Table 2.3) and each 
samples was determined in triplicates. The chromatographic profiles of the ethanol extracts of 
all batches showed significantly different in the content of magnolin and fargesin (Table 5.8), 
ranging from 4.800±0.022% (Sample 5: HGCY, 黄梗串鱼) to 2.304±0.044% (Sample 3: 
EMT, 二毛桃 ) for magnolin and 0.427±0.002% (Sample 5: HGCY, 黄梗串鱼 ) to 
0.051±0.000% (Sample 7: CY, 串鱼) for fargesin.  
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Table 5.8 The contents of magnolin and fargesin in 11 batches of M. biondii varieties.  (n=3) 
 
 
 
1 
HLWH 
2 
EMT 
3 
EMT 
4 
XMT 
5 
HGCY 
6 
CY 
7 
CY 
8 
CY 
9 
EMT 
10 
HLWH 
11 
BZCY 
Mean 
(%, w/w) 
(S.D.) 
3.949 
(0.107) 
3.662 
(0.104) 
2.304 
(0.044) 
2.914 
(0.023) 
4.800 
(0.022) 
3.709 
(0.066) 
4.156 
(0.024) 
3.555 
(0.074) 
3.700 
(0.020) 
3.067 
(0.078) 
3.757 
(0.061) 
Magnolin 
% R.S.D. 2.7 2.8 1.9 0.8 0.4 1.8 0.6 2.1 0.6 2.6 1.6 
Mean 
(%, w/w) 
(S.D.) 
0.351 
(0.006) 
0.355 
(0.013) 
0.056 
(0.002) 
0.141 
(0.009) 
0.427 
(0.002) 
0.063 
(0.002) 
0.051 
(0.000) 
0.090 
(0.005) 
0.321 
(0.004) 
0.302 
(0.010) 
0.098 
(0.002) 
Fargesin 
% R.S.D. 1.6 3.6 3.2 6.6 0.5 3.9 0.8 5.5 1.3 3.2 2.4 
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5.3.5 Determination of contents of magnolin and fargesin in Flos Magnoliae 
products from different herbal suppliers 
Five batches of Flos Magnoliae products from five herbal suppliers were studied (Details of 
the herbal suppliers see Table 2.4). All samples were identified from the botanic origin, M. 
biondii. The contents of magnolin and fargesin are shown in Table 5.9. 
 
Table 5.9 The contents of magnolin and fargesin in five Flos Magnoliae products from 
different herbal suppliers. (n=3)  
 HL TFH TFK EYS KODA 
Mean 
 (%, w/w)  
(S.D.) 
6.513 
(0.015) 
4.483  
(0.007) 
5.368  
(0.023) 
3.669 
 (0.023) 
2.205  
(0.024) 
Magnolin 
% R.S.D. 0.2 0.2 0.4 1.2 1.1 
Mean 
(%, w/w)  
(S.D.) 
0.396 
(0.001) 
0.038 
(0.001) 
0.493  
(0.002) 
0.345 
(0.010) 
0.121  
(0.002) 
Fargesin 
% R.S.D. 0.4 2.5 0.5 0.3 1.6 
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5.3.6 Determination of contents of magnolin and fargesin in samples of M. biondii 
and M. sprengeri from different cultivation sites 
Four batches of M. biondii samples from different cultivation sites in Nanzhao, Henan 
Province, China, were studied (details see Table 2.5). The contents of magnolin and fargesin, 
determined by the optimised method, are shown in Table 5.10. 
 
Two batches of M. sprengeri samples from two cultivation sites in China and one sample 
from Australia were determined (details see Table 2.6). However, no magnolin and fargesin 
were detected from all three batches of M. sprengeri.  
 
Table 5.10 The contents of magnolin and fargesin in four M. biondii batches, collected from 
different cultivation sites. (n=3) 
 DHY XHY YYS TQ 
Mean  
(%, w/w)  
(S.D.) 
 1.988  
(0.012) 
2.686 
(0.025) 
2.860 
 (0.066) 
2.369 
(0.003) 
Magnolin 
% R.S.D. 0.6 0.9 2.3 0.1 
Mean  
(%, w/w)  
(S.D.) 
0.017 
(0.000) 
0.023 
(0.002) 
0.286  
(0.013) 
0.117 
(0.003) 
Fargesin 
% R.S.D. 1.3 7.0 4.6 2.5 
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5.4 Discussion 
Initially, the isocratic elution chromatographic conditions recommended by the current 
Chinese Pharmacopoeia employing acetonitrile – water (35:65) was used to separate 
components in Flos Magnoliae ethanol extract (The Pharmacopoeia Commission of People's 
Republic of China, 2005). However, separation of peaks was unsatisfactory, because there 
were poor resolutions of peaks, broadening of late peaks and long running time. These 
difficulties were explained by previous studies (Lee and Row, 2004), and might result in 
misidentification and/or inaccurate quantification.  
 
Thus, in order to achieve a better separation of these compounds, a gradient elution method 
was used in the present study. Gradient elution has been shown to improve the early eluting 
peaks, limit the broadening of the later peaks and decrease the time of analysis (Kress et al., 
2002, Purcell et al., 1999, Snyder, 1980). With acetonitrile and water as the mobile phase 
(ratio 64% and 71%, respectively), a good separation was achieved for magnolin and fargesin. 
Moreover, a detection wavelength of 278nm was found to be the best wavelength to measure 
absorbance for all the peaks. Thus, an optimised acetonitrile-water gradient system has been 
developed for simultaneous determination of magnolin and fargesin. Under these conditions 
linear calibration curves, excellent intra-day precision and stability, high repeatability and 
good recovery were achieved (R.S.D. less than 3%). 
 
Among the six Magnolia spp., M. biondii, M. denudata and M. sprengeri, have been listed in 
the Chinese Pharmacopoeia (The Pharmacopoeia Commission of People's Republic of China, 
2005). The Chinese species M. biondii was found to contain magnolin and fargesin, and 
matched the chemical specification of Flos Magnoliae required by the Chinese 
Pharmacopoeia (The Pharmacopoeia Commission of People's Republic of China, 2005). The 
dried buds from M. kobus that has been used as authentic Flos Magnoliae species in Japan 
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were also shown to contain magnolin and fargesin. It produced similar chromatographic 
profile to the M. biondii (the chromatogram see Figures 5.7), although M. kobus has a lower 
content of magnolin and fargesin than M. biondii. However, compared to M. biondii, M. 
kobus has a relative higher content of fargesin than magnolin. Another locally grown species, 
M. liliflora, which is one of the common substitutes of Flos Magnoliae in China, only 
contained one of the bioactive compounds, magnolin. In addition, the chromatogram of M. 
liliflora was significantly different from M. biondii and M. kobus. 
 
It is surprising that some of the Flos Magnoliae species, M. denudata, M. sprengeri and M. 
sargentiana, did no contain magnolin and fargesin. This negative finding of magnolin has not 
been reported previously (Chae et al., 1998, Page, 1990, Pan et al., 1987). The species 
variation may lead to the different quantities of active components of CHM. Consequently, 
such differences in the quantity of the lignans and neolignans may affect the clinical efficacy.  
 
In the present study, 11 batches of six M. biondii varieties were contained both magnolin and 
fargesin, including HLWH (华龙五号), EMT (二毛桃), XMT (小毛桃), HGCY (黄梗串鱼), 
CY (串鱼) and BZCY (标准串鱼). All M. biondii batches were collected from Nanzhao, 
Henan Province, China on the same day.  The chromatograms from the 11 batches all 
revealed the same patterns. However, the content of magnolin and fargesin varied. The 
content of magnolin and fargesin ranged from 2.304 – 4.800% and 0.051 – 0.427%, 
respectively. Among six varieties, HGCY (黄梗串鱼 ) has the highest concentration of 
magnolin (4.8%) and fargesin (0.427%). Especially, the content of magnolin in HGCY (黄梗
串鱼) were 12 times above the standard mentioned in the current Chinese Pharmacopoeia that 
suggested the content of magnolin no less than  0.4% (The Pharmacopoeia Commission of 
People's Republic of China, 2005). High contents of magnolin (3.757%) and fargesin (0.098%) 
were also found in BZCY (标准串鱼), which is recognised as a high quality Flos Magnoliae 
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source by local farmer. Three batches of CY (串鱼) varieties, which are the majority variety 
for the cultivation site, have a high content of magnolin, but low content of fargesin. 
Furthermore, one of the three batches of EMT (二毛桃) contained much lower magnolin and 
fargesin that the other two batches from the same variety. This support a number of previous 
studies indicating that the chemical compositions of CHM differ from various botanic species 
and varieties (Xu and Zhao, 2004, Zhang et al., 2002a). Thus, where multiple species and 
varieties of Flos Magnoliae are used as CHM, it is necessary for establishment of the content 
of the bioactive compounds in these plants.  
 
On the other hand, differences of the contents of magnolin and fargesin among five Flos 
Magnoliae products from five different herbal suppliers were observed. The batch from 
Hualong Magnolia Development Co. Ltd. contained higher level of magnolin, compared to 
other three batches from the herbal suppliers in Hong Kong. As one of the major 
manufactures, Hualong Magnolia Development Co. Ltd., cultivated more than 50% of the 
Flos Magnoliae products for the Chinese market (Hualong Magnolia Development Co. Ltd., 
2003). The Flos Magnoliae sample from KODA International was claimed to be the high 
quality herbal extract in powdered form. However, it contained the least content of magnolin 
and second least content of fargesin compared to other four batches. It is not known if these 
changes were caused by manufacturing factors, such as processing, shipping and storage (Liu 
et al., 2003a, Zhang and Feng, 2005). Nevertheless, those extrinsic factors can influence the 
chemical compositions of herbal products, and may result in changes of content of bioactive 
ingredients, and lead to varying quality and efficacy of Flos Magnoliae. 
 
The influences of environmental factors during the cultivation process on the contents of 
lignans were also tested in the present study. Four batches of M. biondii, collected from four 
cultivation sites in Nanzhao, Henan Province, China, were studied using the optimised HPLC 
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method. Three batches, collected from Western Garden, Mt. Yanyi and Tian Bridge, 
contained higher levels of magnolin compared to another batch from Eastern Garden. 
Moreover, the other two batches, collected from Mt. Yanyi and Tian Bridge contained 
significantly higher levels of fargesin than that in two batches collected from Eastern Garden 
and Western Garden. These findings indicate that the differences of the amount of sunlight, 
the soil conditions and climates may alter the accumulation and the chemical compositions of 
Flos Magnoliae. Furthermore, three M. sprengeri batches, two of which were collected from 
China (from Mabian and Jiangyou, respectively), and one from Mt. Dandenong, Australia, 
were found no containing of magnolin and fargesin, indicating these two compounds may not 
be a suitable marker for this species.  
 
In conclusion, an optimised and validated method has been developed and demonstrated to be 
a useful procedure to quantitatively analyse the bioactive lignans, magnolin and fargesin, in 
different samples of Flos Magnoliae. The RP-HPLC coupled with a gradient elution system 
was found to be a rapid, sensitive and reproducible for simultaneous determination of 
bioactive compounds. Present findings also verified that the variations of botanic species and 
varieties, the cultivation environments, and post-cultivation manufacturing process might 
cause significant change of the content of bioactive compounds, which might affect the 
quality and efficacy of related herbal products.  
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Chapter Six  
Identification of Flos Magnoliae Using HPLC Fingerprinting 
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6.1 Background 
The chromatographic fingerprint of CHM has been recognised as one of the most representing 
approaches, to identify and characterise chemical compositions of CHMs (Drasar and 
Moravcova, 2004). As mentioned in Chapter 1 (Section 1.3.4), the CHM fingerprints, 
including chromatograms, electrophotograms and other illustrative grams, have been widely 
used in pharmaceuticals, environmental substances, foods and cosmetics, and forensic 
subjects (Aksenova et al., 1999, Wang et al., 2004f, Berente et al., 2000, Klemenc, 2001). 
Since 1996, the chromatographic fingerprints have been widely used as the quality control 
tool for the authentication and identification of CHMs (CDER, 2004, The European Anency 
for the Evaluation of Medicinal Products, 2002, WHO, 1996). Compared to other commonly 
used approaches that only consider one or several chemical components, the fingerprints of 
CHM products can study the content and consistence of complex chemical compositions.  
 
Previous studies have used various HPLC systems to study the chemical compositions of Flos 
Magnoliae species and determined the levels of bioactive components, magnolin and fargesin, 
M. biondii, M. denudata and M. sprengeri (Table 6.1). However, there is still no systematic 
study on HPLC fingerprints of Flos Magnoliae.  
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Table 6.1 Various HPLC systems for qualitative and quantitative analysis of Flos Magnoliae 
HPLC 
system 
Detector  Column 
Temperature 
of the oven 
Elution 
mode 
Mobile phase Flow rate  Wavelength  Reference 
Waters, 
United States 
Photodiode 
array detector 
µBondapak C18 
(3.9mm x 300mm, 
10µM, Waters, 
United States) 
25°C Isocratic  Methanol : water (60:40) 1.0ml/min 283nm (Yu et al., 
2005b) 
Waters, 
United States 
Photodiode 
array detector 
Hypersil ODS C18 
(4.6mm x 200mm, 
5µM, Agilent, 
United States) 
30°C Isocratic Acetonitrile : water (50:50) 1.0ml/min 278nm (Xu et al., 
2003) 
Shimadzu, 
Japan 
SPD-6A (V) 
detector  
Zorbax SB-C8 
(4.6mm x 150mm, 
5µM, Agilent, 
United States) 
Room 
temperature 
Isocratic 
Acetonitrile –
tetrahydrogenfuran – water 
(35:1:64) 
1.0ml/min 278nm 
(Fang et al., 
2002) 
Spectra-
physics, 
United States 
Spectra –200 
UV detector  
SupelcosilTM LC18 
(4.6mm x 250mm, 
5µM, Supelco, 
United States) 
Room 
temperature  
Isocratic 
Acetonitrile –
tetrahydrogenfuran – water 
(35:1:64) 
1.0ml/min 290nm 
(Zhu et al., 
2002) 
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Aims of this study 
The aim of the present study is to establish and evaluate the HPLC fingerprinting profiles of 
different species or varieties of Flos Magnoliae, including M. biondii, M. denudata, M. kobus, 
M. liliflora, M. sargentiana and M. sprengeri and different varieties of M. biondii. In addition, 
HPLC fingerprinting profiles of different Flos Magnoliae herbal products, and different 
batches of M. biondii grown in different cultivation sites were also studied. The following 
parameters were selected, including the total peak areas of the common peaks, the retention 
time, the relative retention time, the peak area and the relative peak area. The percentage of 
the single peak in the common peaks and the overlapping ratio of peak (ORP) (Lijuan et al., 
2007) were also employed for elucidation of the HPLC fingerprints of Flos Magnoliae.  
 
6.2 Method  
6.2.1 Samples extraction and preparation  
The details of sample collection and preparation are described in Chapter 2, Section 2.2.2 and 
Section 2.7.1, respectively.  
 
6.2.2 Reagents and chemicals 
The details of the reagents and chemicals are described in Section 2.3.3.  
 
6.2.3 Preparation of standard references, magnolin and fargesin 
The details of preparation of standard references are described in Section 2.6.2. 
 
6.2.4 Chromatographic conditions 
The HPLC system (Shimadzu Model SCL-10Avp, Shimadzu, Japan) consisted of a 
photodiode array detector (Shimadzu Model SPD-M10Avp, Shimadzu, Japan). A RP-C18 
column (ODSII, L 250 × 4.6 I.D. mm, 5µM, Phenomenex, U.S.A.) and a pre-column of the 
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same packing material (Security Guide cartridge; 3.0mm; Phenomenex, U.S.A.) were used for 
qualitative and quantitative analysis of the Flos Magnoliae sources. The mobile phase was a 
mixture of acetonitrile and water (programs see Table 2.12). The protocols of the 
chromatographic conditions are described in Section 2.7.2. 
 
6.2.5 Validation parameters  
The intra-day precision, stability and reproducibility of the method were tested using the 
protocols as described in Section 2.7.3. 
 
6.2.6 Data analysis  
The details of the data analysis are described in Section 2.9.4. Testing samples were in 
triplicates and were represented as mean ± S.D. Furthermore, all measurements were 
expressed as R.S.D.s. The retention time and the relative retention time (the ratio between 
retention time of sample constituents to that of internal standard), and the peak area and the 
relative peak area (the ratio between peak of sample constituents to that of internal standard) 
of the common peaks were used to evaluate the quality and quantity of the chemical 
compositions of Flos Magnoliae samples. In addition, the ORPs were used to study the 
correlation of two comparative samples according to their respective total number of peaks 
and common peaks, based on the reference sample. It is defined as follows: ORP (%) = 
2×c/(a+b) ×100, where ORP (%) represents the overlapping ratio; c represents the number of 
common peaks in two samples; a and b represent the number of total peaks in reference 
sample and compared sample, respectively.  
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6.3 Results  
6.3.1 Optimisation of chromatographic conditions 
The ethanol extract of M. biondii, from Hualong Magnolia development Co. Ltd. in Henan 
Province, China, was used for optimisation of the chromatographic fingerprinting method. 
The resolution of 13 common peaks was obtained using a gradient mobile phase consisting of 
acetonitrile and water within 60min, based on their relative retention time (Figure 6.1). Using 
reference standards authenticated two peaks of magnolin (Peak 6) and fargesin (Peak 11) 
(Figure 6.2). The retention times of magnolin and fargesin were 29.64±0.01min and 
32.82±0.01min, respectively. Furthermore, the chromatographic fingerprints of the Flos 
Magnoliae extracts were detected using photodiode array detector at 250nm, 278nm and 
290nm (Figure 6.3). The best resolution was achieved when the detection wavelength was 
278nm.  
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Figure 6.1 The chromatogram of M. biondii from the optimised mobile phase with the gradient elution for 60min (details see Table 2.12). 
Thirteen common peaks were indicated in the chromatogram, among that peak No 6 was indicated as magnolin and peak No 11 was indicated as 
fargesin.  
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Figure 6.2 The chromatogram of the standard solution containing 100ng/ml of magnolin and 10ng/ml of fargesin (60min) 
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Figure 6.3 The chromatograms of M. biondii, using optimised HPLC conditions with different detection wavelengths at 250nm, 278nm and 
290nm. 
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6.3.2 Validation parameters 
6.3.2.1 Precision   
Injections of five replicates of the same M. biondii sample produced a consistently result 
(Table 6.2). The validation practices were focused on the relative retention time and relative 
peak area of nine major common peaks. In the present study, magnolin (peak 6) was regarded 
as the internal standard. The R.S.D.s for the determination were less than 3%.  
 
6.3.2.2 Stability 
Five replicates of one M. biondii sample were performed at room temperature every 12hrs for 
five times within three days and the results are shown in Table 6.3. The validation practices 
were focused on the relative retention time and relative peak area of nine major common 
peaks. In the present study, magnolin (peak 6) was regarded as the internal standard. The 
R.S.D.s for the determination were less than 4%.  
 
6.3.2.3 Repeatability 
Five replicates of the same M. biondii sample were extracted and determined to evaluate the 
repeatability of the identification method. The results are shown in Table 6.4. In the present 
study, magnolin (Peak 6) was regarded as the internal standard. The R.S.D.s for the 
determination were less than 4%. 
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Table 6.2 The precision test for HPLC identification method (n=5). RRT represents relative retention time, and RPA represents relative peak area.  
Peak No.  
4 5 6 7 8 9 10 11 12 
Average 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 
S.D. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RRT 
% R.S.D. 0.14 0.13 0.00 0.13 0.13 0.13  0.13 0.13 0.16 
Average 0.02 0.74 1.00 0.10 0.19 0.13 0.04 0.12 0.03 
S.D. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RPA 
% R.S.D. 2.49 0.04 0.00 0.29 0.23 0.20 1.09 0.79 1.45 
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Table 6.3 The stability test for HPLC identification method (n=5). RRT represents relative retention time, and RPA represents relative peak area.  
Peak No.  
4 5 6 7 8 9 10 11 12 
Average 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.49 
S.D. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 RRT 
% R.S.D. 0.04 0.01 0.00 0.01 0.02 0.02 0.02 0.06 1.08 
Average 0.02 0.74 1.00 0.10 0.19 0.13 0.04 0.13 0.03 
S.D. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RPA 
% R.S.D. 3.16 0.21 0.00 0.52 0.26 0.33 1.51 1.98 2.38 
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Table 6.4 The reproducibility test for HPLC identification method (n=5). RRT represents relative retention time, and RPA represents relative peak 
area.  
Peak No.  
4 5 6 7 8 9 10 11 12 
Average 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 
S.D. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RRT 
% R.S.D. 0.04  0.01 0.00 0.01 0.02 0.02 0.02 0.02 0.03 
Average 0.02 0.74 1.00 0.10 0.18 0.13 0.04 0.12 0.03 
S.D. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 RPA 
% R.S.D. 3.76 0.25 0.00 1.10 0.85 0.50 1.06 1.01 1.87 
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6.3.3 Identification of different Flos Magnoliae species  
The HPLC chromatograms of six Flos Magnoliae species showed significantly different 
pattens (Figure 6.4). As shown in Table 6.5, Peak 1-4, 6-7 and 9-13 were not found in the 
chromatogram of M. denudata, Peak 3, 8 and 10 were absent in the chromatogram of M. 
kobus, Peak 1-3 and 11 were not found in the chromatogram of M. liliflora, Peak 1, 3, 4, 6, 10 
and 11 were absent in the chromatogram of M. sargentiana, and Peak 1-6 and 9-11 were 
absent in the chromatogram of M. sprengeri. Compared to the quantity of chemical 
components in the chromatograms of six Flos Magnoliae species (Table 6.6), Peak 6 
(magnolin) was the highest peak (7551815±11255.9) that was found in the chromatogram of 
M. biondii. Peak 8 was the highest peak in the chromatograms of M. denudata and M. 
sprengeri. Peak 9 was the highest peak (7232110.0±26758.8) in the chromatogram of M. 
kobus. Peak 5 was the highest peak (605316.6±7701.2) in the chromatogram of M. liliflora, 
while Peak 2 was the highest peak (263557.2±32598.8) in the chromatogram of M. 
sargentiana.  
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Figure 6.4 HPLC chromatograms of six Flos Magnoliae species (with 10µl injection volume of stock solution; peak 6, magnolin; peak 11, fargesin) 
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Table 6.5 The retention time of 13 common peaks of six Flos Magnoliae species. Peak 6 indicated magnolin and Peak 11 indicated fargesin. (n=3)  
Number of the common peaks  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 
M. biondii (HL) 7.57 13.37 23.99 26.72 29.07 29.63 30.20 30.80 31.60 32.06 32.82 43.80 44.78 
M. denudata - - - - 29.04 - - 30.81 - - - - - 
M. kobus 7.55 13.52 - 26.65 29.03 29.62 30.25 - 31.56 - 32.77 43.68 44.62 
M. liliflora - - - 26.67 28.96 29.47 30.08 30.75 31.53 32.19 - 43.70 44.67 
M. sargentiana - 13.42 - - 29.08 - 30.35 30.77 31.55 - - 43.74 44.65 
M. sprengeri - - - - - - 30.24 30.92 - - - 43.65 44.97 
Mean 7.563 13.448 23.992 26.682 29.036 29.575 30.223 30.809 31.558 32.122 32.795 43.715 44.739 
%R.S.D. 0.18 0.58 0.09 0.14 0.15 0.29 0.32 0.22 0.09 0.28 0.11 0.13 0.32 
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Table 6.6 The peak areas of 13 common peaks of six Flos Magnoliae species. Peak 6 indicated magnolin and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks  
Mean (%, w/w) 
(% R.S.D.) 
 
1 2 3 4 5 6 7 
M. biondii (HL) 
833987.4 
(4.04) 
942559.9 
(6.90) 
177831.0 
(4.21) 
176575.0 
(2.55) 
5734722.8 
(5.00) 
7551815.8 
(0.15) 
738912.3 
(0.43) 
M. denudata - - - - 
35693  
(1.03) 
- - 
M. kobus 
1109179.9  
(2.57) 
1028542.3 
(1.86) 
- 
2106445.5  
(0.62) 
5672324.8 
(0.41) 
125524.2 
(0.61) 
751598.8  
(0.40) 
M. liliflora - - - 
73386.0 
(1.94) 
605316.6  
(1.27) 
247061.7 
(2.31) 
409213.3 
(1.50) 
M. sargentiana - 
263557.2 
(12.37) 
- - 
14133.2 
(4.02) 
- 
18526.9 
(0.84) 
M. sprengeri (JY) - - - - - - 
68070.9  
(1.10) 
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Continued Table 6.6 The peak areas of 13 common peaks of six Flos Magnoliae species. Peak 6 indicated magnolin and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks  
Mean (%, w/w) 
 (% R.S.D.) 
 
8 9 10 11 12 13 Total  
M. biondii (HL) 
1400263.5 
(0.26) 
1012449.6 
(0.37) 
300903.1  
(1.09) 
931563.3   
(0.76) 
251961.6  
(7.02) 
133588.4  
(8.50) 
20187133.7 
M. denudata 
181251.8  
(0.39) 
- - - - - 216944.8 
M. kobus - 
7232110.0 
(0.37) 
- 
513318.2  
(2.05) 
58502.5  
(5.42) 
40384.5  
(4.47) 
18637930.7 
M. liliflora 
577489.8  
(0.83) 
66190.5  
(2.85) 
552216.5  
(1.02) 
- 
109290.8  
(1.96) 
128156.2 
(1.98) 
2768321.4 
M. sargentiana 
9792.6  
(7.39) 
9249.4 
(5.44) 
- - 
14254.2  
(8.92) 
3200.5  
(38.92) 
332714.0 
M. sprengeri (JY) 
218513.6  
(0.77) 
- - - 
65736.5  
(3.35) 
37293.2  
(8.79) 
389614.2 
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6.3.4 Identification of different varieties of M. biondii  
Replicate extracts of 11 batches of M. biondii from six different varieties were employed in 
the present study (details see Table 2.3). Triplicate HPLC runs were performed for each 
ethanol extract. Thirteen common peaks (defined in Figure 6.1) of ethanol extractions were all 
found in the chromatograms of 11 batches of M. biondii samples (Figure 6.5 – 6.10). Peak 6 
in the chromatogram indicates the bioactive component, magnolin, which was used as internal 
standard for fingerprinting analysis. Peak 11 represents another bioactive lignan, fargesin. 
Based on the R.S.D. (less than 1%) of the relative retention time of each common peak in 11 
M. biondii samples, these peaks were authenticated as the same peaks (Table 6.7). 
 
Six non-common peaks (A-F) were also identified based on the retention time of the peaks in 
the chromatograms of 11 samples of M. biondii (Table 6.8). In the present study, ORP in 11 
M. biondii samples were calculated, when sample 5 (HGCY) was as the reference standard 
(Table 6.9). ORP of each sample was no less than 70.27%.  
 
Furthermore, it was also demonstrated that the peak area and the peak area percentage of 
single peak owned in 13 common peaks in the chromatographic fingerprints of 11 M. biondii 
samples (Table 6.10). The total peak area of the common peaks from Sample 5 (HGCY) was 
the highest among 11 M. biondii samples, while the total peak area of Sample 3 (EMT) was 
the lowest. Peaks 5-11 were also identified as the main common peaks that the total peak 
areas of those dominant peaks were more than 85%. Moreover, in the chromatographic 
fingerprints, peak 6 (magnolin) was use as the internal standard. The relative peak area were 
elucidated in Table 6.11 
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Figure 6.5 HPLC chromatograms of Sample 1 and Sample 10 (HLWH) (with 10µl injection volume; peak 6, magnolin; peak 11, fargesin) 
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Figure 6.6 HPLC chromatograms of Sample 2, Sample 3 and Sample 9 (EMT) (with 10µl injection volume; peak 6, magnolin; peak 11, fargesin) 
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Figure 6.7 HPLC chromatogram of Sample 4 (XMT) (with 10µl injection volume; peak 6, magnolin; peak 11, fargesin) 
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Figure 6.8 HPLC chromatogram of Sample 5 (HGCY) (with 10µl injection volume of stock solution; peak 6, magnolin; peak 11, fargesin) 
 
Minutes 
0 5 10 15 20 25 30 35 40 45 50 55 60 
m
Au 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
                     No 5 
A 
B 
C E 
D F 
mAu 
6. Magnolin 
11. Fargesin  
 241 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 HPLC chromatograms of Sample 6, Sample 7 and Sample 8 (CY) (with 10µl injection volume; peak 6, magnolin; peak 11, fargesin) 
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Figure 6.10 HPLC chromatogram of Sample 11 (BZCY) (with 10µl injection volume; peak 6, magnolin; peak 11, fargesin) 
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Table 6.7 The relative retention times of 13 common peaks of 11 batches of M. biondii. Peak 6 indicated magnolin and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 
1 (HLWH) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.52 
2 (EMT) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.52 
3 (EMT) 0.26 0.46 0.81 0.90 0.98 1.00 1.02 1.04 1.06 1.08 1.11 1.48 1.51 
4 (XMT) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.08 1.47 1.51 
5 (HGCY) 0.26 0.47 0.82 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.51 
6 (CY) 0.26 0.46 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.50 
7 (CY) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.03 1.07 1.08 1.11 1.48 1.51 
8 (CY) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.06 1.08 1.11 1.48 1.50 
9 (EMT) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.06 1.08 1.11 1.48 1.51 
10 (HLWH) 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.06 1.08 1.11 1.48 1.51 
11 (BZCY) 0.25 0.46 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.51 
Mean  0.257 0.467 0.811 0.901 0.980 1.000 1.018 1.038 1.065 1.080 1.104 1.479 1.509 
% R.S.D. 0.46 0.65 0.39 0.09 0.02 0.00 0.02 0.25 0.03 0.03 0.60 0.11 0.33 
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Table 6.8 The non-common peaks appeared in the chromatograms of 11 batches of M. biondii samples 
 
Peak No. 
Retention time (min) 
 A B C D E F 
 12.18 28.76 46.22 46.89 49.27 51.01 
1 (HLWH) - - - - + - 
2 (EMT) + - - - + + 
3 (EMT) + - - - + - 
4 (XMT) + + + + - + 
5 (HGCY) + + + + + + 
6 (CY) + + - + - - 
7 (CY) + + + + - + 
8 (CY) + + - + - - 
9 (EMT) + + - - + + 
10 (HLWH) - + - - + + 
11 (BZCY) + + + - + - 
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Table 6.9 The overlapping ratio of peaks (ORPs) of 11 batches of M. biondii  
Sample ID Number of common peaks Total number of peaks ORP (%) 
1 (HLWH)  14 78.79 
2 (EMT)  16 74.28 
3 (EMT)  15 76.47 
4 (XMT)  18 70.27 
5 (HGCY) (references standard) 13 19 - 
6 (CY)  16 74.28 
7 (CY)  17 72.22 
8 (CY)  16 74.28 
9 (EMT)  17 72.22 
10 (HLWH)  16 74.28 
11 (BZCY)  17 72.22 
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Table 6.10 The peak area of 13 common peaks of 11 batches of M. biondii. Peak 6 indicated magnolin and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks  
Peak area  
(% peak area of single peak owned in 13 common peaks) 
 
1 2 3 4 5 6 7 
1 (HLWH) 775599.6 
(5.18) 
194547.7 
(1.30) 
110766.0 
(0.74) 
104695.1 
(0.70) 
4257723.7 
(28.46) 
5735934.5 
(38.34) 
440699.5 
(2.95) 
2 (EMT) 655833.3 
(4.54) 
260214.5  
(1.80) 
137585.0 
(0.95) 
121267.8 
(0.84) 
4105156.6 
(28.39) 
5392253.2 
(37.29) 
425414.1 
(2.94) 
3 (EMT) 524837.7 
(6.62) 
323379.2 
(4.08) 
35435.8 
(0.45) 
44275.6 
(0.56) 
1657387.2 
(20.89) 
3508641.4 
(44.23) 
637043.6 
8.03) 
4 (XMT) 444537.1 
(4.09) 
365699.8 
(3.37) 
58788.8 
(0.54) 
122701.5 
(1.13) 
2470228.7 
(22.74) 
4484932.6 
(41.28) 
586129.9 
(5.40) 
5 (HGCY) 715848.1 
(4.57) 
338031.9 
(2.16) 
181427.2 
(1.16) 
164151.5 
(1.05) 
4940026.6 
 (31.52) 
5630288.3  
(35.93) 
411538.9  
(2.63) 
6 (CY) 750958.8 
(5.80) 
403681.7  
(3.12) 
125714.9 
(0.97) 
102172.8  
(0.79) 
4680505.9 
(36.15) 
5128337.6 
(39.60) 
379363.7 
(2.93) 
7 (CY) 463599.4 
(4.83) 
200307.2 
(2.09) 
59983.4 
(0.63) 
61208.1 
(0.64) 
1484744.1 
(15.47) 
4945111.8 
(51.53) 
802954.5 
(8.37) 
8 (CY) 665625.7 
(5.13) 
255934.5 
(1.97) 
78983.5 
(0.61) 
69136.7 
(0.53) 
4985640.0 
(38.39) 
5031863.8 
(38.75) 
450630.7 
(3.47) 
9 (EMT) 588843.1 
(5.04) 
170787.5 
(1.46) 
108463.8 
(0.93) 
102104.9 
(0.87) 
3363808.9 
(28.78) 
4468813.6 
(38.24) 
331356.1 
(2.84) 
10 (HLWH) 745212.4 
(7.20) 
236582.8 
(2.28) 
105917.5 
(1.02) 
84351.2 
(0.81) 
2677608.7 
(25.86) 
3813064.8 
(36.82) 
328350.5 
(3.17) 
11 (BZCY) 489723.1 
(4.01) 
230201.2 
(1.89) 
162551.4 
(1.33) 
61181.3 
(0.50) 
4658796.2 
(38.16) 
4890809.1 
(40.06) 
275597.8 
(2.26) 
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Continued Table 6.10 The Peak area of 13 common peaks of 11 batches of M. biondii. Peak 6 indicated magnolin and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks  
Peak area  
(% peak area of single peak owned in 13 common peaks)  
8 9 10 11 12 13 Total 
1 (HLWH) 1300037.1 
(8.69) 
813256.4 
(5.44) 
180547.6 
(1.21) 
973867.3 
(6.51) 
61055.3 
(0.41) 
10605.3 
(0.07) 14959335.1 
2 (EMT) 1352464.2 
(9.35) 
782052.8 
(5.41) 
171540.7 
(2.94) 
994686.4 
(2.13) 
52134.8 
(0.26) 
9177.6 
(0.04) 14459781.0 
3 (EMT) 342359.5 
(4.32) 
433242.4 
(5.46) 
232859.1 
(2.94) 
169180.4 
(2.13) 
20354.9 
(0.26) 
3273.1 
(0.04) 7932269.7 
4 (XMT) 837020.3 
(7.70) 
530902.3 
(4.89) 
221549.4 
(2.04) 
383838.8 
(3.53) 
221476.9 
(2.04) 
135734.2 
(1.25) 10863540.4 
5 (HGCY) 1336726.7 
(8.53) 
753290.5 
(4.81) 
144138.2 
(0.92) 
995866.7 
(6.35) 
54322.1 
(0.35) 
9425.8 
(0.06) 15675082.7 
6 (CY) 252271.9 
(1.95) 
735269.2 
(5.68) 
159963.1 
(1.24) 
178081.7 
(1.38) 
40184.7 
(0.31) 
12523.5 
(0.06) 12949029.4 
7 (CY) 260925.5 
(2.72) 
606904.5 
(6.32) 
387891.9 
(4.04) 
120793.6 
(1.26) 
118146.5 
(1.23) 
84369.8 
(0.88) 9596940.1 
8 (CY) 371471.2 
(2.86) 
623008.6 
(4.80) 
176709.4 
(1.36) 
225039.8 
(1.73) 
42760.2 
(0.33) 
9744.2 
(0.08) 12986548.3 
9 (EMT) 1021971.8 
(8.74) 
606503.8 
(5.19) 
127389.8 
(1.09) 
744811.5 
(6.37) 
45957.3 
(0.39) 
6595.8 
(0.06) 11687407.9 
10 (HLWH) 971923.5 
(9.39) 
506817.9 
(4.89) 
127079.5 
(1.23) 
708575.9 
(6.84) 
30663.9 
(0.30) 
19703.1 
(0.19) 10355851.8 
11 (BZCY) 338888.6 
(2.78) 
670243.5 
(5.49) 
128646.4 
(1.05) 
247622.7 
(2.03) 
43574.9 
(0.36) 
9763.7 
(0.08) 12207599.8 
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Table 6.11 The relative peak areas of seven main common peaks of 11 batches of M. biondii. 
Peak 6 indicated magnolin and Peak 11 indicated fargesin. RPA represents relative peak area. 
(n=3)  
Number of the common peaks  
RPA (% R.S.D.) 
 
5 6 7 8 9 10 11 
0.74 0.08 0.23 0.14 0.03 0.17 1 
(HLWH) (0.05) 
1.00 
(1.34) (0.51) (1.22) (2.27) (0.94) 
0.76 0.08 0.25 0.15 0.03 0.18 2 
(EMT) (0.10) 
1.00 
(0.86) (0.35) (0.59) (1.34) (0.21) 
0.47 0.18 0.10 0.12 0.07 0.05 3 
(EMT) (0.34) 
1.00 
(0.26) (0.76) (1.20) (3.51) (4.63) 
0.55 0.13 0.19 0.12 0.05 0.09 4 
(XMT) (4.48) 
1.00 
(0.76) (0.36) (0.37) (0.55) (1.41) 
0.88 0.07 0.24 0.13 0.03 0.18 5 
(HGCY) (0.14) 
1.00 
(0.07) (0.18) (0.37) (0.39) (0.47) 
0.91 0.07 0.05 0.14 0.03 0.03 6 
(CY) (0.13) 
1.00 
(1.08) (1.71) (0.31) (3.36) (2.26) 
0.30 0.16 0.05 0.12 0.08 0.02 7 
(CY) (0.02) 
1.00 
(0.08) (0.43) (0.49) (0.93) (1.01) 
0.99 0.09 0.07 0.12 0.04 0.04 8 
(CY) (0.03) 
1.00 
(0.58) (1.54) (0.45) (1.39) (1.81) 
0.75 0.07 0.23 0.14 0.03 0.17 9 
(EMT) (0.03) 
1.00 
(0.27) (0.05) (0.18) (0.28) (0.23) 
0.70 0.09 0.25 0.13 0.03 0.19 10 
(HLWH) (0.19) 
1.00 
(2.79) (0.38) (0.63) (2.04) (0.05) 
0.95 0.06 0.07 0.14 0.03 0.05 11 
(BZCY) (0.14) 
1.00 
(0.72) (0.73) (0.21) (1.53) (1.01) 
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6.3.5 Identification of different Flos Magnoliae products from five herbal suppliers 
The chromatograms of five Flos Magnoliae products samples (details see Table 2.4) are 
shown in Figure 6.11. The results demonstrated that the five samples contained all 13 
common peaks, based on the percentage of R.S.D (less than 1%) of the relative retention time 
of these peaks (Table 6.12).   
 
The peak area and the peak area percentage of single peak owned in 13 common peaks show 
quality differences of the chemical compositions of five Flos Magnoliae products (Table 6.13). 
Among five herbal products, the total peak area of the common peaks of the product from 
Hualong Magnolia Development Co. Ltd. was the highest, while the total peak area of the 
concentrated herbal powder from KODA International was the lowest.  
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Figure 6.11 HPLC chromatograms of five Flos Magnoliae products from different herbal suppliers (with 10µl injection volume; peak 6, magnolin; peak 11, 
fargesin) 
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Table 6.12 The relative retention times of 13 common peaks of five Flos Magnoliae products from different herbal suppliers. Peak 6 indicated magnolin 
and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 
HL 0.26 0.44 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.51 
TFH 0.26 0.45 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.51 
EYS 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.52 
TFK 0.25 0.46 0.80 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.52 
KODA 0.26 0.45 0.80 0.90 0.98 1.00 1.02 1.04 1.06 1.09 1.11 1.47 1.50 
Mean 0.256 0.454 0.807 0.901 0.981 1.000 1.018 1.038 1.065 1.083 1.106 1.477 1.511 
% R.S.D. 0.0013 0.0105 0.0063 0.0009 0.0018 0.0000 0.0002 0.0003 0.0005 0.0044 0.0007 0.0042 0.0055 
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Table 6.13 The peak area of 13 common peaks of five Flos Magnoliae products from different herbal suppliers. Peak 6 indicated magnolin and Peak 11 
indicated fargesin. (n=3) 
Number of the common peaks  
Peak area  
(% peak area of single peak owned in 13 common peaks)  
1 2 3 4 5 6 7 
833987.4 942559.9 177831.0 176575.0 5734722.8 7551815.8 738912.3 
HL 
(4.13) (4.67) (0.88) (0.87) (28.41) (37.41) (3.66) 
891973.6 1482802.4 131394.6 79678.0 2202398.2 5307902.4 725149.6 
TFH 
(6.96) (11.56) (1.02) (0.62) (17.17) (41.39) (5.65) 
415711.9 200368.5 67079.6 68112.8 2181897.5 2672591.0 202148.5 
EYS 
(5.59) (2.69) (0.90) (0.92) (29.34) (35.93) (2.72) 
703555.3 287457.6 131091.5 124861.9 4644081.3 6040824.0 437553.1 
TFK 
(4.40) (1.80) (0.82) (0.78) (29.06) (37.80) (2.74) 
754508.5 125333.8 16050.7 90375.1 2056309.5 2615908.1 256609.0 
KODA 
(10.67) (1.77) (0.23) (1.28) (29.07) (36.99) (3.63) 
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Continued Table 6.13 The peak area of 13 common peaks of five Flos Magnoliae products from different herbal suppliers. Peak 6 indicated magnolin 
and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks 
Peak area  
(% peak area of single peak owned in 13 common peaks)  
8 9 10 11 12 13 Total 
1400263.5 1012449.6 300903.1 931563.3 251961.6 133588.4 
HL 
(6.94) (5.02) (1.49) (4.61) (1.25) (0.66) 
20187133.7 
323756.2 617985.3 398412.0 86955.6 352080.9 222809.5 
TFH 
(2.52) (4.82) (3.11) (0.68) (2.75) (1.74) 
12823298.3 
692136.0 340040.5 68026.8 483385.3 40864.7 5212.7 
EYS 
(9.31) (4.57) (0.91) (6.50) (0.55) (0.07) 
7437575.8 
1394983.7 823886.0 163940.1 1037603.6 164727.1 28551.8 
TFK 
(8.73) (5.15) (1.03) (6.49) (1.03) (0.18) 
15983117.1 
472705.0 283600.0 79065.2 265520.4 39153.9 17467.0 
KODA 
(6.68) (4.01) (1.12) (3.75) (0.55) (0.25) 
7072606.1 
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6.3.6 Identification of M. biondii samples from four different cultivation sites  
Four M. biondii samples, which were collected from four different cultivation sites from 
Nanzhao, Henan Province, China, were employed in the present study (details see Table 2.5). 
Figure 6.12 showed the chromatograms of four M. biondii batches. The results demonstrated 
that the four samples contained all 13 common peaks, based on the percentage of R.S.D (less 
than 1%) of the relative retention time of these peaks (Table 6.14).   
 
Under the optimised chromatographic conditions, the peak area and the peak area percentage 
of single peak owned in 13 common peaks were shown quality differences of the chemical 
compositions in four M. biondii batches collected from different cultivation sites (Table 6.15). 
The peak area percentages of Peak 5 and Peak 6 (magnolin) were more than 59% of the total 
peak area of 13 common peaks. The total peak area of the common peaks of the samples, 
from Mt. Yanyi (YYS), was the highest among four M. biondii samples, while the total peak 
area of the batch that was collected from Eastern Garden (DHY), was the lowest.  
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Figure 6.12 HPLC chromatograms of four M. biondii sample, collected from four cultivation sites (with 10µl injection volume; peak 6, magnolin; peak 11, 
fargesin) 
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Table 6.14 The relative retention time of 13 common peaks of four M. biondii samples, collected from different cultivation sites. Peak 6 indicated 
magnolin and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 
DHY 0.26 0.45 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.51 
XHY 0.26 0.45 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.47 1.51 
YYS 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.07 1.08 1.11 1.48 1.51 
TQ 0.26 0.47 0.81 0.90 0.98 1.00 1.02 1.04 1.06 1.08 1.11 1.47 1.51 
Mean 0.256 0.460 0.810 0.901 0.980 1.000 1.018 1.038 1.065 1.081 1.106 1.476 1.507 
% R.S.D. 0.202 2.236 0.128 0.028 0.004 0.000 0.016 0.014 0.019 0.021 0.018 0.182 0.050 
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Table 6.15 The peak area of 13 common peaks of four M. biondii samples collected from different cultivation sites. Peak 6 indicated magnolin and Peak 
No11 indicated fargesin. (n=3) 
Number of the common peaks  
Peak area  
(% peak area of single peak owned in 13 common peaks) 
 
1 2 3 4 5 6 7 
391973.6 395715.1 43915.7 39939.7 1062447.6 2574979.0 346171.8 
DHY 
6.76 6.82 0.76 0.69 18.32 44.40 5.97 
481167.7 434144.0 63264.5 47609.1 1217948.6 3284572.6 517179.5 
XHY 
6.51 5.87 0.86 0.64 16.48 44.45 7.00 
546050.6 263190.3 88124.3 89468.3 2865990.8 3510532.1 265516.3 
YYS 
5.59 2.69 0.90 0.92 29.34 35.94 2.72 
520897.1 285579.0 77090.2 81429.7 1574373.7 2897464.3 349956.7 
TQ 
6.97 3.82 1.03 1.09 21.07 38.77 4.68 
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Continued Table 6.15 The peak area of 13 common peaks of four M. biondii samples collected from different cultivation sites. Peak 6 indicated magnolin 
and Peak 11 indicated fargesin. (n=3) 
Number of the common peaks 
Peak area  
(% peak area of single peak owned in 13 common peaks) 
 
8 9 10 11 12 13 Total 
152717.4 298607.5 186175.9 35276.6 166324.9 104950.9 
DHY 
2.63 5.15 3.21 0.61 2.87 1.81 
5799195.8 
 
209623.8 372950.7 254576.1 47294.0 296856.0 163008.8 
XHY 
2.84 5.05 3.44 0.64 4.02 2.21 
7390195.4 
 
909142.3 446653.8 89355.3 634941.7 53677.1 5887.2 
YYS 
9.31 4.57 0.91 6.50 0.55 0.06 
9768530.3 
 
582325.7 356923.4 156396.7 263313.3 228229.9 98618.7 
TQ 
7.79 4.78 2.09 3.52 3.05 1.32 
7472598.5 
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6.4 Discussion  
In order to develope an accurate, valid and optimised chromatographic fingerprint, proper 
selections of HPLC parameters, including mobile phase, column, column temperature, flow 
rate of mobile phase and detection wavelength are necessary. Two steps, which are modelling 
of retention and optimisation, are required for establishment of a HPLC gradient method 
(Dolan et al., 1999a, Dolan et al., 1999b, Dolan et al., 1999c). Based on the results from 
Chapter 5 and previous literatures (Fang et al., 2002, Xu et al., 2003, Yu et al., 2005b, Zhu et 
al., 2002), a gradient acetonitrile – water system was used as the mobile phase to achieve a 
better HPLC separation. Hence, with a stringent demand on resolution and peak capacity, the 
well separation of the 13 common peaks from M. biondii samples was achieved. Furthermore, 
the detection wavelengths, as one of the key factors to contribute to a reliable and 
reproducible HPLC fingerprint, were tested at 250nm, 278nm and 290nm. It was found that 
the chromatographic fingerprints at 278nm produced the best resolution of a sufficiently large 
number of detectable peaks, under this condition. 
 
The R.S.D.s of relative retention times and relative peak areas of nine of the 13 common 
peaks for the injections of five independently prepared samples were found less than 4%. The 
R.S.D.s of relative retention times and relative peak areas of the common peaks for five times 
injections consistently were detected less than 3%, while the R.S.D.s of relative retention 
times and relative peak areas of the common peaks in stability test were less than 4%. All 
results indicated that the present method of the HPLC fingerprinting analysis was valid and 
satisfactory. 
 
It is well known that M. biondii is the authentic species of Flos Magnoliae (Fu, 2000). For 
each separated peak of the 13 common peaks, the R.S.D. of retention time should be less than 
1 %, if not, these peaks could not be identified as the same peak (Cai and Liu, 2005). Among 
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the common peaks, two peaks were authenticated using reference standards. Peak 6 and Peak 
11 represented magnolin and fargesin, respectively. The HPLC profiles of M. kobus and M. 
liliflora, commonly used as the substitutes of Flos Magnoliae in Japan and China, were found 
to contain the ten and nine common peaks, respectively. Meanwhile, magnolin were identified 
from the ethanol extracts of M. kobus and M. liliflora, while fargesin were only found in M. 
kobus, which are in agreement with the findings in Chapter 5. Another three species, 
including M. denudata, M. sargentiana and M. sprengeri were discovered having significant 
differences in the quality and quantity of the chemical compositions. Therefore, the HPLC 
profiles can be used for the identification and differentiation of different Flos Magnoliae 
species.  
 
In the present study, the HPLC fingerprints of 11 batches of M. biondii samples were also 
conducted. Thirteen common peaks were all found in the chromatograms of 11 M. biondii 
batches. The similar relative retention time of each peak in all samples indicated the peak 
locality in the chromatographic fingerprints, which may provide qualitative and quantitative 
information on the chemical compositions of ethanol extracts of M. biondii, and thus, 
contribute to quality control of different botanic varieties of M. biondii (Cai and Liu, 2005). 
Further findings from another parameter of chromatographic fingerprints, the ORPs, indicate 
slight differences of the chemical compositions among 11 M. biondii batches. These findings 
can be used further in compare of the diversities between various M. biondii samples. The 
total peak area of 13 common peaks of Sample 5 (HGCY, 黄梗串鱼) was almost two-folded 
as the total peak area of Samples 3 (EMT, 二毛桃). This suggests that differences exist in the 
quality of these M. biondii samples. As mentioned before, Peak 6 (magnolin) and Peak 11 
(fargesin) were detected from all 11 batches of M. biondii samples, while Peak 6 (magnolin) 
owned the highest percentage (35.93% - 51.53%) in 13 common peaks. The M. biondii 
batches also had high percentage of Peak 5 (15.47% - 38.39%). These two chemical 
 261 
compounds may play key roles in the therapeutic effects of Flos Magnoliae. Moreover, the 
dominant common peaks have been recognised as one of the fingerprinting parameters to 
ensure the consistency of the CHM quality (Cai and Liu, 2005). It has been suggested that the 
percentage of the toil peak area of the dominant common peaks is more than 80% of the total 
peak area of all the common peaks (Cai and Liu, 2005). Therefore, the HPLC fingerprints of 
relative peak areas of seven main common peaks (Peak 5-11) in 11 M. biondii batches were 
demonstrated in the present study, when Peak 6 (magnolin) was used as the internal standard. 
The quality consistency was not found in different varieties of M. biondii, collected from the 
same cultivation sites. Thus, botanic sources may influence the quality of the chemical 
compositions of M. biondii.  
 
All 13 common peaks were detected from five Flos Magnoliae products, based on the relative 
retention times. The findings are in agreement with the results from the previous Chapter that 
identified M. biondii as the source of these five products. In addition, differences of the 
content of the chemical compositions of five Flos Magnoliae products from different herbal 
suppliers were demonstrated. For instance, the total peak area of 13 common peaks of the 
Flos Magnoliae products from Hualong Magnolia Development Co. Ltd., China was more 
than 2.8-fold higher than the total peak areas of the local sample from KODA International. It 
is not clear about the reason of this change, but the manufacturing process may influence the 
quality of Flos Magnoliae products (Liu et al., 2003a, Zhang and Feng, 2005). 
 
The environmental factors during the cultivation process, including the amount of sunlight 
and moisture, soil conditions, nutrients and climate are important in affecting the chemical 
compositions of CHM (Bensky and Gamble, 1993, Yu et al., 1999). This is supported by the 
present findings that among four M. biondii batches, differences of the peak area and the 
percentage peak area of each single peak of 13 common peaks were demonstrated.  
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In conclusion, a validated HPLC fingerprinting method has been developed for qualitative 
and quantitative analysis of the Flos Magnoliae samples for the first time. Under the 
optimised chromatographic conditions, qualitative and quantitative differences of the 
chemical compositions among six Flos Magnoliae species were observed. Moreover, 13 
common peaks were obtained for the identification of the authentic species, M. biondii. These 
chromatographic fingerprinting data may help to ensure the consistency of the quality of Flos 
Magnoliae products. The findings also support the suggestions that botanic species and 
varieties, cultivation sites and manufacturing process may influence the quality of Flos 
Magnoliae.  
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Chapter Seven 
Effects of Flos Magnoliae and Its Active Components on 
Mast Cell-Derived Histamine Release in Rat Peritoneal Mast Cells 
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7.1 Background  
7.1.1 Mast cell-dependent allergy 
7.1.1.1 Allergy  
The immune system is very important to defence the body against invaded pathogens (such as 
bacteria, viruses, fungi and parasites) (Roitt and Delves, 2001). It is also involved in various 
inflammatory conditions, including allergy. The inflammatory process of immunopathological 
reactions, can be clarified as the acute and the chronic inflammatory responses (Willoughby et 
al., 2000). The acute responses are often initiated by hypersensitivity reactions, microbial 
infections, irritant and corrosive substances (Brook, 1996, Umetsu and DeKruyff, 1997, 
Kligman and Kligman, 1998), involving changes in blood flow, permeability of blood vessels, 
and leukocytes emigration (Rang et al., 2003). The chronic inflammation may be caused by 
infectious microbes (e.g. mycobacterium tuberculosis) that can avoid phagocytosis and 
continue to exist in the tissue for a long-lasting period (Drennan et al., 2004), irritant 
inhalation of toxic materials (e.g. mineral particles) that cannot be eliminated by enzymic 
breakdown, or phagocytosis (Muhle and Mangelsdorf, 2003) or auto-immune disease 
(autoimmune hepatitis) (Frank, 2002). The chronic inflammation can last for weeks, months 
even an indefinite period (Roitt and Delves, 2001).  
 
Hypersensitive response is also a kind of inflammatory responses. It has been classified into 
four categories, immediate or anaphylactic hypersensitivity (allergy) (Type I), antibody-
dependent cytotoxic hypersensitivity (Type II), immune complex-mediated hypersensitivity 
(type III) and cell-mediated (delayed-type) hypersensitivity (Type IV) (Roitt and Delves, 
2001).  
 
In 1902, Richet and Portier firstly used the term anaphylaxis to describe sensitivity to 
relatively foreign antigens (such as grass pollen, dead house dust mites and certain food), 
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contrary to prophylaxis (Cohen and Zelaya-Quesada, 2002). Anaphylaxis occurs by gathering 
of Immunoglobulin E (IgE) receptors through cross-linking after re-exposure to a same 
antigen (Noone and Osguthorpe, 2003). Binding IgE to the high-affinity IgE receptor (FcεRI) 
immediately triggers release of inflammatory mediators from mast cells, basophils, 
eosinophils, etc. (Venarske and deShazo, 2003). 
 
A number of cells have been shown involved in the allergic process (Table 7.1), including 
vascular endothelial cells, mast cells, macrophages, platelets and leucocytes that are believed 
to contribute to inflammatory reactions in tissues (Roitt and Delves, 2001). Studies have 
indicated that mast cells play a central role in mediating Type I hypersensitivity (Marone et al., 
1998). A number of mediators, such as histamine, leukotrienes and cytokines, are involved in 
allergic reactions (Table 7.2).  
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Table 7.1 Cells involved in allergy 
Cell types Roles in allergic inflammation 
Mast cells  
Degranulation triggers secretion of mediators, e.g. histamine, leukotrienes, interleukins, 
prostaglandins, PAF and nerve growth factor (NGF) (Hart, 2001) (Details see Section 7.1.1.2).  
Neutrophils 
Gulfs and kills the micro-organisms, however, it also contributes to the allergic inflammation 
through the potential inflammatory function of variable enzymes released from neutrophils 
(Monteseirin et al., 2001).  
Eosinophils 
Similar as neutrophils. It is a primary pathogenesis of inflammation by producing a number of 
potent granule constituents (Venarske and deShazo, 2003). 
Polymorphonuclear 
leucocytes 
Basophils 
It concerns basophils involved in the late inflammatory reaction, while it has the similar 
characteristics to the mast cells (Chugh, 1998).  
Leucocytes 
Mononuclear cells 
Monocytes/ 
macrophages 
They ingest and kill pathogens through their highly adherent, motile and phagocytic functions, 
nevertheless, they are implicated in the chronic inflammation (O'Connor et al., 2004). 
Vascular endothelial cells 
It releases NO that contributes to vasodilation, chemokines and cytokines during allergic 
inflammation (Yamamoto and Nagata, 1999, Laberge and El Bassam, 2004). 
Platelets 
Low-affinity receptors for IgE are found in it, and a number of inflammatory substances (e.g. 
PAF) are released from platelets, that are believed to contribute to both early and late phases of 
allergic inflammation (Klinger, 1997). 
Neurons 
The neuropeptides develops during airway hypersensitivity released from activated neurons, 
which is termed to “neurogenic inflammation” (Richardson and Vasko, 2002). 
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Table 7.2 Mediators involved in allergy 
Mediators type Roles in allergic inflammation 
Histamine  
Mediating allergic reaction, such as urticaria and hay fever 
(Repka-Ramirez and Baraniuk, 2002). (Details see section 7.1.1.3) 
Prostaglandin (PG) 
PGD2, PGE2, PGF2, PGI2 
PGE2 plays a predominant role in the acute and chronic 
inflammation through its vasodilation functions, and is a major 
mediator of fever (Ushikubi et al., 2000). Both PGI2 and PGD2 
have effects on vasodilation and inhibition of platelet aggregation 
(Takahashi et al., 2002, Matsuoka et al., 2000).  
Leukotrienes (LT) 
LTA4, LTB4, LTC4, LTD4, LTE4 
LTB4 is an important mediator during allergic inflammatory 
process, particularly in asthma through its adherence by leukocyte, 
thereby stimulating the proliferation of cytokines (Hart, 2001). 
Also LTC4 and LTD4 have been found to play roles in 
inflammation due to their potent bronchoconstrictory actions 
(Wenzel, 2003). 
Platelet-activating factor (PAF) 
PAF is an important mediator during the acute and persisting 
allergic inflammation that include bronchial constriction, 
vasodilation, erythema etc. (Page, 1990). 
Bradykinin (BK) 
The pathological functions, including vasodilation, increased 
vascular permeability, etc., contribute to many allergic and 
inflammatory phenomenon (Kaplan et al., 2002). 
Nitric oxide (NO) 
iNOS – induced NO, is considered to be a potent inflammatory 
mediator through its vasodilation and vascular permeability (Guzik 
et al., 2003). 
Neuropeptides  
Substance P and Neurokinin A, two of the main neuropeptides, 
perform on mast cells to release histamine and other inflammatory 
mediators (Joos et al., 2003). Moreover, another constituent 
calcitonin gene-related peptide (CGRP), which is a potent 
vasodilator, also contribute to the inflammation (Holzer, 1998).  
Cytokines 
Interleukins (IL) chemokines, 
interferons (IFN), colony-
stimulating factors, growth 
factors and tumour necrosis 
factors (TNF) 
TNF-α and IL-1α are regarded as primary pro-inflammatory 
cytokines (Bachert et al., 1995). Thus a cascade of numerous 
cytokines (chemokines) are initiated and defined performing in the 
inflammatory site (Sindern, 2004). Other cytokines that inhibit the 
inflammation are the anti-inflammatory cytokines, e.g. IL-10, IL-
12 and IFN-γ (Chung, 2001).  
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7.1.1.2 Mast cells  
Mast cells, whose precursor cells originate from bone marrow, are distributed abundantly in 
the tissues (Galli and Hammel, 1994, Marone et al., 1997). Mast cells have been identified 
playing a central role in allergic diseases (Marone et al., 1998), such as allergic rhinitis and 
conjunctivitis, (Parikh et al., 2003), asthma (Robinson, 2004), dermatitis (Leung, 1995), food 
allergy (Metcalfe, 1984), and anaphylactic shock caused by drug allergy (Orta et al., 2003). 
 
Mast cells are classified into two sub-types, mucosal mast cells and connective tissue mast 
cells. The mucosal mast cells are mainly located in intestine and lung, while the connective 
mast cells are distributed in most tissues (Roitt and Delves, 2001). There are some differences 
between these two types of mast cells. Notably, mucosal mast cells are T-cell dependent, 
while connective tissue mast cells are T-cell independent (Welle, 1997). Additionally, certain 
serine proteinases, eg. chymase, were found only in the connective tissue mast cells, but not in 
mucosal mast cells, although both types of cells contain tryptase (Roitt and Delves, 2001). 
Nevertheless, the high affinity receptor of IgE are expressed on the surfaces of both types of 
mast cells (Marone et al., 1997).  
 
Mast cells can be stimulated or degranulated by various pathways, one of the best clarified 
mechanisms of activation is through the high affinity IgE receptor, FcεRI, cross-linked by IgE 
and antigen (Galli and Hammel, 1994). Primary exposure to the allergens, such as pollen, 
drugs, foods, insect products, mould and animal hair, leads to the formation of a pool of 
specific IgE antibodies, which then bound to the surface of mast cells and its circulating 
counterpart, basophils (Parikh et al., 2003). After secondary exposure to same allergen, mast 
cells become activated to trigger degranulation (Reed and Kita, 2004, Parikh et al., 2003), 
leading to the rapid release of inflammatory mediators (Bradding, 2003, Brightling et al., 
2003, Galli and Hammel, 1994), including preformed mediators [e.g. histamine, 5-
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hydroxytryptamine (5-HT), protease (tryptase and chymase), and proteoglycans] (Forsythe 
and Ennis, 1998, Alfaro, 2004), and newly synthesized mediators, such as arachidonic acid 
metabolites, including PGD2 and LTs (LTB4, LTC4 and LTD4), and lipid-derived mediator, 
PAF (Hart, 2001, Henderson, 1991). Moreover, activated mast cells synthesized and secreted 
various cytokines, including TNF-α, IL-3, IL-4, IL-5, IL-6, IL-8, IL-13, IL-16, IL-18 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Lorentz and Bischoff, 2001, 
Hart, 2001).  
 
7.1.1.3 Histamine  
Histamine is an essential vasoactive amino acid. Histamine [2-(4-imidazolyl ethylamine)], 
formed by decarboxylation of L-histidine (Weltman, 2000), primarily presents in the mast 
cells granules and basophils, and binds to the carboxyl sulphate groups of the cytoplasmic 
secretory granules (Graff et al., 2002) (Figure 7.1). The content of histamine in human mast 
cells is 3pg/cell, and that in basophil is 1pg/cell (Marone et al., 2003). 
 
Histamine involves in a number of allergic diseases, including seasonal allergic rhinitis (hay 
fever), asthma, food or drug allergy and dermatitis (Storms, 2004, Turner et al., 2005, Mittag 
et al., 2004, Thong and Yeow, 2004, Ikoma et al., 2005). Histamine also exists ingastric 
enterochromaffin-like (ECL) cells, as a regulator of stomach acid production (Qvigstad and 
Waldum, 2004). Histamine is also considered as a neurotransmitter in histaminergic neurons 
in brain (Watanabe and Yanai, 2001). Its pharmacological actions include vasodilatation, 
smooth muscle contraction, mucus hypersecretion and increased vascular permeability 
(MacGlashan, 2003), which are likely to mediate some inflammatory responses, eg. nasal 
effects (sneezing, swelling, itching and congestion), skin sensations (itching, burning and 
flushing), contraction of bronchial, stomach pain (acid secretion increases, small intestine 
contraction and pain) and headache (Roitt and Delves, 2001). Histamine acts via histamine 
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receptors, which have four subtypes (Table 7.3). The subtype involved in allergy is mainly H1 
receptor (Akdis and Blaser, 2003, MacGlashan, 2003). 
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Figure 7.1 The biosynthesis and metabolism of histamine  
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Table 7.3 Classification of histamine receptors and their functions 
Classification Functions Reference 
H1 receptor 
• Vasodilation  
• Bronchial smooth muscle contraction 
• Mucous secretion 
• Increased vascular permeability  
• Pruritus (bronchial obstruction) 
• Wheal and flares in urticaria 
(MacGlashan, 2003, 
Akdis and Blaser, 2003) 
H2 receptor 
• Vasodilation  
• Elevation cAMP 
• Gastric acid secretion  
• Inhibition of chemotaxis in eosinophils 
• Inhibition of chemotaxis and activation of 
neutrophils 
• Inhibition of superoxide development 
• Inhibition degranulation 
(Akdis and Blaser, 2003) 
H3 receptor 
• Modulation of neurotransmitters in the central 
/ peripheral nervous system  
• Regulation of histamine synthesis and release  
• Increased gastric mucous production 
(Bertaccini et al., 1991) 
H4 receptor 
• Meditation of histamine signalling and 
chemotaxis of mast cells 
• New member of the family, and the 
pharmacological functions have not been 
identified clearly.   
(Nguyen et al., 2001) 
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7.1.2 Actions of Flos Magnoliae on mast cell-dependent allergy  
The anti-allergic and anti-inflammatory actions of Flos Magnoliae have been demonstrated in 
various in vivo and in vitro studies (Kim et al., 2003, Kim et al., 1999, Kimura et al., 1992, 
Kobayashi et al., 1998). For example, M. biondii inhibited the capillary permeability of blood 
vessels (Kim et al., 1999, Kimura et al., 1990, Kimura et al., 1991), and secretions of the 
inflammatory and allergic mediators, including histamine, PGE2, PAF, NO, and pro-
inflammatory cytokines IL-1α and TNF-α (Lim et al., 2002, Wang et al., 2000b). Among 
these, the inhibition of mast cells derived histamine release by Flos Magnoliae was considered 
as the main mechanism of its anti-allergic reactions (Li and Zhang, 2002). Furthermore, some 
active components of Flos Magnoliae, such as magnolin and fargesin have been suggested 
that they may have effects on the anti-allergic actions (Ma and Han, 1995, Brown et al., 2001, 
Mitsuo, 2001). However, still little studies have been done in terms of differences of the anti-
histamine release effects by different Flos Magnoliae species. 
 
7.1.3 Aims of this study 
The aim of this study was to investigate and compare the effect of six commonly used Flos 
Magnoliae species, namely, M. biondii, M. denudata, M. sprengeri, M. kobus, M. liliflora and 
M. sargentiana, and 11 M. biondii batches from six varieties on compound 48/80 induced 
histamine release in RPMC. In addition, the effects of five Flos Magnoliae products, four M. 
biondii batches and three M. sprengeri batches, collected from different cultivation sites, as 
well as Flos Magnoliae volatile oil and the active lignans, magnolin and fargesin, on mast cell 
derived histamine release in RPMC were determined. 
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7.2 Method  
7.2.1 Plant materials and herbal products 
See Chapter 2 (Section 2.2.3). Same plant materials as in qualitative and quantitative studies 
(in Chapter 5-7) were used in this study. Furthermore, the essential oil of Flos Magnoliae and 
two isolated chemical components, magnolin and fargesin, were used.  
 
7.2.2 Reagents and chemicals  
The details of the reagents and chemicals are described in Section 2.3.4.  
 
7.2.3 Samples extraction and preparation 
Samples were extracted using an Accelerated Solvent Extraction machine (ASE-100, Dionex, 
U.S.A.). The details of the extraction and preparation procedure are described in Section 2.8.1. 
The ethanol extract was filtered with PTFE syringe filters (25mm, 0.45µm) (Alltech 
Associates, Australia) and stored at -20°C for further analysis.  
 
7.2.4 Animals  
Male SD rats at 10 – 12 weeks of age (250 – 350 g) were used for experiments (see Section 
2.8.2).  
 
7.2.5 Isolation and preparation of RPMC  
Briefly, after injection of the Tyrode’s Buffer containing 0.3% BSA and 5.0 units/ml heparin 
sodium, the peritoneal solution was collected. After being washed by the Tyrode’s Buffer for 
three times, the RPMC were resuspended in the Tyrode’s Buffer, which contained 0.1% BSA 
(see Section 2.8.3).  
 
 
  
275 
7.2.6 Effects of herbal extracts on compound 48/80 induced histamine release in 
RPMC  
After being pre-incubated at 37°C for 10min, different concentration of herbal extracts was 
added, followed by 10min incubation, then 0.5µg/ml compound 48/80 was added. After 
stopping the histamine release in RPMC, spermidine was added as an internal standard for 
further analysis (see Section 2.8.4). 
 
7.2.7 HPLC system for determination of compound 48/80 induced histamine 
release in RPMC  
A Shimadzu HPLC instrument with a post-derivatization system using a fluorescent detector 
was employed for the present study. For details, see Section 2.8.5. 
 
7.2.8 Data analysis and statistics  
The details of the data analysis and statistics are described in Section 2.9.5. Data were 
represented as mean ± S.E.M.  
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7.3 Results  
7.3.1 Effects of compound 48/80 on histamine release in RPMC  
Unstimulated RPMCs in Tyrode’s buffer had a basal level of histamine at 32.4±2.4ng/ml 
(n=6). Compound 48/80 (0.0001–0.5µg/ml) caused a concentration-dependent increase of 
histamine release in RPMC, with the maximum response at 0.5µg/ml being 529.1±67.6ng/ml 
(n=7). Consequently, 0.5µg/ml of compound 48/80 was used for the subsequent experiments 
(Figure 7.2). The vehicle control (equal volume of absolute ethanol) slightly inhibited the 
compound 48/80 induced histamine release (9.5±1.2%, n=6, P>0.05, compared with 
compound 48/80 alone group, T-test). The increase in histamine release by compound 48/80 
was significantly inhibited by 100µM EDTA (35.3±1.1%, n=7, P<0.01, compared with 
compound 48/80 alone group, T-test) (Figure 7.3). The 30% HClO4 caused the total release of 
histamine in RPMC, being 566.5±85.8ng/ml.   
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Figure 7.2 Dose-response curve of compound 48/80 induced histamine release in RPMC 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 The effects of 100µΜ EDTA on compound 48/80 induced histamine release in 
RPMC. Each value represents the mean ± S.E.M. of 8 preparations. **P<0.01, t-test. 
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7.3.2 Effects of different species of Flos Magnoliae on compound 48/80 induced 
histamine release in RPMC  
The typical HPLC chromatograms, which present the baseline, control vehicle (ethanol), total 
release (30% HClO4), positive control (100µM EDTA), showing the effects of Flos 
Magnoliae extracts on compound 48/80 (0.5µg/ml) induced histamine release in RPMC, are 
illustrated in Figure 7.4. The retention time of histamine is 3.5min of the whole running time 
(8min), while the internal standard (spermidine) was detected at 6.0min.  
 
Four Flos Magnoliae species, M. biondii (HL), M. denudata, M. kobus and M. sprengeri 
(MD) showed a concentration-dependent (0.1–0.01mg/ml) inhibition of histamine release. 
However, at a higher concentration (0.5mg/ml) the effect was partly reduced. Other two Flos 
Magnoliae species, M. liliflora and M. sargentiana, showed a concentration-dependent (0.5–
0.01mg/ml) inhibitory effect. All six Flos Magnoliae species significantly (P<0.05, one-way 
ANOVA followed by the Tukey’s test) inhibited the histamine release at the concentration of 
0.05µg/ml or above. At the lowest concentration tested, no significant (P>0.05, one-way 
ANOVA followed by the Tukey’s test) effects were observed for M. sargentiana and M. 
sprengeri (MD).  
 
The comparison of the inhibitory effects of six Flos Magnoliae species was shown in Figure 
7.5 (A-D). At the highest concentration (0.5mg/ml), M. liliflora has the most potent inhibitory 
effects on histamine release (61.1±1.0%), which significantly (P<0.05, one-way ANOVA 
followed by the Tukey’s test) higher than the anti-histamine release effects of M. biondii, M. 
denudata, M. kobus and M. sargentiana. At the concentrations from 0.1–0.01mg/ml, M. 
biondii and M. kobus showed significantly (P<0.05, one-way ANOVA followed by the 
Tukey’s test) higher inhibition, than M. sargentiana and M. sprengeri. On the other hand, M. 
sargentiana was the least potent among six Flos Magnoliae species tested at a given 
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concentration (0.1 – 0.01mg/ml), although at high concentration (0.5mg/ml), it significantly 
inhibited the histamine release up to 47.7±1.0%.  
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Figure 7.4 The representative HPLC chromatograms of compound 48/80 (0.5µg/ml) induced histamine release in RPMC. The chromatograms 
characterised baseline, vehicle control (ethanol), total release (30% HClO4) positive control (100µM EDTA) and the ethanol extracts of M. 
biondii (0.1mg/ml) sample on histamine release. 
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Figure 7.5 The effects of ethanol extracts of six Flos Magnoliae species on compound 48/80 induced histamine release in RPMC. The 
concentrations of the herbal extract included 0.5mg/ml (A), 0.1mg/ml (B), 0.05mg/ml (C), and 0.01mg/ml (D).  ♠ significantly different from 
vehicle control (ethanol), * significantly different from M. biondii, ● significantly different from M. kobus, ♦ significantly different from M. 
liliflora.  ♠ *, ●, ♦ P<0.05, one-way ANOVA, followed by a Tukey’s test. Each value represents the means ± S.E.M. of 5-6 preparations. 
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Continued Figure 7.5 The effects of ethanol extracts of six Flos Magnoliae species on compound 48/80 induced histamine release in RPMC. 
The concentrations of the herbal extract included 0.5mg/ml (A), 0.1mg/ml (B), 0.05mg/ml (C), and 0.01mg/ml (D).  ♠ significantly different from 
vehicle control (ethanol), * significantly different from M. biondii, ● significantly different from M. kobus, ♦ significantly different from M. 
liliflora.  ♠ *, ●, ♦ P<0.05, one-way ANOVA, followed by a Tukey’s test. Each value represents the means ± S.E.M. of 5-6 preparations. 
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7.3.3 Effects of different varieties of M. biondii on compound 48/80 induced 
histamine release in RPMC  
Eleven M. biondii batches from six varieties (details see Table 2.3) showed a concentration-
dependent (0.1–0.01mg/ml) inhibition on histamine release. All 11 M. biondii batches 
significantly (P<0.05, one-way ANOVA followed by the Tukey’s test) inhibited the histamine 
release at the concentration of 0.1mg/ml and 0.05mg/ml. At the lowest concentration 
0.01mg/ml, Sample 7, 8 (CY, 串鱼) and Sample 10 (HLWH, 华龙五号) have no significant 
effects.   
 
The comparisons of the inhibitory effects of these M. biondii samples are illustrated in Figure 
7.6 (A – C). At the highest concentration (0.1mg/ml) tested, Sample 11 (BZCY, 标准串鱼) 
had the most potent inhibitory effect on histamine release (39.3±1.9%). Sample 7 (CY, 串鱼) 
was the least potent (19.3±0.9%), being significantly (P<0.05, one-way ANOVA followed by 
the Tukey’s test) weaker than the anti-histamine release effects of Sample 1 (HLWH, 华龙五
号), Sample 2 (EMT, 二毛桃), Sample 5 (HGCY, 黄梗串鱼) and Sample 11 (BZCY, 标准串
鱼). At the concentrations of 0.05mg/ml, Sample 11 (BZCY, 标准串鱼) had the most potent 
inhibitory effect (27.7±1.2%), while Sample 7 (CY, 串鱼) was the least potent (15.4±0.5%). 
At the lowest concentration (0.01mg/ml) tested, Sample 5 (HGCY, 黄梗串鱼) was the most 
potent inhibitor (21.9±2.7%), while Sample 8 (CY, 串鱼) was the least potent (7.3±1.7%). 
However, at the concentrations of 0.05mg/ml and 0.01mg/ml, no significant differences of the 
anti-histamine release effects were found among 11 M. biondii batches.  
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Figure 7.6 The effects of ethanol extracts of 11 M. biondii batches on compound 48/80 
induced histamine release in RPMC. The concentrations of the herbal extract included 
0.1mg/ml (A), 0.05mg/ml (B), and 0.01mg/ml (C). ♠ significantly different from vehicle 
control (ethanol), * significantly different from Sample 7 (CY, 串鱼). ♠, * P<0.05, one-way 
ANOVA, followed by a Tukey’s test. Each value represents the means ± S.E.M. of 5-6 
preparations 
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7.3.4 Effects of different Flos Magnoliae products from five herbal suppliers on 
compound 48/80 induced histamine release in RPMC  
Five Flos Magnoliae products containing M. biondii, were provided by five different herbal 
suppliers in China or Australia (details see Table 2.4). Five Flos Magnoliae products showed 
concentration-dependent inhibitory effects on histamine release with the concentration range 
from 0.1 – 0.01mg/ml. All batches significantly (P<0.05, one-way ANOVA followed by the 
Tukey’s test) inhibited the compound 48/80 induced histamine release in RPMC at the 
concentrations of 0.5mg/ml and 0.1mg/ml. No significant (P>0.05, one-way ANOVA 
followed by the Tukey’s test) anti-histamine release effects were found from the products 
from Tung Fong Hung Medicine Co. Ltd and KODA International at the lowest concentration 
(0.01mg/ml). 
 
The comparison of the inhibitory effects of five Flos Magnoliae products on histamine release 
induced by compound 48/80 in RPMC are illustrated in Figure 7.7 (A-D). At the highest 
tested concentration (0.5mg/ml), sample from Tsang Fook Kee Medicine Co. had the most 
potent inhibitory effects (42.7±2.2%) on histamine release, which was significantly (P<0.05, 
one-way ANOVA followed by the Tukey’s test) higher than the anti-histamine release effects 
of Tung Fong Hung Medicine Co. Ltd. The sample has the lowest anti-histamine release 
effect (14.7±5.3%). At concentrations 0.1mg/ml to 0.01mg/ml, the sample, provided by 
Hualong Magnolia Development Co. Ltd., had the highest anti-histamine release effects. In 
contrast, at the lowest concentrations of 0.1mg/ml and 0.05mg/ml, the sample from KODA 
International has the lowest anti-histamine effects (12.2±1.1% and 6.3±0.9%, respectively) 
among all five batches. This product had significantly weaker anti-histamine release effects 
than the effects of the samples from Hualong Magnolia Development Co. Ltd., Tung Fong 
Hung Medicine Co. Ltd. and Tsang Fook Kee Medicine Co. At the lowest concentration 
(0.01mg/ml), the sample from Hualong Magnolia Development Co. Ltd. has the most potent 
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inhibitory effects on histamine release (46.1±1.3%), which significantly (P<0.05, one-way 
ANOVA followed by the Tukey’s test) higher than other four Flos Magnoliae products.  
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Figure 7.7 The effects of ethanol extracts of five Flos Magnoliae products on compound 48/80 induced histamine release in RPMC. The 
concentrations of the herbal extract included 0.5mg/ml (A), 0.1mg/ml (B), 0.05mg/ml (C), and 0.01mg/ml (D). ♠ significantly different from vehicle 
control (ethanol), * significantly different from HL, ● significantly different from TFK, significantly different from EYS, ■ significantly different 
from KODA. ♠, *, ● ,♦ ,■  P<0.05, one-way ANOVA, followed by a Tukey’s test. Each value represents the means ± S.E.M. of 5-6 preparations 
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7.3.5 Effects of different M. biondii and M. sprengeri samples, from different 
cultivation sites, on compound 48/80 induced histamine release in RPMC  
Four M. biondii batches, grown in different cultivation sites in Nanzhao, Henan Province, 
China, were included in the present study (details see Table 2.5). At the highest concentration 
(0.1µg/ml) tested, the batch from Tian Bridge (TQ) had the highest anti-histamine release 
effect (40.2±2.2%), while the sample Eastern Garden (DHY) has the lowest anti-histamine 
release effects (32.6±1.0%). At the concentration 0.05mg/ml and 0.01mg/ml, the sample 
Eastern Garden (DHY) and Tian Bridge (TQ) had the lowest anti-histamine release effects 
among four samples, respectively.  In contrast, the sample Mt. Yanyi (YYS) had the highest 
anti-histamine release effect. However, no significant difference of the anti-histamine release 
effects were determined among these four M. biondii samples (Figure 7.8).  
 
Three M. sprengeri batches, grown in different cultivation sites in China and Australia, were 
included in the present study (details see Table 2.6). At the tested concentrations of 0.1mg/ml 
and 0.05mg/ml, the batch JY cultivated from Jiangyou, Sichuan Province, China, had the 
highest anti-histamine release effects. At the highest tested concentration of 0.1mg/ml, 
another Chinese sample, MB, which was cultivated in Mabian, Sichuan Province, China, had 
the lowest anti-histamine release effects (44.3±3.4%). At the tested concentrations 0.05mg/ml 
and 0.01mg/ml, the sample, MD, cultivated in Mt. Dandenong, Victoria, Australia, had the 
lowest anti-histamine release effects. However, no significant difference of the anti-histamine 
release effects was found among three M. sprengeri batches (Figure 7.9).  
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Figure 7.8 The effects of ethanol extracts of four M. biondii batches, collected from different 
cultivation sites, on compound 48/80 induced histamine release in RPMC. The concentrations 
of the herbal extract included 0.1mg/ml (A), 0.05mg/ml (B), and 0.01mg/ml (C). ♠ 
significantly different from vehicle control (ethanol). ♠, P<0.05, one-way ANOVA, followed 
by a Tukey’s test. Each value represents the means ± S.E.M. of 5-6 preparations 
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Figure 7.9 The effects of ethanol extracts of three M. sprengeri batches, collected from 
different cultivation sites, on compound 48/80 induced histamine release in RPMC. The 
concentrations of the herbal extract included 0.1mg/ml (A), 0.05mg/ml (B), and 0.01mg/ml 
(C). ♠ significantly different from vehicle control (ethanol). ♠, P<0.05, one-way ANOVA, 
followed by a Tukey’s test. Each value represents the means ± S.E.M. of 5-6 preparations. 
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7.3.6 Effects of volatile oil from M. biondii on compound 48/80 induced histamine 
release in RPMC 
The effect of a volatile oil from M. biondii, provided by Hualong Magnolia Development Co. 
Ltd. was studied of five different concentrations, ranged from 10% to 0.001%. At higher 
tested concentrations (10% and 1%), it had no significant effect on histamine release, while at 
the lower tested concentrations (0.1 – 0.001%), it showed a significant (P<0.05, one-way 
ANOVA followed by the Tukey’s test) concentration-dependent inhibitory effect (Figure 
7.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10 The effects of volatile oil from M. biondii on compound 48/80 induced histamine 
release in RPMC. *, P<0.05, and **, P<0.01, one-way ANOVA, followed by a Tukey’s test. 
Each value represents the means ± S.E.M. of 7-8 preparations. 
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7.3.7 Effects of magnolin and fargesin on compound 48/80 induced histamine 
release in RPMC 
Magnolin showed a concentration-dependent (1 – 0.1µg/ml) inhibition on histamine release.  
However, at the highest concentration (5µg/ml) the effect was partly reduced (Figure 7.11). In 
contrast, fargesin (5 – 0.1µg/ml) had no significant effect on histamine release (Figure 7.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11 The effects of magnolin and fargesin on compound 48/80 induced histamine 
release in RPMC. *, P<0.01, one-way ANOVA, followed by a Tukey’s test. Each value 
represents the means ± S.E.M. of 7-8 preparations. 
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7.4 Discussion  
To our best knowledge, this is the first report to evaluate the anti-allergic actions of different 
Flos Magnoliae species and varieties on mast cell-derived histamine release in RPMC. The 
present study compared anti-histamine release effects of six Flos Magnoliae species, 11 M. 
biondii batches from six varieties, five Flos Magnoliae products, as well as four M. biondii 
samples and three M. sprengeri samples, collected from different cultivation sites, using a 
HPLC post-derivatization method. Furthermore, the anti-histamine release effects of the 
volatile oil and lignans, including magnolin and fargesin, were studied. The major finding is 
that different Flos Magnoliae species had the anti-histamine release effects in RPMC, which 
is in agreement with previous studies on the inhibition of mast cells derived histamine release 
(Li and Zhang, 2002)  
 
Compound 48/80 was used in this study as a histamine releaser. Compound 48/80 selectively 
targeted connective tissue mast cells, such as peritoneal mast cells, by increasing intracellular 
Ca2+ concentrations, hence inducing the release of histamine (Chakravarty and Yu, 1986, 
Marshall et al., 1994). It has been reported that the stimulation of immunity-independent 
histamine release from mast cells by compound 48/80 involved phospholipase C activation, 
and changes of GTPase activity and Ca2+ recruitment through guanine nucleotide-binding 
regulatory protein (Wu et al., 1993, Barrocas et al., 1999, Koibuchi et al., 1985). It is a 
calmodulin antagonists (Gietzen et al., 1983). It was also reported that compound 48/80 
increased permeability of the lipid bilayer membrane of mast cells by causing the perturbation, 
as an crucial trigger for the release of mediators from activated mast cells (Tasaka et al., 
1986). Compound 48/80 has been employed widely as a histamine releaser and degranulators 
for a number of in vivo or in vitro studies in rats or mice (Yuzurihara et al., 2000a, Yuzurihara 
et al., 2000b, Ikarashi et al., 2001b, Kim et al., 1999).  
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In the present study, Flos Magnoliae inhibited the compound 48/80 induced histamine release 
in mast cells, possibly by acting on the intracellular calcium channel or the lipid bilayer 
membrane, which may affect the prevention of the perturbation being induced by compound 
48/80 and regulate the degranulation of the mast cells.  
 
Two Flos Magnoliae species, M. liliflora and M. sargentiana, showed a concentration-
dependent inhibitory effect between 0.01 – 0.5mg/ml, while other four samples, M. biondii 
(HL), M. denudata, M. kobus and M. sprengeri (MD) had a concentration-dependent effect 
between 0.01-0.1mg/ml, but at a higher concentration (0.5mg/ml), the effects of these herbal 
extracts were partly reduced. It is not clear if additional ingredient(s), which may exist in 
higher concentration Flos Magnoliae extract, is involved in these effects, or some active 
ingredients of Flos Magnoliae extract may have multiple actions on RPMC function. 
Nevertheless, the present findings indicated for certain Flos Magnoliae species the best anti-
mast cell-derived histamine release effect may be achieved at lower concentrations. Further 
study is necessary to reveal the relationships between the potency of anti-histamine release 
and composition of chemical components of different Flos Magnoliae species. Furthermore, 
this study demonstrated different potencies among six Flos Magnoliae species. For example, 
M. kobus and M. biondii seem to be more potent than M. sargentiana, M. denudata, M. 
sprengeri and M. liliflora against the mast cell-derived histamine release at lower 
concentrations. Although the present findings may not directly apply to a clinical condition, 
but if such differences also exist in action of these herbas in human, the potential changes of 
anti-allergic actions by different substitutes or adulterants of Flos Magnoliae species may 
occur. Thus, there may be implications for interchangeable use of different Flos Magnoliae 
species for the same conditions.  
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In addition, M. biondii from Nanzhao area has been recognised as the authenticated species, 
which is the most commonly used Flos Magnoliae in China (HuaLong, 2003). All 11 batches 
tested, had a similar dose-dependent anti-histamine release effect. Only at the highest tested 
concentration (0.1mg/ml), the anti-histamine release effects of Sample 7 (CY, 串鱼) showed a 
significantly lower effect than other M. biondii batches. Therefore, the present findings 
indicate M. biondii varieties tested may have similar pharmacological actions and chemical 
compositions, as shown in previous chapters.  
 
As described in Chapter 1, a number of factors, including manufacturing process, may affect 
the CHM quality. Thus, five Flos Magnoliae products from different herbal suppliers were 
tested in the present study. The significant differences of the anti-histamine release effects 
were found among five batches, indicating the importance of quality control of manufacturer 
products. Although the reasons of this difference is not known, it is likely to involve the 
different use of herbal sources and manufacturing processes as described previously (Chapter 
1, Section 1.2.2).  
  
An interesting finding from the present study is the observation that M. biondii and M. 
sprengeri, cultivated in different locations in China or Australia, showed similar inhibitory 
effects on histamine release. These finding may provide a useful example of comparable 
pharmacological actions of same herbs grown at different locations. However, cautions should 
be taken when apply this to other Flos Magnoliae species, since the environmental conditions 
for CHM cultivation may affect the quality of CHM (Bensky and Gamble, 1993, Yu et al., 
1999).    
 
The anti-histamine release effect of Flos Magnoliae is likely to be caused by component(s) 
existed in Flos Magnoliae. Volatile oil and lignans have been recognised as the active 
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components for anti-allergic reactions in Flos Magnoliae (Yang and Zhang, 1998). The 
present findings indicated that the volatile oil from Flos Magnoliae has the significant anti-
histamine release effects at the lower concentration ranges (0.1 – 0.001%). However, increase 
of histamine release in RPMC was found from the higher tested concentrations (10 – 1%) of 
volatile oil. The reason for this is not clear, but it may be due to the complex nature of volatile 
oil, containing ingredients which either antagonist or having an opposite effects of other 
active compositions. Previous studies showed that Flos Magnoliae contains about 1.0 % - 4.5 
% of volatile oil (Chen et al., 1994a, Wang et al., 2000a). The yield of volatile oil may vary 
with the species, growing locations and cultivation seasons (Hu and Wu, 1995). Analysis of 
the quantity of volatile oil in M. biondii, M. sprengeri, M. denudate and M. liliflora, by GC-
MS have found that M. denudate contained 4.5% of volatile oil, whereas that of M. liliflora 
was least (1.2%). However, it is not clear about the exact nature of the active component(s) 
involved in volatile oil in these species, for example M. biondii, M. denudata and M. 
sprengeri, have been shown to contain 91, 71 and 88 volatile components, respectively (Hu 
and Wu, 1995, Yang et al., 1998). It is possible multiple ingredients may be involved in the 
anti-histamine release effects of Flos Magnoliae. Other major components in Flos Magnoliae 
species include lignans, which are regarded having Ca2+ antagonist activities (Mitsuo, 2001, 
Mitsuo et al., 1992b). Given compound 48/80 may target RPMC by increasing intracellular 
Ca2+ concentrations hence inducing the release of histamine (Chakravarty and Yu, 1986, 
Marshall et al., 1994). In the present study, magnolin showed a concentration-dependent 
effect between 1 – 0.1µg/ml, but at a higher concentration (5µg/ml), the effect were partly 
reduced. However, no significant anti-histamine release effect of fargesin in RPMC was not 
found. This finding support to use magnolin, but not fargesin as bioactive marker for anti-
histamine release effects of Flos Magnoliae. Present findings are in line with the previous 
findings that the lignans derived from Flos Magnoliae may contribute to the regulation of 
mast cells degranulation (Ma and Han, 1995, Brown et al., 2001, Mitsuo, 2001). It would be 
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interesting to investigate the like of magnolin with other known pharmacological actions of 
Flos Magnoliae. For instances, recent studies reported the inhibitory effects of Flos Magnoliae 
on PGE2 and pro-inflammatory cytokines IL-1α and TNF-α (Wang et al., 2000c). Therefore, 
the anti-histamine release effects demonstrated in the present study, together with the 
inhibitory effects of Flos Magnoliae on other allergic mediators, may help to elucidate the 
mechanism of anti-allergic actions of Flos Magnoliae.  
 
Quality of herbal materials is critical for ensure the efficacy and safety of herbal products. It is 
known that the herb quality is affected by many factors, including grown conditions, 
processing and preparation procedures, even the storage conditions. Thus, different Flos 
Magnoliae, even the same species from different cultivations and post-harvesting 
backgrounds may possess different biological actions. There is evidence in the literature 
regarding the changes of active ingredients in the herbal species(Choi et al., 2002). It would 
be interesting to further investigate the correlations between the biological actions and the 
chemical compositions of Flos Magnoliae. Although differences of the pharmacological 
actions between the commonly used Flos Magnoliae species and varieties are yet to be well 
studied, the present study certainly provides some foundation work contributing to the quality 
control of Flos Magnoliae products. 
 
In conclusion, all six species of Flos Magnoliae and 11 M. biondii batches have a similar but 
different potency in inhibition of compound 48/80 induced histamine release in RPMC. These 
findings may impact on the clinical application of these species if they are used 
interchangeable. M. kobus and M. biondii seem act better than other Flos Magnoliae species 
against mast cell-derived histamine release in PRMC. In addition, the findings of differences 
in actions of some Flos Magnoliae commercial products suggest a proper quality control 
procedure is needed to regulate the CHM productions in order to ensure the efficacy and 
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safety of these products. Finally, the demonstration of pharmacological effect of magnolin 
and volatile oil may be important for future development of a proper method for quality 
control of Flos Magnoliae products.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
299 
 
 
 
 
 
 
Chapter Eight 
General Discussion and Conclusion 
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8.1 Background  
With increasing prevalence of CHM, the risks associated with CHM emerge as an urgent 
problem for the expanding CHM industry (WHO, 2002). For instance, between 1997 and 
1998, 140 cases of adverse effects were reported that the health risks might associate with the 
botanic dietary products containing one of the CHMs Herba Ephedrae (Ma-huang) in the 
United States [2]. Considering the gaining complaints of the usage of herbal products 
containing Herba Ephedrae, the public sale of this herb was stopped by FDA [3]. Recent 
scandals that were involved CHM included an eight-herb product, PC-SPES, which was 
discovered contaminated with feminizing hormone and anticoagulant [4]. In Singapore, six 
death and more others seriously ill were directly led to the withdraw of the herbal remedy, 
Slim-10, in 2002 [5]. Those infamous cases are associated with the poor manufacturing 
practice and lack of quality control system. Therefore, scientists attempt to launch reliable and 
precise data that manufacturers and regulators can use for ensure the quality, safety and 
efficacy of CHM and its related products.  
 
In other cases, the amount of the CHM or the active ingredients in some commercial CHM 
products is considerably variable [1]. As one of the commonly used CHM, more than 20 Flos 
Magnoliae species have been found in the market for clinical application (Bensky & Gamble, 
1993; Fu, 2000). Therefore, the identification and authentication of varying botanic sources of 
Magnolia spp. may contribute to the quality control of Flos Magnoliae (Ernst, 2004; Leon et 
al., 2004). The major aims of this thesis include establish DNA (RAPD and PCR-RFLP) and 
chromatographic (TLC and HPLC) fingerprinting profiles of different Flos Magnoliae species 
and varieties. Then, the anti-histamine release effects induced by compound 48/80 in RPMC 
of different Flos Magnoliae species and varieties were demonstrated using HPLC with post-
derivatization. Furthermore, in order to understand the influence of other factors on the 
quality of Flos Magnoliae, such as manufacturing process and cultivation conditions, different 
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Flos Magnoliae samples from various herbal suppliers and cultivation sites were used for the 
present study.  
 
8.2 Main achievements  
8.2.1 Application of advanced techniques for Flos Magnoliae identification and 
authentication 
DNA fingerprinting techniques have been introduced for authentication and evaluation of 
CHM for last two decades (Shaw, Wang, & But, 2002). It is particularly important, since 
DNA-based techniques are less affected by geographic differences, climatic variations, 
cultivation conditions, manufacturing processes and other factors (Hon, Chow, Zeng, & 
Leung, 2003). In the present study, the DNA fingerprinting profiles of fresh and dried 
medicinal Flos Magnoliae species were firstly reported using RAPD and PCR-RFLP of 5S 
rRNA region.  
 
With the express development of instrumentation, TLC has been frequently employed for the 
identification and authentication of CHM, due to its features of rapidity and simultaneousness 
(CAMAG, 2006). In the present study, the optimised and simple TLC approach was 
specifically used for the identification and authentication of M. biondii, in which magnolin 
and fargesin was used as marker compounds.   
 
Fast and sensitive HPLC determination of the active components or marker compounds has 
been recognised as one of the fundamental approaches for CHM quality control (Drasar & 
Moravcova, 2004). The contents of magnolin and fargesin from different Flos Magnoliae 
samples were demonstrated using HPLC with a gradient acetonitrile – water system. In 
addition to the determination of the single or several chemical components from CHM, 
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chromatographic fingerprinting techniques have been commonly used for revealing the 
consistence and the content of multiple chemical compositions (Drasar & Moravcova, 2004). 
The optimised and validated RP-HPLC method with a gradient acetonitrile – water system for 
the identification of different Flos Magnoliae samples was introduced as the first time.  
 
The regulation of the safety and quality of CHM is also suggested to be supported by reliable 
data of their pharmacological and toxicological activities (Briggs, 2002). Anti-histamine 
release effect of Flos Magnoliae is regarded as one of the important anti-allergic actions (W.K. 
Wang, Shen, & Qi, 2000; W.K. Wang, Shen, Qi, & Nie, 2000). It is firstly reported that the 
inhibitory effects of different Flos Magnoliae samples on compound 48/80 induced histamine 
release in RPMC were revealed using HPLC with post-derivatization.  
 
8.2.2 Quality differences of Flos Magnoliae species and varieties  
The present results suggested that the variations of botanic species and varieties might cause 
quality differences of Flos Magnoliae species. Chinese species, M. biondii, is the most 
commonly used Flos Magnoliae species (Fu, 2000). With the largest genetic dissimilarity 
among all Flos Magnoliae species, M. biondii was determined containing the highest contents 
of magnolin, fargesin and total peak area of 13 common peaks. Later, the most potent anti-
histamine release effects were demonstrated from the ethanol extract of M. biondii. Another 
Chinese species, M. sargentiana, which was found to have the second largest genetic 
distances among all Flos Magnoliae species, no magnolin and fargesin were found to use TLC 
and HPLC. Based on the present findings, bioactive lignans, magnolin and fargesin, were 
detected from M. kobus, while only magnolin was found in the ethanol extract of M. liliflora. 
Further, high content of chemical compositions and potent anti-histamine release effects of M. 
kobus and M. liliflora were found. The findings suggested that locally grown Magnolia spp. 
could be applied for clinical usage for anti-allergy.  
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However, significant differences of the total peak area indicated that the qualities of the lipid-
soluble from different M. biondii varieties are varying. The highest total peak area was found 
in the ethanol extract of Sample 5 (HGCY, 黄梗串鱼), which had the highest potent anti-
histamine release effects induced by compound 48/80 in RPMC. In contrast, Sample 7 (CY, 
串鱼), which was found has lowest total peak area of the 13 main peaks, had the weakest anti-
histamine release effects in RPMC. Interestedly, the high amount of magnolin was found in 
the ethanol extract of Sample 7 (CY, 串鱼), which suggested that the anti-histamine release 
effects of different M. biondii varieties may relate to the content of the main lipid 
compositions of the ethanol extracts, rather than the magnolin or fargesin only. Thus, quality 
differences of the different species and varieties of Flos Magnoliae, in terms of the quality of 
the chemical compositions and the potency of the anti-histamine release effects, need to be 
concerned in order to insuring the quality, efficacy and consistency of CHM products.  
 
8.2.3 Other factors may influence the quality of Flos Magnoliae 
Although five Flos Magnoliae products were authenticated from M. biondii, qualitative and 
quantitative differences of the chemical compositions were identified using HPLC 
fingerprinting. It may lead to different potencies of the anti-histamine release effects of five 
Flos Magnoliae products. For instances, the products, which were provided by Hualong 
Magnolia Development Co. Ltd., contained the highest amount of 13 common peaks, as well 
as had the highest potency of anti-histamine release effects in RPMC. On the other hand, the 
local product, which was found to contain the lowest content of the main components, had the 
weakest effects on anti-histamine release from RPMC. Moreover, different content of 
magnolin and fargesin were detected from M. biondii samples, collected from different 
cultivation sites. Once again, the correlation between the qualities and quantities of the 
chemical compositions and the potencies of anti-histamine release effects were revealed. For 
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instances, the sample from Mt. Yanyi, contained the highest amount of main components, was 
found the strongest inhibitory effect on histamine release in RPMC. In contrast, the sample 
from Eastern Garden, contained the lowest content of the main components, had the weakest 
anti-histamine release effect. Thus, the present findings suggested that the other factors, 
including manufacturing factors and cultivation conditions, might influence on the quality of 
Flos Magnoliae products, while as the cautions should be taken when apply this to other 
CHMs.  
 
8.3 Limitation of this thesis and future direction  
There are some unexplained facts in the present study. For example, the larger genetic 
divergence between Chinese Flos Magnoliae species and local species, as well as the local M. 
sprengeri sample and another local M. denudata sample, were shown in the present study. 
These findings are not in agreement with previous studies (Wang et al., 2004a, Wang et al., 
2004b) and Magnoliaceae taxonomy (Magnolia Society, 2003). Meanwhile, except magnolin 
and fargesin, the chemical structures of other 11 common peaks are remained unknown. Due 
to the time constraints, the present study has focused on molecular (RAPD and PCR-RFLP) 
and chromatographic (TLC and HPLC) fingerprinting profiles of Flos Magnoliae. Coupled 
with other potential identification approaches (Figure 8.1), the systematic quality profiles may 
produce a more comprehensive understanding of the quality and therapeutic actions of Flos 
Magnoliae. For instance, with the extensive investigation of molecular profiles using 
sequencing-based markers and DNA microarrays have been previously reported for the 
identification and authentication of CHM (Cui, Lo, Yip, Dong, & Tsim, 2003; Jayasinghe et 
al., 2007; Ma, Duan, Zhu, Dong, & Tsim, 2000; Zhao et al., 2003). Therefore, combined with 
the chromatographic fingerprinting profiles of different Flos Magnoliae sources, by using 
TLC, HPLC and GC techniques, comprehensive, it will be ideally established a integrated 
fingerprints approaches for the continuation of this thesis.  
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Flos Magnoliae has a long history for clinical application for Allergic rhinitis (AR) treatment 
(The Pharmacopoeia Commission of People's Republic of China, 2005). AR is one of the 
major chromic respiratory disorders, which has been estimated to affect between 10% and 
40% of the global population (Bousquet et al., 2001). In Australia, 15.6% of the national 
population are affected by AR  (Australian Institute of Health and Welfare, 2005). AR has 
been reported that it considerably reduced the quality of life in several important domains, 
included work productivity and limits social activities (Bousquet et al., 1994). Furthermore, 
AR also can severely impact on concentration and learning performance and is a main cause 
of school absenteeism in adolescents for children, who are also recognized as major sufferers, 
with the prevalence of current AR at 12% in 6-7 years old and 19.6% in 13-14 years old, in 
Australia (Robertson et al., 1998). Substantial direct and indirect medical cost has been 
reported to be associated with the high prevalence of AR. In Australia, the significant 
economic burden of respiratory diseases, included AR, has been reported, with an estimated 
8.0% of total healthcare costs in 1993-1994 (Australian Institute of Health and Welfare, 
1998). Furthermore, AR is commonly associated with other disorders, for instances, otitis 
media, Eustachian tube dysfunction, sinusitis, nasal polyps, allergic conjunctivitis, sleep 
disorders and fatigue (Berger, 2003). Orthodox management of AR includes the 
administration of H1-antihiatamines, decongestants, antibiotics and nasal steroids. However, 
unwanted side effects such as local dryness, minor epistaxis, skin thinning, cataract, 
glaucoma, metabolic changes and impairment on performance have been revealed in previous 
studies (Wiseman and Benfield, 1997). In recent years, the treatment of allergic rhinitis has 
been revolutionized by the nasal steroids spray, which is quickly metabolized to less-active 
metabolites, has minimal systemic absorption, and has minimal systemic adverse effects 
(LaForce, 1999). However, side effects, including suppressive effects on adrenal function and 
serum osteocalcin, and considerable cost of these therapeutic products have been reported 
(Mehle, 2003). These limitations associated with existing western medial approaches are yet 
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to be addressed fully. In other hand, the use of CAM in AR management has increased 
recently (Schafer et al., 2002). Previous studies have demonstrated the efficacy and safety of 
CHM in the treatment of AR (Brinkhaus et al., 2004, Xue et al., 2003b, Xue et al., 2003a). 
Based on the literature review (details see Chapter 1), due to the outstanding anti-histamine 
release effects and high concentration of volatile oil contained, clinical studies indicate that 
Flos Magnoliae has excellent applicability in the treatment of AR by a single herb or 
combined with other CHM (Xue et al., 2003b, Wang et al., 2000c, Wang et al., 2000a, Wang 
et al., 2000b, Yang and Zhang, 1998). Meanwhile, even though the inhibitory effects of mast 
cells derived histamine release were demonstrated in the present study, other factors, such as 
effects on the production of PGE2, NO and cytokines (such as, TNF-α and IL-1α) may also be 
responsible for the anti-allergic effects of Flos Magnoliae (Bachert, Wagenmann, & Hauser, 
1995; Guzik, Korbut, & Adamek-Guzik, 2003; Ushikubi, Sugimoto, Ichikawa, & Narumiya, 
2000).  
 
Towards the end of this thesis, the findings suggest that with the largest genetic dissimilarity 
among all Flos Magnoliae species, M. biondii was determined containing the highest contents 
of magnolin, fargesin and total peak area of 13 common peaks. Later, potent anti-histamine 
release effects were demonstrated from the ethanol extract of M. biondii. The findings 
suggested that M. biondii could be the best candidate for further research on anti-allergic and 
anti-inflammatory actions of Flos Magnoliae. Interestedly, the high amount of magnolin was 
found in the ethanol extract of M. biondii, which may contribute to the anti-histamine release 
effects. Unlike western medications whose therapeutic effects generally derive from synthetic 
chemicals, the bioactivities of CHMs arise rather from a series of chemical compositions than 
a single compound. For instance, this thesis demonstrated the potencies of the anti-histamine 
release effects from six M. biondii varieties may relate to the content of the main lipid 
compositions of the ethanol extracts, rather than the magnolin or fargesin only. Six varieties 
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of M. biondii were collected from Nanzhao, Henan Province, China. It would have been 
interesting to characterise the chemical structures of these components, which may contribute 
to the anti-allergic effects of Flos Magnoliae, if it had not been for time constraints. Thus, 
development an herbal therapeutic product that offer greater topical activity with lower 
systemic exposure and improved safety by administering target organ directly has highly 
marketing potential in Australia. In order to achieve better understanding of the therapeutic 
potential of M. biondii or its bioactive components, the future direction is designed to separate 
and identify the major chemical components and further pharmacological evaluation of their 
anti-allergic and anti-inflammatory actions (Figure 8.1). It may also involve the development 
a new nasal formulation of bioactive components from M. biondii, which could appear to be a 
relatively safe treatment and rapidly improve nasal allergenic tolerance, reduce symptom, 
reflecting a general improvement in patients' well-being in Australia.  
 
Typically, an analytical liquid chromatography – electrospray ionization tandem mass 
spectrometry (LC-ESI-MS/MS) will be used to identify the containing seven chemical 
components (Peak 5 – Peak 11). Among selected seven peaks, Peak 6 and Peak 11 indicate 
magnolin and fargesin, respectively. And then the analytical LC conditions will be linearly 
scaled up to afford target lignans on the preparative-HPLC. The optimized the compositions 
of the chemical fractions that are collected from the lab-scale preparative chromatography 
experiments, a preparative – HPLC system, will be used for further anti-allergic testing, 
including effects on PGE2 production and COX-2 protein expression, effects on NO 
production and NOS expression, effects on cytokines production from RAW 264.7 cell lines, 
etc. The pharmacokinetics parameters and absolute bioavailability in rat plasma samples with 
sufficient sensitivity to facilitate analysis of sample collected after an intravenous or 
intranasal administration of the potential therapeutic product containing the bioactive 
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components from M. biondii will be evaluated by a LC-MS/MS method. oral and intravenous 
administration (Hsieh et al., 2006). 
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Figure 8.1 Schematic diagram of quality control of Flos Magnoliae 
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